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Abstract 
The emergence of extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae 
represents a major challenge to public and animal health in many countries including Lebanon.  
Carriage of ESBLs confers resistance to β-lactam antibiotics and more than 200 different sub-
types have been identified, all of which are primarily encoded by genes located on conjugative 
plasmids.   
Despite the high prevalence of ESBLs, there is still a paucity of information regarding the impact 
of ESBL plasmid carriage on the host bacterium and how the spread of antibiotic resistance 
relates to antibiotic use in hospital environments.  Therefore, the aim of this study was, firstly, to 
characterise the genetic and phenotypic properties of ESBL-producing Escherichia coli and 
Klebsiella pneumoniae isolated from a hospital in Lebanon.  Secondly, to assess the fitness of 
isolates harbouring different sub-types of ESBLs in order to better understand the influence of 
the plasmid on the host bacterium, and thirdly, to correlate hospital antibiotic consumption data 
calculated using ABC Calc software (in defined daily doses (DDD) per 100 bed days), with 
antimicrobial susceptibility profiles obtained over a three year period. 
A total of 140 isolates of E. coli and K. pneumoniae that were resistant to at least one 3
rd-
 or 4
th-
 
generation cephalosporin were collected from the Centre Hospitalier Du Nord (CHN) in 
Lebanon, between 1
st
 May 2011 and the 31
st
 December 2012.  ESBL-production was confirmed 
in all isolates using the double disk synergy assay and the E-test ESBL strip.  Out of 140 isolates, 
35 were also found to harbour a chromosomal AmpC β-lactamase, whereas none harboured the 
plasmidic gene.  PCR analyses showed that all isolates harboured CTX-M type β-lactamase, with 
74% also harbouring TEM and approximately 40% harbouring either SHV or OXA type β-
lactamases.  Most E. coli isolates belonged to phylogenetic group B2, and harboured genes 
important in iron uptake. 
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PFGE analysis of both E. coli and K. pneumoniae indicated significant clonal diversity amongst 
the isolates.  Analysis of the β-lactamase-encoding plasmids from selected isolates revealed the 
plasmids were conjugative and bore similarities to pEC_L8 and Inc group types.  Plasmid curing 
studies indicated that ESBL plasmids influenced bacterial host cell fitness through altered carbon 
metabolism and generation time.  Both positive and negative correlations were found between 
antibiotic consumption and the susceptibility of E. coli and K. pneumoniae to different types of 
antibiotics. 
This study highlights the diversity of ESBL-producing isolates found among members of the 
Enterobacteriaceae in Lebanon and supports the idea that horizontal transfer of CTX-M-15 
harbouring ESBL plasmids, rather than clonal expansion of particular isolates, has occurred.  
Moreover, the use of β-lactam antibiotics and quinolones may promote their spread, and thus 
effective hospital infection control programs and more pragmatic antimicrobial usage is 
recommended. 
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CHAPTER 1 
1. Introduction 
Since their discovery antibiotics have proved to be effective in the treatment of a multitude of 
bacterial infections in animals and humans (Humphery-Smith, 2014).  Their use has been 
compromised by the emergence of antibiotic resistant bacteria in many different settings 
(Humphery-Smith, 2014).  Consequently, the presence of antibiotic resistant populations 
converts infections that were once treatable into potentially life‐threatening events.  While 
antibiotics limit the growth of organisms that lack resistance mechanisms, they have no or little 
impact on those that are resistant and these pathogens are able to continue to survive and 
multiply in the host (Laxminarayan, 2001).   
The emergence of antibiotic resistant organisms is occurring at a faster rate than the development 
of new antibiotics and thus a greater understanding of the mechanisms, epidemiology, and spread 
of resistance genes and the bacteria that harbour them, is urgently required to protect public and 
animal health (Shlaes et al., 2004).    
Antimicrobial resistant isolates of bacteria can have a serious negative impact on the treatment of 
individuals (McGowan, 2001).  The failure of infections to respond to standard therapies can 
result in increases in the severity and duration of illness and increases in the likelihood of 
resistance, potentially resulting in longer hospital stays.  In addition, antimicrobial resistant 
bacteria can significantly affect economies and societies (McGowan, 2001).   
The treatment of infections caused by antimicrobial resistant pathogens challenges health care 
systems worldwide, significantly increasing costs and placing a huge burden on resources 
(French, 2005).  Thus, the emergence of antimicrobial resistance has become a grave concern 
due to its impact on patients, physicians, health-care systems and pharmaceutical producers 
(McGowan, 2001). 
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Furthermore, antimicrobial resistance can also affect animal health and welfare (Butaye et al., 
2003).  The past use of antibiotics, such as avoparcin, penicillins, bacitracin, tetracycline and 
macrolides, as growth promoters to advance daily weight gain in food animals, has also 
contributed to the emergence of drug-resistant animal pathogens (Butaye et al., 2003; Lin et al., 
2007).  As well as complicating the treatment of infections, animals may also act as reservoir for 
antibiotic resistant organisms, which may be transmitted to humans via direct contact or 
indirectly via the food chain (Lin et al., 2007).  The increasing detection of antimicrobial 
resistant organisms in humans and animals particularly those that exhibit multiple resistances, is 
a serious threat to public health. 
One of the leading factors affecting the prevalence of antimicrobial resistant organisms is 
antibiotic consumption in hospitals (Sharma et al., 2005; Borg et al., 2008).  The continual 
selection pressure exerted on bacterial populations by the prolonged use of antibiotics can favour 
the survival of those organisms that are resistant (Sharma et al., 2005).  Not only will this result 
in a decreased effectiveness of current therapeutics, but it could also increase the likelihood of 
resistant bacteria spreading in the environment.  Even though a causal relationship between 
bacterial resistance and antibiotic use has been described (Kaier et al., 2009), such as the 
increase in antimicrobial use and the widespread distribution of antimicrobial resistant 
pathogens, this relationship is fluid and subject to change depending on the bacterial species, the 
class of antibiotic in question, and the ecological environment. 
Tackling the spread of resistant populations of bacteria is complicated by gaps in our 
understanding of the mechanisms of drug resistance and of how resistance genes spread within 
and between bacterial species.  For example, many antimicrobial resistance genes are located on 
conjugative plasmids, which facilitate their movement between bacteria of the same and different 
species (Chaudhary et al., 2004).  Whether these plasmids also confer added benefits to the host 
organism, in addition to antibiotic resistance, is unclear.   
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The focus of this thesis was on the dissemination and characterisation of extended spectrum β-
lactamases (ESBLs) in Escherichia coli and Klebsiella pneumoniae, two clinically important 
bacterial species that were isolated from a major Lebanese hospital.  These Gram negative 
bacilli, which are often associated with diseases such as urinary tract infections (UTIs), bacterial 
meningitis, and septicemia among other conditions, can cause prolonged sicknesses and high 
mortality and morbidity rates (Moissenet et al., 2010; Della-Latta et al., 2011; Daoud et al., 
2011).  The huge diversity and increasing incidence of ESBLs found among members of the 
Enterobacteriaceae, is remarkable and poses a serious challenge to modern medicine (Paterson et 
al., 2005).   
ESBL enzymes confer resistance to 3
rd-
 generation cephalosporins (Kaier et al., 2009), 
commonly prescribed antibiotics used in the treatment of infections caused by Gram negative 
bacteria.  Understanding the distribution, spread and prevalence of ESBLs is central to the 
effective treatment of patients.  Key questions to be considered include which type of ESBL 
predominate in Lebanon? Do resistant isolates form part of a clonal complex? What fitness cost, 
if any, does carriage of ESBL plasmids confer to the host bacterium?  
 
1.1  E. coli and K. pneumoniae 
Escherichia coli was discovered by the German bacteriologist and paediatrician Theodor 
Escherich in 1885 (Hacker et al., 2007).  Part of the Enterobacteriaceae family, E. coli is a 
facultative anaerobic, motile, non-sporulating, Gram negative rod-shaped bacterium.  It is a 
genetically diverse species that contains isolates of varying pathogenic potential.  Most E. coli 
isolates reside harmlessly in the gastrointestinal tract of humans and animals as part of their 
normal micro-flora and benefit the hosts by producing key nutrients, such as vitamin K (Suvarna 
et al., 1998).  Isolates belonging to enterotoxigenic E. coli, enteropathogenic E. coli, 
enteroinvasive E. coli, enterohaemorrhagic E. coli, and enteroaggregative E. coli pathotypes, can 
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cause enteritis and severe disease while resident in the intestine (Welch et al., 2002).  For 
example, E. coli O157:H7 produces potent cytotoxins known as Shiga-like toxins that cause life-
threatening kidney disease in humans.  Some isolates of E. coli are able to colonise sites outwith 
the intestine and cause extraintestinal disease (Sharma et al., 2007).  For example, E. coli is also 
recognised as a major cause of urinary tract infections (UTIs) that can lead to the development of 
acute cystitis and pyelonephritis (Sanders et al., 1996; Pohlenz et al., 2005; DeCory et al., 2005).  
Other E. coli isolates are recognised as the second leading cause of bacterial neonatal meningitis, 
a bloodstream infection which results in inflammation in the membranes that surround the brain 
and spinal cord (Moissenet et al., 2010; European Centre for Disease Prevention and Control 
network).   
E. coli is the most common species isolated in UTI and faecal specimens (Trepeta et al., 1984).  
E. coli grows optimally at 37˚C and can be easily identified biochemically based on its response 
to oxidase, citrate, urease, indole, and lactose tests (Trepeta et al., 1984).  Samples suspected of 
containing E. coli are routinely cultured on MacConkey agar, a selective and differential medium 
used for the isolation of Gram negative organisms including E. coli.  Some isolates of E. coli are 
motile and exhibit peritrichous flagella arrangements (McCarter, 2005).  Because of its ease of 
manipulation and long history of laboratory culture, E. coli plays an important role in 
biotechnology and industrial microbiology (Hauptmann et al., 2006).     
Klebsiella pneumoniae was described by the German bacteriologist Edwin Klebs and is a Gram-
negative, non-motile, encapsulated, rod-shaped bacterium (Brisse et al., 2006).  Like E. coli, K. 
pneumoniae is a member of the Enterobacteriaceae family and clinically is the most important 
member of the Klebsiella genus.  Although normally found as a commensal at various sites in the 
human body, this organism can also behave as an opportunistic pathogen.  It is a major cause of 
nosocomial (hospital-acquired) infections, ranging from mild UTI to vigorous pneumonia and 
bacteriaemia that are associated with a high rate of mortality and morbidity (Fouts et al., 2008).  
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K. pneumoniae infections are particularly severe in immunocompromised hosts, where 
underlying permanent lung damage often results from pneumonia (Meyer et al., 1993; Paterson 
et al., 2004; Fouts et al., 2008).  Patients, whose care requires special attention such as 
ventilators or intravenous catheters, are most at risk for Klebsiella infections (Ayan et al., 2003).  
As a significant cause of nosocomial infections, healthcare personnel should follow specific 
prevention measures in order to prevent the spread of Klebsiella infections in the hospital (Meyer 
et al., 1993; Sydnor et al., 2011). 
Identification of K. pneumoniae is based on its response to oxidase, urease, glucose and lactose 
fermentation, citrate utilisation, methyl red, and Voges-Proskauer tests (Alves et al., 2006).  Like 
E. coli, it is usually cultured on MacConkey agar, appearing as pink colonies and reflecting its 
ability to ferment lactose (Alves et al., 2006).  K. pneumoniae naturally occurs in the soil, and 
some isolates can fix nitrogen in anaerobic conditions (Desnoues et al., 2003).  It is most closely 
related to K. oxytoca from which it is distinguished by being indole-negative (Maslow et al., 
1993). 
Many E. coli and K. pneumoniae isolates remain susceptible to antibiotics (Gupta et al., 2003).  
The presence of ESBLs, a large group of genetically diverse enzymes that hydrolyze β-lactam 
antibiotics (Wiegand et al., 2007), has resulted in the development of resistance in these 
organisms to many broad spectrum drugs (Kim et al., 2002).  In addition, resistance to 
fluoroquinolone antibiotics is commonly found (Chaudhary et al., 2004; Rawat et al., 2010). 
In recent years, the prevalence of antibiotic resistance to 3
rd-
 generation cephalosporins among 
various ESBL-producing isolates of E. coli and K. pneumoniae has increased significantly 
(Lautenbach et al., 2001).  Several factors are thought to contribute to the increased incidence of 
ESBL-producing E. coli or K. pneumoniae in hospitals, including prior hospitalization, the 
inappropriate use of antibiotics and the use of venous catheters (Lautenbach et al., 2001; Kim et 
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al., 2002).  Not only do ESBL-infections lead to increased cost of care but they also have a 
negative impact on the survival and general outcome of treatment (Kim et al., 2002).  Before 
observing the rise in the rates of resistance, the Clinical and Laboratory Standards Institute 
(CLSI) guidelines recommended screening only E. coli and K. pneumoniae for ESBL-
production; other Enterobacteriaceae were screened only under specific conditions such as when 
Proteus mirabilis was isolated from the bloodstream (Wiegand et al., 2007).  ESBL-production 
is screened in most Enterobacteriaceae isolates due to the increased spread of resistant bacteria 
(Wiegand et al., 2007). 
A large number of acquired carbapenemase enzymes have been isolated among Gram negative 
pathogens including E. coli and K. pneumoniae (Castanheira et al., 2011).  Carbapenem resistant 
E. coli and K. pneumoniae are difficult to treat because they also exhibit high levels of resistance 
to other antibiotics (Roy et al., 2011).  Examples of carbapenemases include K. pneumoniae 
carbapenemase (KPC), New Delhi metallo β-lactamase (NDM) and OXA-48 carbapenemase, all 
of which have arisen in many countries (Rimrang et al., 2012).  Therefore, detection of 
carbapenemase-producing organisms is also of major importance for the successful treatment of 
patients.   
 
1.2  Relationship between bacterial fitness, virulence and resistance to antibiotics  
Global dissemination of acquired resistance genes in pathogens relies on the transmission of the 
resistance gene/s within microbial populations as well as the spread and survival of drug-
resistant bacteria in other hosts and the environment.  The ability of an organism (whether or not 
carrying resistance genes) to survive and reproduce within a particular environment is often 
referred to as the organism‘s fitness (Durso et al., 2004).  The fitness of an organism is a fluid 
parameter which can vary depending upon many factors including the niche it occupies, the 
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extra-chromosomal elements it carries and the substrates that are available (Smith et al., 1998; 
Durso et al., 2004). 
Over millions of years, infectious agents have evolved numerous mechanisms to enable them to 
attach, colonise and disseminate from hosts while simultaneously avoiding the activities of the 
host immune system (Skurnik et al., 2013).  These are considered the virulence determinants of 
the bacterium and include factors such as toxins, adhesion-promoting structures, biofilm 
production and haemolysins (Duplessis et al., 2011).  In terms of an organism‘s ability to cause 
an infection, virulence factors can have a significant impact on their fitness within a host.  As an 
example the ability to form biofilms can aid the survival of bacteria because cells growing in 
biofilms are more resistant to the components of the human immune system, physiological 
processes as well as to many antibacterial agents, than planktonic cells (Norouzi et al., 2010).  
Virulence factors may also function additively to defeat normal host defenses (Sharma et al., 
2007).  The capacity of a bacterium, such as E. coli, to cause an infection may depend on the 
presence and expression of several virulence factors (Sharma et al., 2007).  For example, for E. 
coli to survive in the bloodstream, capsules such as the K antigen, iron scavenging systems (e.g. 
haemolysins, the aerobactin system) and resistance to serum (Increased Serum Resistance - ISS) 
are likely to be important (Johnson, 1991).  The more virulence factors an organism expresses, 
the more severe and serious the infection may be (Johnson, 1991).  The diversity of virulence 
determinants may also increase an organism‘s ability to infect different hosts and tissues, thus 
improving its overall ability to be a successful pathogen. 
However, the carriage of antimicrobial resistance genes, or indeed any additional genetic 
material may impose a fitness cost to the host organism, possibly due to the energetic 
requirements of replicating extra-chromosomal DNA elements (e.g. plasmids) or producing 
increased levels of protein (e.g. efflux pumps).  The selective pressure imposed on microbial 
populations by the presence of antibiotics can also alter their fitness.  Susceptible bacterial 
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isolates often have very low fitness levels in the presence of antibiotic treatment, but relatively 
high fitness levels in its absence (Schulz zur Wiesch et al., 2010).  Loss of fitness upon exposure 
to antibiotics can be compensated for by the introduction of mutations.  Mutations enable new 
variant genes to be produced.  However, they will only become established within the population 
if they do not also pose a fitness cost to the organism (Marcusson, 2007). 
The impact of antibiotic resistance in relation to an organism‘s fitness has been poorly studied, 
partially due to a lack of systematic studies in this area and the availability of appropriate in vitro 
and in vivo models.  The availability of in vitro models for measuring fitness usually involves 
comparing the growth and/or survival of resistant and sensitive populations under defined 
conditions (Pope et al., 2010).  In particular, measurement of an organism‘s specific growth, 
respiration rate or generation time has been used to determine fitness costs associated with 
carriage of antimicrobial resistance.  For example, in the presence of different stress modulators, 
the carbon utilisation can be used to measure differences in bacterial fitness based on respiration 
(Bochner et al., 2001; Alqasim et al., 2014; Kirchner et al., 2014).  Such studies reflect the 
growth of the organism in artificial controlled conditions which do not accurately replicate real-
life scenarios.  The studies that have been conducted in vitro may not accurately reflect the 
complexity of nutrient availability in vivo (Gustafsson et al., 2003).  Thus, fitness may be 
measured more accurately using animal models (Chart et al., 2000; Gustafsson et al., 2003; 
Randall et al., 2008).    
1.3 Antibiotics 
1.3.1 Definition 
Antibiotics are capable of killing or inhibiting the growth of microorganisms.  These agents can 
be divided into four main classes depending on the type of organism they target: antibacterial, 
antiviral, antifungal, and anti-parasitic (Jenssen et al., 2006).  Therapeutic antibiotics have been 
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largely developed over the last 60 years in order to fight bacterial infections in humans and 
animals.  In addition, some have been used to increase growth rates of livestock i.e. as growth 
promoters.     
1.3.2 General classification of antibacterial agents 
Antibacterial agents can be divided into bacteriostatic antibiotics, which inhibit the growth and 
reproduction of bacteria without killing them, or bactericidal antibiotics, which are 
antimicrobials that kill bacteria (Fleming, 1929; Dawson et al., 1943; Bakker-Woudenberg et al., 
2005; Ocampo et al., 2014). 
These agents can also be divided into four groups based on their mechanism of action and target 
in the cell (Neu et al., 1996; Samaha-Kfoury et al., 2003; Tenover, 2006):  
 Cell wall synthesis includes the β-lactams which disrupt the synthesis of the 
peptidoglycan layer (Neu et al., 1996; Samaha-Kfoury et al., 2003; Tenover, 2006). 
 Cell membrane inhibitors include the polymyxins which disrupt both the outer and 
inner membranes (Neu et al., 1996; Samaha-Kfoury et al., 2003; Tenover, 2006). 
 Protein synthesis inhibitors include aminoglycosides, macrolides, tetracycline which 
interfere with ribosomal function (Neu et al., 1996; Samaha-Kfoury et al., 2003; Tenover, 
2006). 
 Nucleic acid synthesis inhibitors include quinolones which blocks DNA replication 
(Neu et al., 1996; Samaha-Kfoury et al., 2003; Tenover, 2006). 
1.3.3 Mode of action of β-lactam antibiotics 
β-lactams are a group of broad spectrum antibiotics that interfere with bacterial cell wall 
synthesis (Samaha-Kfoury et al., 2003).  The bacterial cell wall is composed of peptidoglycan 
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that preserves the shape and provides structural integrity to the cell.  The glycan strands are made 
of polymers of two alternating amino sugars: N-acetyl muramic acid (NAM) and N-acetyl 
glucosamine (NAG), linked by a β-1,4 glycosidic bonds (Waxman et al., 1983).  Peptide stems 
of Gram-negative peptidoglycan (consisting of five amino acids: L-alanine (L-ala), D-glutamic 
acid (D-glu), meso-diaminopimelic (meso-DAP), D-alanine (D-ala) and D-alanine (D-ala)) or of 
Gram-positive peptidoglycan (consisting of five amino acids: L-alanine (L-ala), D-glutamic acid 
(D-glu), L-lysine (L-Lys), D-alanine (D-ala) and D-alanine (D-ala) (Neu et al., 1996; Meroueh et 
al., 2006)), are attached to the NAM and adjacent strands are cross-linked via the action of a 
―transpeptidase‖ (Meroueh et al., 2006).  Through this mechanism peptidoglycan forms a ‗mesh‘ 
like structure that helps the bacteria resist damage from a range of sources.   
β-lactam antibiotics contain a four-membered β-lactam ring that mimics the structure of the 
terminal D-ala amino acid in the peptide stem (Neu et al., 1996).  Incorporation of the β-lactam 
ring instead of the D-ala-D-ala during peptidoglycan synthesis effectively stops cell wall 
elongation and eventually causes cell lysis (Bycroft et al., 1985; Kohanski et al., 2010). 
1.3.4 Types of β-lactam antibiotics 
β-lactams are one of the most important groups of antibiotics used in clinical settings (Samaha-
Kfoury et al., 2003).  These drugs are well-tolerated because they have a low toxicity, circulate 
efficiently in the body, and function in a time-dependent manner (Nau et al., 2010).  The clinical 
achievement of penicillin G (the first β-lactam), encouraged the development of new and 
additional antimicrobial derivatives (Drawz et al., 2010).  The emergence of antimicrobial 
resistant microorganisms established a significant clinical threat and led to an urgent need for the 
development of more potent and broader spectrum of antibiotics (Drawz et al., 2010).  
Penicillins, cephalosporins, carbapenems and monobactams are subtypes of β-lactams that 
exhibit differing effectiveness against bacterial pathogens (Torres et al., 2010). 
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1.3.4.1 Penicillins  
Penicillins were discovered in 1928 and were mainly prescribed for the treatment of Gram-
positive bacterial infections (Lax, 2004).  Penicillins are bactericidal and highly efficient against 
microorganisms that are susceptible (Miller, 2002).  They can be further categorized according to 
their spectrum of activity into natural penicillins (penicillin G and penicillin V), β-lactamase 
resistant penicillins (penicillin M), and extended spectrum antibiotics (aminopenicillins, 
carboxypenicillins, and ureidopenicillins).  Carboxypenicillins and ureidopenicillins are also 
called antipseudomonal penicillins (Hayat, 2013). 
1.3.4.2 Cephalosporins 
Cephalosporins are the most used antibiotics since they act on a broader range of both Gram 
positive and Gram negative bacteria (Neu et al., 1996).  They are commonly used for the 
treatment of several bacterial infections including E. coli and Klebsiella spp. (Baldwin et al., 
1988).  They are categorized based on their spectrum of activity, as follows (PL Detail-
Document, 2012): 
 1st- generation (have narrow spectrum of activity mainly on the Gram-positive 
organisms): cephalotin, cefazolin, and others (Samaha-Kfoury et al., 2003; PL Detail-
Document, 2012). 
 2nd- generation (have a greater Gram-negative spectrum and some activity against Gram-
positive bacteria): cefoxitin (cephamycins), cefuroxime, and others (Samaha-Kfoury et 
al., 2003; PL Detail-Document, 2012).   
 3rd- generation (have a noticeable activity against Gram-negative bacteria): cefotaxime, 
ceftazidime, cefpodoxime, and others (Samaha-Kfoury et al., 2003; PL Detail-Document, 
2012). 
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 4th- generation (have the broadest spectrum of activity): cefepime, cefpirome, and others 
(Samaha-Kfoury et al., 2003; PL Detail-Document, 2012). 
 5th- generation (is unique in its activity against multidrug-resistant Staphylococcus 
aureus): ceftaroline and others (PL Detail-Document, 2012). 
1.3.4.3 Carbapenems 
Carbapenems include imipinem, ertapenem, doripenem, and meropenem, and are highly 
effective against both Gram-negative and Gram-positive bacteria (Edwards et al., 2000; Samaha-
Kfoury et al., 2003).  They are the treatment of choice for serious infections related to Gram-
negative bacteria that have developed resistances to the previous classes of antibiotics (Kanj et 
al., 2011; Gholipour et al., 2014; Zhao et al., 2015).  Carbapenem usage is usually confined to 
hospitals (Edwards et al., 2000). 
1.3.4.4 Monobactams 
Monobactams have a narrow spectrum of activity and are only effective against Gram-negative 
bacteria (Drawz et al., 2010).  However, monobactams are unique since they are the only β-
lactam compounds in which the β-lactam ring is not fused to any other chemical moiety (Bassetti 
et al., 2013).  Monobactams, like the other β-lactams, interfere with the synthesis of the bacterial 
cell wall (Lindner et al., 2000).  Aztreonam is commercially the most commonly used 
monobactam (Drawz et al., 2010). 
In summary in terms of clinical use, penicillin, aminopenicillins, and the 1
st-
 and 2
nd-
 generation 
cephalosporins are the treatments of choice for most community acquired bacterial infections.  In 
contrast, carbapenems, monobactams, the 3
rd-
 and 4
th-
 generation cephalosporins, are reserved for 
hospital use and for the treatment of highly-resistant microorganisms (Suarez et al., 2009).   
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1.4 Antibiotic usage 
The most common antibiotic groups prescribed in hospitals are the extended-spectrum and 
combination penicillins, 1
st-
 and 3
rd-
 generation cephalosporins and quinolones (Borg et al., 
2008).  Antibiotic consumption is usually measured using ABC Calc, a simple computerized tool 
which transforms aggregated data supplied by hospital pharmacies into meaningful antibiotic 
utilisation rates expressed as defined daily doses/100 bed-days (DDD/100 bed-days) (Monnet, 
2006; Keuleyan et al., 2010).  On average the consumption of β-lactam antibiotics in Southern 
and Eastern Mediterranean hospitals accounts for more than half of all antibiotics used, with 3
rd-
 
generation cephalosporins predominating over other groups of antibiotics in this setting (Borg et 
al., 2008).  The use of 3
rd-
 generation cephalosporin antibiotics also dominated in a Croatian 
hospital (Tonkic et al., 2005).   
Antibiotic usage in hospitals is a leading risk factor for the emergence of antimicrobial resistance 
(Sharma et al., 2005; Borg et al., 2008).  Antibiotic treatment kills or inhibits susceptible bacteria 
in an infected patient and thus aids the prevention of the transmission of the infection to another 
healthy individual.  Prolonged consecutive use of antibiotics can result in a decrease in their 
effectiveness (Laxminarayan, 2001).  This is because repeated use of antibiotics induces a 
selective pressure that favors the survival of resistant bacteria, and thus treatment of the now-
resistant isolates with the same antibiotic, becomes ineffective (Sharma et al., 2005).  This 
phenomenon places physicians in a position of responsibility for prescribing the optimal dose 
and antibiotic for each case that they encounter in order to try and prevent the emergence of 
resistant isolates (Laxminarayan, 2001).   
It is widely believed that hospital departments with the highest level of antibiotic usage exhibit 
the highest rates of antimicrobial resistance (Shlaes et al., 1997).  For example, in a tertiary care 
center in Lebanon, Kanafani et al., reported that treatment with 3
rd-
 generation cephalosporins 
was the greatest risk factor for individuals acquiring infections caused by ESBL-producing 
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isolates (Kanafani et al., 2005).  In a study to assess the compliance of surgical personnel in 
adhering to antibiotic use policies, Keuleyan and colleagues collected data comparing total 
antibiotic consumption and the percentage of resistant organisms recorded at the Surgery Clinic 
of a national hospital in Bulgaria (Keuleyan et al., 2010).  Total antibiotic consumption was 
found to be between 47.9 and 61.9 DDD/100 bed-days, which was evaluated as ―middle to high‖ 
usage between 2006 and 2009 (Keuleyan et al., 2010).  The most commonly prescribed category 
of antibiotic was first generation cephalosporins.  During the same period, the frequency of 
ESBL-producing Enterobacteriaceae obtained from surgical infections ranged between 14% and 
23% (Keuleyan et al., 2010) compared to 36.6% in Algeria (Nedjai et al., 2013).  The data from 
several studies indicate that more frequently prescribed groups of antibiotics are usually 
associated with increasing numbers of resistant organisms (Dancer, 2001; Knobler et al., 2003). 
Although reports on ESBL-producing Enterobacteriaceae have focused on hospitalized patients, 
ESBL-producing bacteria have also been isolated from patients within the community suggesting 
that the community may act as a reservoir for resistance elements as well as resistant isolates 
(Mesa et al., 2006).  Further complicating the interpretation of many studies is the realisation that 
the prevalence of ESBL-producing isolates varies from patient to patient, from year to year, from 
area to area and even from hospital to hospital (Tonkic et al., 2005; Mesa et al., 2006). 
Even though the use of 3
rd-
 generation cephalosporins has been reported in several studies (e.g. 
Rahal et al., 1998; Lin et al., 2003) as an important factor resulting in increased numbers of 
ESBL-producing organisms; quinolones, aminoglycosides, and carbapenems have also been 
implicated (Demirdag et al., 2010).  Quinolones were found to be the major type of antibiotic 
associated with an increase in the prevalence of ESBL-producing organisms in a study 
undertaken in Turkey (Demirdag et al., 2010).   
While non-ESBL-producing organisms (particularly from the community) were found to be 
susceptible to many antibiotics, isolation of an ESBL-producing Enterobacteriaceae (from 
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patients with less than 48 hours of hospital stay) was potentially associated with the consumption 
of cefotaxime and gentamicin antibiotics in the hospital (Sarma et al., 2010).  It is possible that 
overexposure to these two antibiotics has contributed to an increase in the prevalence of ESBL-
producing bacteria.  According to this study, the presence of ESBL-producing isolates was 
highly associated with resistance to different and specific classes of antibiotics (Sarma et al., 
2010). 
Hospitals are being encouraged to perform strict surveillance of antimicrobial consumption and 
resistance in order to try to decrease the incidence of resistance and to attempt to reduce the mis-
use and overuse of antibiotics (Kanafani et al., 2005; Borg et al., 2008; Meyer et al., 2013).  
Such approaches can be effective as extensive restrictions on cephalosporin use greatly 
decreased the incidence of nosocomial, plasmid-mediated, cephalosporin resistant E. coli and K. 
pneumoniae infections in India (Murki et al., 2010).  The use of piperacillin/tazobactam instead 
of extended spectrum cephalosporins, coincided with a decrease in the incidence of ESBL-
producing K. pneumoniae and E. coli isolates obtained from children‘s hospital in Korea (Lee et 
al., 2007).  Reducing the use of 3
rd-
 generation antibiotics has not always resulted in a decline in 
the proportion of ESBL-producing organisms.  For example, despite reduced cephalosporin and 
β-lactam consumption between 2001 and 2003 in Spain, the Spanish National Health System 
found that the proportion of ESBL-producing organisms still increased (Oteo et al., 2005). 
Overall, consumption of broad spectrum cephalosporins and the presence of ESBL-producing 
isolates have both increased globally.  Antibiotic consumption and prolonged hospital stay are 
now considered to be the main risk factors for the emergence of ESBL-producing organisms in 
this setting (Kim et al., 2002; Kanafani et al., 2005; Trang et al., 2013).  Several studies have 
reported a relationship between infection with ESBL-producing pathogens and the consumption 
of 3
rd-
 generation cephalosporins and/or fluoroquinolones (Kanafani et al., 2005; Kaier et al., 
2009; Demirdag et al., 2010).  Overall, there is an urgent need for improvements in antibiotic 
34 
 
stewardship programs and better regulation of the prescription of antibiotics in order to protect 
public health. 
 
1.5 Antimicrobial Resistance 
1.5.1 Definition  
Antimicrobial resistance can be defined as the ability of microorganisms to survive and replicate 
in the presence of a chemical that would normally kill or limit their growth (Sharma et al., 2005).  
Resistance to antibiotics can arise when a bacterium acquires new (foreign) DNA or by mutation 
of the bacterium‘s original genetic material (Ohl et al., 2001; Tenover, 2006).  Often, 
antimicrobial resistance can occur in response to the selective pressure that is created when an 
antibiotic targets the bacterial population (Sharma et al., 2005). 
1.5.2 Mechanisms of resistance  
Resistance to antibiotics can be mediated in microorganisms by one or more of the mechanisms 
outlined in Figure 1.  Bacterial cells can use efflux pumps (represented by (a) in Figure 1) or 
alter membrane permeability ((d) in Figure 1) to limit the amount of antibiotic present inside the 
cell, they can inactive the antibiotic through enzymatic activity ((b) in Figure 1) or limit the 
ability of it to bind to its target site ((c) in Figure 1).  It is not unusual for a single organism to 
exhibit more than one of these mechanisms (Livermore, 2002; Meletis et al., 2013).  Resistance 
to 3
rd-
 generation cephalosporins is usually mediated via enzymes referred to as β-lactamases that 
inactivate the drug inside the cell (see section 1.6).   
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Figure 1: Major antibiotic resistance mechanisms in bacteria.   
Schematic diagram of bacterial cell showing the main mechanisms conferring drug resistance; (a) efflux pumps – 
where antibiotics are actively pumped out of the cell; (b) enzymatic degradation – where enzymes render the drug 
inactive; (c) alteration of target molecules – when the drug no longer binds to its target molecule; and (d) changes in 
membrane permeability due to decreases in the membrane-bound porins or changes in their shapes (Adpated from 
Bbosa et al., 2014). 
1.5.3 Spread and transmission of resistance 
Bacterial resistance to antibiotics has increased over the last few decades (Threlfall et al., 2000).  
The rate and degree of increase in resistance varies widely with different pathogen-drug 
combinations and geographical locations (Lipsitch, 2001; Seo et al., 2014).  Many studies have 
focused on developing effective treatments for combatting infections caused by resistant isolates, 
such as by modifying dosage or through the use of another class of antibiotics (Chopra et al., 
2001; Kolara et al., 2001).  The emergence of some rare isolates of Gram-positive and Gram-
negative bacteria, which exhibit resistance to a wide range of antibiotics such as vancomycin-
resistant Enterococci, methicillin-resistant Staphylococcus aureus, and multi-resistant Gram-
negative bacteria, is a concern (Sharma et al., 2005).  Understanding how resistance genes, and 
the bacteria that harbour them spread, is critical to controlling this on-going global issue.   
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Bacterial resistance can be intrinsic or acquired.  Intrinsic resistance is mediated chromosomally 
while acquired resistance may be due to one or more mutations, or the acquisition of plasmids 
and other transposable DNA elements (Chinedum, 2005).  Intrinsic resistance is known and 
predictable because it is based on the inherent properties of the species (Chinedum, 2005) and 
thus is relatively easy to deal with.  For example, Gram-negative organisms are intrinsically 
resistant to vancomycin (Chinedum, 2005).  Acquired resistance, on the other hand, is 
unpredictable since it reflects the random acquisition of resistance genes by genetic processes 
such as conjugation, transduction and transformation (Davison, 1999; Chinedum, 2005).  
Bacterial conjugation involves the transfer of genetic material between bacteria through direct 
cell-to-cell contact and was first demonstrated to occur in E. coli by Lederberg et al. in 1946 
(Lederberg et al., 1946; Zinder et al., 1952).  The transfer of genetic material by the action of 
viruses is referred to as transduction whereas transformation involves the uptake of naked DNA 
from the environment (Davison, 1999; Tenover, 2006).  In addition, bacteria may acquire 
resistance to drugs via the accumulation of point mutations in key genes.  For example, a point 
mutation was found in the ligand-binding region of the penicillin binding proteins (PBPs) of 
isolates of group B Streptococcus that exhibited decreased susceptibility to β-lactam antibiotics 
(Dahesh et al., 2008). 
Many factors contribute to the occurrence and spread of resistant bacterial isolates (Levy, 2001; 
Coque et al., 2008).  For instance, clonal spread is one of the major factors affecting the spread 
of ESBL-producing organisms (Coque et al., 2008).  Increase length of hospital stay, 
instrumentation, and antibiotic exposure are risk factors for methicillin-resistant Staphylococcus 
aureus infection (Polin et al., 2003).   
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1.5.4 Socio economic impacts of antimicrobial resistance 
The treatment of bacterial infections is increasingly complex due to the increase in antimicrobial 
resistance and the presence of multiple resistances within one organism (French, 2005).  
Economic factors that affect patients, health-care personnel, physicians, pharmaceutical 
companies and the community all contribute to the problem (McGowan, 2001).  The increase in 
infections caused by resistant bacteria may lead to inappropriate therapy and the use of less 
efficient, more toxic and more expensive drugs (Simonsen et al., 2004).  In addition, 
antimicrobial resistance can be associated with treatment failure and prolonged hospitalization, 
as well as increased costs (French, 2005).  In this situation, patients with low-to-middle class 
incomes may fail to seek proper medical attention and/or fail to follow their prescribed treatment 
plan thereby, further exacerbating the problem and contributing to the spread of resistant 
populations (Bodenheimer, 2005). 
1.5.5 Prevalence of antimicrobial resistance  
Reports from participating laboratories in the south and east of the Mediterranean region have 
indicated that the incidence of antibiotic resistance appears to be significant, although pan-
regional studies are scarce (Borg et al., 2006).  Susceptibility testing of several bacterial species 
including E. coli, has been performed on isolates collected from clinical laboratories situated in 
Algeria, Cyprus, Egypt, Jordan, Lebanon, Malta, Morocco, Tunisia and Turkey (Borg et al., 
2006).  Preliminary data from this study found that the occurrence of penicillin resistance in 
Streptococcus pneumoniae ranged from 0% (Malta) to 36% (Algeria) whereas methicillin 
resistance in Staphylococcus aureus varied from 10% in Lebanon to 65% in Jordan.  Higher rates 
of resistance were generally reported for E. coli, with 72% of isolates from Egyptian hospitals 
reported to be resistant to 3
rd-
 generation cephalosporins and 40% of isolates resistant to 
fluoroquinolones in Turkey (Borg et al., 2006).  In contrast, lower frequencies of resistance were 
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found to vancomycin, a glycopeptide usually used to treat infections caused by Gram positive 
organisms.  These ranged from 0.9% of Enterococcus faecalis in Turkey to 3.8% in Cyprus 
(Borg et al., 2006).  Most experts in the field agree that the overuse of antimicrobials contributes 
to the emergence of antimicrobial resistance; most likely this occurs due to the selective pressure 
instigated by action of the antimicrobial.  Hence, the evolution of resistance represents an 
adaptive selection, which is to some extent, an inevitable result of the widespread use of 
antibiotics. 
1.6 β-lactamases 
1.6.1 Definition and classification schemes 
β-lactamases are a large group of genetically diverse enzymes that are capable of hydrolyzing the 
four-membered β-lactam ring present in the β-lactam-type antibiotics (Wiegand et al., 2007).  
These enzymes represent the most common mechanism of resistance found in Gram-negative 
bacilli including E. coli and Klebsiella spp., which are resistant to β-lactam antibiotics (Paterson 
et al., 2005; Bush et al., 2010).   
Two systems are used to categorize β-lactamases: the Ambler scheme and the Bush-Medeiros-
Jacoby system (Ambler, 1980; Bush et al., 1995).   
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           Figure 2.  Schematic representation of the Ambler and Bush classification scheme for β-lactamases.   
The enzymes are categorized into four main classes (A, B, C, D) and further subdivided into BSBLs (broad 
spectrum β-lactamases), ESBLs (extended spectrum β-lactamases), MBLs (Metallo β-lactamases), the AmpC-β-
lactamases and the OXA β-lactamases based on Ambler and Bush classification (Adapted from Bush et al., 2010). 
 
The Ambler classification (as shown in Figure 2) relies on amino acid sequence characteristics 
and divides the known β-lactamases into four main classes (class A, B, C and D).  Class A, C 
and D are serine β-lactamases because serine residues are present in the active site of the 
enzyme, whereas class B has zinc atoms and are collectively known as the metallo β-lactamases 
(Ambler, 1980; Bush et al., 1995; Bush et al., 2010).  In contrast, the Bush-Medeiros-Jacoby 
classification scheme uses the enzymes‘ substrate and inhibition profiles, to categorise the β-
lactamases into different groups and subgroups (Bush et al., 1995).  This ‗functional‘ 
classification scheme is of more relevance to the clinical setting because enzymes are grouped 
based on the different classes of antibiotics to which they are resistant (Bush et al., 2010).  With 
the advent of sequencing technology, it is now easier (and perhaps more informative in terms of 
mapping the evolution of resistance) to classify based on the sequence of the gene.  Nevertheless, 
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the schemes can be used side-by-side; for example, ESBLs belong to group 2be in the Bush-
Medeiros-Jacoby system and to class A in the Ambler system (Linscott et al., 2005; Goyal et al., 
2008).  An extensive discussion of the basis, merits and limitations of the two classification 
schemes is beyond the scope of this thesis and only a description of the AmpC (which belong to 
class C in the Ambler classification and group 1 in the Bush classification (Bush et al., 1995)) 
and ESBL groups of β-lactamases will follow. 
 
1.6.2 AmpC β-lactamase 
AmpC β-lactamases are chromosomally-determined or plasmid-mediated enzymes that show 
enhanced activity against cephalosporin and are thus considered as cephalosporinases (Jacoby, 
2009).  AmpC β-lactamases also confer resistance to aminopenicillins, cephamycins and 
monobactams (Peter-Getzlaff et al., 2011).  These enzymes are poorly inhibited by clavulanic 
acid and can be differentiated from ESBL-producing organisms by their ability to hydrolyze 
cephamycins (Khan et al., 2008).  A wide variety of bacterial species have been shown to 
harbour AmpC β-lactamases including E. coli, K. pneumoniae, Proteus mirabilis, and 
Enterobacter aerogenes (Khan et al., 2008).  Additionally there have been frequent reports of 
Enterobacteriaceae organisms harbouring both ESBLs and AmpC β-lactamases (Paterson et al., 
2005). 
1.6.3 Extended spectrum β-lactamases (ESBLs) 
The term ESBL, which stands for extended spectrum β-lactamase, designates a pattern of 
resistance to penicillins and cephalosporins, but not to carbapenems or cephamycins (Tenover et 
al., 2003).  Over 200 different ESBL enzymes have been discovered (Liu et al., 2008; Fernandes 
et al., 2014).  Although ESBLs are most commonly encountered in Klebsiella species and E. 
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coli, they have also been reported in other Gram-negative bacteria such as Salmonella, 
Enterobacter, Proteus species and Pseudomonas aeruginosa (Khan et al., 2008). 
Identifying organisms that harbour ESBLs is important in the diagnostic clinical microbiology 
laboratory because the mis-identification of ESBLs can result in a failure to treat infections 
(Manchanda et al., 2005; Wiegand et al., 2007).  Such errors may also hinder the implementation 
of suitable infection control measures and further contribute to the spread of ESBL-producing 
organisms throughout a population (Wiegand et al., 2007).  Within the context of this thesis, 
ESBLs of the type TEM, SHV, CTX-M, and OXA β-lactamases will be described further. 
1.6.3.1 TEM   
TEM-type ESBLs are so-named because they are derivatives of enzymes first detected in an E. 
coli isolate from a patient called Temoneira who lived in Athens, Greece (Datta et al., 1965; 
reviewed in Paterson et al., 2005; Lin et al., 2010).  In this original isolate, two β-lactamases 
were detected and named TEM-1 and TEM-2, respectively.  Both enzymes confer resistance to 
penicillin and narrow-spectrum cephalosporins, and are inhibited by clavulanic acid.  They are 
not considered as ESBLs because they lack activity against the broad-spectrum cephalosporins 
(Leverstein-van Hall et al., 2002).  TEM-1 is the most frequently encountered β-lactamases in 
Gram-negative bacteria.  For example, carriage of this enzyme accounts for up to 90% of 
ampicillin resistance in isolates of E. coli (Bradford, 2001).  It is thought that ESBL-type TEM 
enzymes emerged in the mid-1980s, following a two amino acid substitution which gave them 
enhanced activity against cefotaxime, a 3
rd-
 generation cephalosporin (Sougakoff et al., 1988).  
Many different TEM-type ESBL enzymes have now been reported and they are highly prevalent 
in both Klebsiella spp. and E. coli (Wollheim et al., 2011).   
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1.6.3.2 SHV (sulfhydryl variable)   
The SHV family of ESBLs appear to have arisen from the non-ESBL progenitor β-lactamase, 
SHV-1, in the early 1980s (Kliebe et al., 1985).  Compared to SHV-1, ESBLs in this family have 
amino acid changes around the serine active site, most usually at positions 238 and 240 
(Hammond et al., 2008).  These substitutions enlarge the enzyme‘s active site and allow 
hydrolysis of an extended range of substrates, thereby conferring resistance to the 3
rd-
 generation 
(oxyimino) cephalosporins (Huletsky et al., 1993).  In 2005, Paterson and Bonomo reported that 
the SHV-type ESBLs were more frequently found in clinical isolates than any other type of 
ESBL (Paterson et al., 2005).  This may now be superseded by the rapidly expanding distribution 
of the CTX-M enzyme type that has gained in prominence and spread worldwide (Livermore et 
al., 2007) (see below).  SHV-type ESBLs are still detected in Enterobacteriaceae and in 
Pseudomonas aeruginosa and Acinetobacter spp., and remain a significant part of ESBL clinical 
picture (Paterson et al., 2005).     
1.6.3.3 CTX-M & Toho   
In the early 1990s, a new family of ESBLs emerged, the CTX-M type enzymes. These were first 
described in Germany and South America (reviewed in Bonnet, 2004).  Unlike ESBLs belonging 
to the TEM and SHV families, the CTX-M family was thought to have arisen due to the plasmid-
borne acquisition of chromosomally-encoded β-lactamases from Kluyvera spp. (Poirel et al., 
2002).   
CTX β-lactamases are defined as such because they confer strong hydrolytic activity against 
cefotaxime (Paterson et al., 2005).  Organisms generating CTX-M-type β-lactamases usually 
hydrolyze cefotaxime, but can only have minimal effects on ceftazidime, another 3
rd-
 generation 
cephalosporin, due to an amino acid substitution (Poirel et al., 2001).  It is possible that the same 
organism may harbour several different β-lactamases types (for example both CTX-M-type and 
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SHV-type ESBLs), and this may significantly alter the antibiotic resistance phenotype of each 
isolate (Yan et al., 2000). 
CTX-M-type β-lactamases share around 40% amino acid identity with TEM and SHV-type 
ESBLs (Paterson et al., 2005).  Toho-1 and Toho-2 are β-lactamases that are structurally linked 
to the CTX-M-type β-lactamases and share similar hydrolytic activity against cefotaxime (Ma et 
al., 1998). 
For some years, CTX-M ESBLs were mostly commonly isolated in three areas: the Far East, 
South America, and Eastern Europe.  In recent years, a number of studies have reported the 
isolation of CTX-M-type ESBLs in Western Europe and North America (reviewed in Paterson et 
al., 2005).  The extensive distribution of CTX-M-type ESBLs in India and China makes CTX-
M-type ESBLs the most commonly detected ESBL type β-lactamase worldwide (Paterson et al., 
2005).  The CTX-M family has emerged worldwide both in the community and nosocomially 
(Jesusa et al., 2010).  Within this family, E. coli isolates producing CTX-M-15 type ESBLs have 
been detected primarily in urinary tract infections (Ruiz et al., 2011).   
1.6.3.4 OXA  
OXA-type β-lactamases are distinguished by their ability to hydrolyze cloxacillin and oxacillin at 
high levels (Bush et al., 1995).  They are primarily produced in P. aeruginosa, but can also be 
detected in many Gram-negative organisms such as E. coli (Livermore, 1995).   
In France, an enzyme of the OXA family called OXA-10 derivative (numbered OXA-28) was 
found in a P. aeruginosa isolate (Poirel et al., 2001).  OXA-10 β-lactamase hydrolyzes 
cefotaxime, ceftriaxone, and aztreonam, conferring a reduced susceptibility to these antibiotics 
(Paterson et al., 2005).  Moreover, OXA-1, the most common OXA-type β-lactamase, has been 
found in one to 10% of E. coli isolates (Livermore, 2005).  Other OXA ESBLs, such as OXA -
11, -14, -16, -17, -19, and -45, also exhibit resistance to these antibiotics (Toleman et al., 2003). 
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Other plasmid-mediated ESBLs, such as VEB, GES, PER, and IBC β-lactamases, have been 
reported but are uncommon (Bonnet, 2004).  A new subgroup of metallo β-lactamases, named 
NDM-1 (New Delhi Metallo-β-lactamase), has recently emerged (Berrazeg et al., 2014).  This 
metallo β-lactamase confers resistance to a broad range of β-lactam antibiotics except aztreonam 
(Yong et al., 2009).  NDM-1 producing organisms have been isolated from several infection sites 
and have been reported as nosocomial and as community acquired infection (Dortet et al., 2014).  
Therefore, it is believed that an urgent response is now needed in view of the worldwide 
emergence of this type of β-lactamase (Berrazeg et al., 2014). 
1.7 ESBL plasmids 
Plasmids are DNA molecules that can replicate independently of the chromosomal DNA.  
Moreover, some plasmids are termed ‗self-transmissible‘ because they harbour all the machinery 
(translocation apparatus) necessary for them to transfer between cells via conjugation.  ESBLs 
are usually located on large (80 Kb or more), conjugative plasmids that frequently carry 
resistance to several other antibiotics (Chaudhary et al., 2004).  The most common co-resistances 
in ESBL-producing isolates are to fluoroquinolones, tetracyclines, and aminoglycosides 
(Chaudhary et al., 2004; Rawat et al., 2010).   
The first report of plasmid-encoded β-lactamases having the ability to hydrolyze extended 
spectrum cephalosporins was in 1983 (Knothe et al., 1983).  It appears that the spread of ESBLs 
(and thereby antibiotic resistance) is mainly due to the horizontal transfer of plasmids between 
and within species (Kim et al., 2004; Sabra et al., 2009).  Analysis of 84 plasmids isolated 
between 1917 and 1954 prior to the extensive use of antibiotics indicates that nearly 80% are 
from the same incompatibility (Inc) type as those currently in circulation (Datta et al., 1983).  
Thus, it is the insertion of resistance genes into these plasmids rather than the emergence of 
previously rare plasmid types that is behind the spread of resistance.  As well as plasmids 
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playing a role in the spread of resistance, it is also likely that other mobile genetic elements such 
as transposons, insertion sequences and integrons, contribute to the spread of genes within 
plasmids (Chong et al., 2011).  Insertion sequences surround all CTX-M genes and are probably 
a remnant of the chromosomal origin of these resistance genes.  Thus, the same ESBL can be 
carried by different plasmid types (Bradford et al., 1994) and equally that cells of the same 
species may or may not harbour resistant plasmids (Chaudhary et al., 2004). 
Finally, several Gram negative species also have natural ESBL genes encoded on their 
chromosome such as Proteus vulgaris or Erwinia persicina (Naas et al., 2008).  These organisms 
might produce low-level expression of the resistance phenotype due to a single β-lactamase gene 
copy (Vimont et al., 2002).  These isolates might constitute potential threats since they are 
usually resistant to amino-penicillins, variably resistant to carboxy-penicillins, 1
st-
 and 2
nd-
 
generation cephalosporins, but susceptible to 3
rd-
 generation cephalosporins (Naas et al., 2008).      
1.8 Epidemiology of ESBL-producing isolates 
ESBL-producing bacteria have become globally ubiquitous (Paterson et al., 2005; Hunter et al., 
2010; Kumar et al., 2014).  Their prevalence and worldwide distribution varies, and a review of 
their epidemiology is useful to help understand their spread. 
1.8.1 Emergence and global spread of ESBLs 
ESBL-producing organisms were first detected in Europe in 1983 (Knothe et al., 1983; Coque et 
al., 2008).  Even though the first reports were from Germany and England, the bulk of reports 
after the detection of ESBLs were from France where the first large outbreak of ESBL-producing 
isolates occurred in 1986 (Brun-Buisson et al., 1987).  The proliferation of ESBLs in France was 
remarkable as by the the early 1990s, 25 to 35% of nosocomial infections caused by K. 
pneumoniae in France produced ESBLs (Marty et al., 1998).   
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ESBL-producing organisms have been reported in most European country and resistance due to 
ESBL-production represents a major threat (reviewed in Canton et al., 2008).  TEM and SHV 
enzymes were first described in K. pneumoniae during the 1980s, mainly in Europe (Winokur et 
al., 2001; reviewed in Canton et al., 2008).  ESBLs are being detected in E. coli, with an 
increasing incidence of CTX-M enzymes (Woodford et al., 2004; Canton et al., 2008).   
A study undertaken in a Swedish hospital during the period stretching between 2001 and 2006 
demonstrated that out of the 87 ESBL positive isolates, 80 encoded CTX-M type ESBL (Fang et 
al., 2008).  More than half of the ESBL isolates also harboured TEM type and OXA type β-
lactamases, but only a few isolates were found to harbour SHV type β-lactamase (Fang et al., 
2008).  ESBL-producing organisms could be isolated from any site of infection.  According to 
Fang et al. among the 87 ESBL isolates of E. coli, 68 were isolated from urine, 13 from wounds, 
four from blood, and one from sputum (Fang et al., 2008).  In addition, the recovery of ESBL-
producing K. pneumoniae from the urine, respiratory tract, blood, wound, catheter, rectal swab 
and bile of patients increased significantly between 1989-2000 and 2001-2004 in Spain 
(Valverde et al., 2008).   
In 2003, the Norwegian surveillance system for antimicrobial resistance reported ESBL-
production in less than 1% of clinical isolates of K. pneumoniae and E. coli (Tofteland et al., 
2007).  CTX-M was found to be the most widespread ESBL type in Norwegian E. coli isolates 
(Tofteland et al., 2007).  This result is consistent with the emergence of CTX-M producing E. 
coli isolates worldwide (Boyd et al., 2004).  In contrast, SHV-5-like enzymes were found to be 
the most common (79%) ESBL types among Norwegian clinical K. pneumoniae isolates 
indicating a species-specific difference in the types of ESBLs carried (Tofteland et al., 2007).   
In the USA, the first report of ESBL-producing organisms was in 1988, when infections with 
TEM 10 producing K. pneumoniae were reported in Chicago (Jacoby et al., 1988; Quinn et al., 
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1989).  Additionally, other reports of outbreaks showed infections with TEM and SHV-type 
ESBLs (Meyer et al., 1993; Jacoby, 1997).  CTX-M-type ESBLs have emerged subsequently in 
the USA and Canada (Smith Moland et al., 2003; Boyd et al., 2004).   
In China in 1988, SHV-2 was reported in isolates of K. pneumoniae (Jacoby et al., 1988).  
National studies identified the presence of ESBLs in five to eight% of E. coli isolates from 
Korea, Singapore, Japan, and Malaysia, but in 12 to 24% of isolates in Thailand, Philippines, 
Taiwan, and Indonesia (Lewis et al., 1999; Yamasaki et al., 2003).  The rates of ESBL-
producing K. pneumoniae were 5% in Japan and much higher (20 to 50%) elsewhere in Asia 
(Lewis et al., 1999; Yamasaki et al., 2003).  Even though SHV-type ESBLs have been reported 
in Japan and Taiwan, the presence of CTX-M ESBLs in China and India, in addition to more 
frequent reports on CTX-M-type ESBLs in Korea, Japan, and Taiwan, negates doubts that the 
CTX-M ESBLs are indeed the dominant ESBL types in Asia (Chang et al., 2001; Karim et al., 
2001; reviewed in Paterson et al., 2005; Wang et al., 2013). 
In Thailand, Kiratisin et al. (Kiratisin et al., 2008) found that CTX-M, mainly CTX-M-14, CTX-
M -15, and CTX-M-55, was highly widespread.  Most ESBL-producing isolates found in this 
study were sporadic and consisted of multiple clones, and only a small number of isolates 
showed clonal relationships (as defined by a similarity >80%).  A review of the medical records 
proposed that these isolates did not significantly share occurrence periods and patient 
demographics (Kiratisin et al., 2008).  This study also reported the detection of SHV-27-, -71-, 
and -75-producing isolates for the first time in Thailand (Kiratisin et al., 2008). 
A number of studies have reported infections with ESBL-producing Klebsiella isolates in South 
Africa (Karas et al., 1996; Cotton et al., 2000).  In one report, 36% of K. pneumoniae isolates 
collected in South Africa between 1998 and 1999 were shown to be ESBL-producers (Bell et al., 
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2002).  The majority of these ESBLs were SHV and TEM types (Hanson et al., 2001; reviewed 
in Paterson et al., 2005). 
Overall, the percentages of ESBLs found in Europe are higher than those in the USA, but lower 
than those reported for Asia and South America (Winokur et al., 2001; Canton et al., 2008).  
Furthermore, the increase in ESBL-producing isolates was found to be mainly due to various 
plasmid-encoded genes and the spread and proliferation of specific clones (Canton et al., 2008).         
1.8.2 Epidemiology of ESBLs in Lebanon 
Lebanon is currently witnessing an increase in the number of bacterial infections that are 
associated with a wide spectrum of resistance to common antibiotics (Moubareck et al., 2005).  
In 1997, the percentage of ESBL-producing E. coli and K. pneumoniae was 1.3% and 7.5%, 
respectively as compared to non-ESBL-producing isolates of the same species.  By 2001 the 
percentage of ESBL-producing E. coli and K. pneumoniae was 4% and 24%, respectively 
(Daoud et al., 2003; Moubareck et al., 2005).  Recent data show that the percentage of ESBL-
producing E. coli and K. pneumoniae has now reached 30% and 32%, respectively (Hamouche et 
al., 2012; reviewed in Moghnieh et al., 2014).  ESBL-producing organisms have now been 
reported in hospitals as well as in the community (Moubareck et al., 2005). 
Data on the type and extent of antimicrobial resistance found in the Middle East is limited.  A 
prospective multicenter surveillance study that collected fecal samples from both patients and 
healthy volunteers found that the percentage of ESBL-producing E. coli isolates recovered was 
higher than that of ESBL-producing K. pneumoniae, Enterobacter cloacae, and Citrobacter 
freundii organisms (Moubareck et al., 2005).  Further molecular analysis of the isolates revealed 
that CTX-M-15 was the most prevalent ESBL type since it was present in 83% of the resistant 
isolates.  The CTX-M-15 β-lactamase was not only detected in E. coli and K. pneumoniae, but 
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also in E. cloacae.  SHV-5a but not TEM-type ESBLs, were detected in the remaining isolates 
(see Table 1; Moubareck et al., 2005). 
Table1: Number and types of ESBL-producing Enterobacteriaceae obtained from tertiary care hospitals in 
Lebanon.  Isolates were obtained from five different hospitals and analysed for species and sub-type of ESBL 
present.  (Adapted from Moubareck et al., 2005). 
 
Species No. of isolates ESBL type(s) 
E. coli 51 CTX-M-15 
E. coli 7 SHV-5a 
E. coli 1 CTX-M-15, SHV-5a 
K. pneumoniae 4 CTX-M-15 
K. pneumoniae 4 SHV-5a 
E. cloacae 4 CTX-M-15 
C. freundii 1 SHV-5a 
 
Many outbreaks caused by ESBLs in hospitals have been reported during the previous decade; 
most of which carried derivatives of TEM-1, TEM-2, or SHV-1 type enzymes (Daoud et al., 
2008).  Even though in the previous study (Moubareck et al., 2005) E. coli was the most 
commonly found resistant isolate, a recent study by Daoud et al. (Daoud et al., 2008), showed 
that K. pneumoniae was the species most commonly associated with nosocomial infections.  As 
found for E. coli, molecular analysis revealed that the CTX-M-15 gene was the most frequently 
isolated ESBL-type (Daoud et al., 2008). 
Harajly and colleagues collected 53 isolates of E. coli, K. pneumoniae, and Shigella sonnei from 
a tertiary care center in Lebanon (Harajly et al., 2010).  All these isolates were found to be 
resistant to 3
rd-
 generation cephalosporins and 96% of ESBL-producing E. coli and K. 
pneumoniae were found to carry a plasmid-borne copy of the blaCTX-M-15 gene (Harajly et al., 
2010).  This study also demonstrated the prevalence of ESBL-producing organisms and supports 
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the conclusion that isolates harbouring an ESBL plasmid that carries the blaCTX-M-15 gene were 
circulating in the center. 
The frequency of blaCTX-M, blaSHV and blaTEM genes among ESBL-producing organisms in a 
Lebanese hospital was found to be 96%, 67% and 57% in E. coli, and 40%, 84% and 82% in 
Klebsiella spp., respectively (Kanj et al., 2008).  The majority (96.1%) of E. coli harboured the 
blaCTX-M gene, but the blaSHV (84.1%) gene was the most commonly found in Klebsiella spp. 
(Kanj et al., 2008).  These data were consistent with the studies conducted by Moubareck et al. 
and Hammond et al. who showed that most of the E. coli isolates harboured the blaCTX-M gene 
(Moubareck et al., 2005), while the majority of Klebsiella pneumoniae isolates harboured the 
blaSHV gene (Hammond et al., 2008).   
The emergence of ESBL-producing isolates has also been reported for Shigella species 
(Levesque et al., 1995; Sabra et al., 2009).  In a recent study to determine antimicrobial 
resistance in S. sonnei, sixty isolates were collected from stool samples taken from patients 
admitted to a tertiary care center in Beirut, Lebanon.  Eleven of the 60 isolates were selected for 
further analysis, specifically six randomly selected β-lactam susceptible isolates (as controls) and 
the five β-lactam resistant isolates.  Of these, further analyses revealed that four S. sonnei isolates 
were ESBL-producers and all contained the blaCTX-M-15 subtype (Sabra et al., 2009), once again 
confirming the prevalence of this gene. 
Overall, these studies support the observation that the prevalence of ESBL-producing species in 
Lebanon is increasing and that the most common ESBL type detected is CTX-M-15.  It is likely 
that the use and mis-use of antibiotics, has driven the emergence and spread of resistant 
organisms in this country (Kanafani et al., 2005).   
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1.8.3 Animals as a reservoir for ESBLs 
Food animals are significant reservoirs of infectious microorganisms (Threlfall, 2002).  As an 
example, cattle are recognised as an important reservoir of E. coli O157:H7, a group of 
organisms which can cause infections in humans following the consumption of contaminated 
ground beef (Martin et al., 1986; La Ragione et al., 2005; La Ragione et al., 2008).  ESBL-
producing Enterobacteriaceae have also been found in animals (Mesa et al., 2006; Smet et al., 
2008; Horton et al., 2011).  In one study, ESBL-producing isolates were collected from floor 
samples of faecal material from all 10 poultry farms, eight of the 10 pig farms, and two of 10 
rabbit farms (Mesa et al., 2006).  A total of 51 E. coli were identified on the poultry farms as 
ESBL-producers, 39 E. coli on pig farms, and two E. coli and one Enterobacter cloacae on 
rabbit farms (Mesa et al., 2006).  It has been demonstrated that the use of antibiotics such as 
penicillin in animal chow, increases the number of resistant organisms inside the animal bowel 
(Chinedum, 2005).  The presence of such organisms seems to increase the proportion of resistant 
pathogens in man (Chinedum, 2005).  Some resistant bacterial isolates can be transmitted from 
animals to humans via direct contact (Chinedum, 2005; Graveland et al., 2011).  In order to 
decrease the selection of multidrug resistant microorganisms, caution must be taken when using 
antibiotics in farm animals (Threlfall, 2002; Umeh et al., 2014).   
1.9 Detection of ESBLs 
Due to the emergence of antibiotic resistance in Enterobacteriaceae throughout the world, 
numerous detection strategies for the presence of ESBLs have been developed (Taneja et al., 
2008).  These can be divided into phenotypic methods (such as the disk diffusion method, the 
double disk synergy test, E-test strips, the Vitek 2 system, and the MicroScan Walk Away-96 
System) and molecular methods (such as DNA, PCR, and sequencing) (Spanu et al., 2006; Goyal 
et al., 2008; Taneja et al., 2008).  In-depth studies comparing the different methods have shown 
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inconsistent results with respect to their sensitivity and specificity (Spanu et al., 2006; Anderson 
et al., 2007; Goyal et al., 2008; Taneja et al., 2008).  Hereafter follows a brief overview of the 
main methods to detect ESBL-producing bacteria. 
1.9.1 Phenotypic methods 
The double disk synergy test is a simple method used to detect ESBL-production (Spanu et al., 
2002).  In this method, disks containing 30µg of aztreonam, 30µg of cefotaxime, 30µg of 
ceftazidime, 30µg of ceftriaxone, and 30µg of cefepime are placed around a disk containing 
amoxicillin (20µg) plus clavulanic acid (10µg) (Spanu et al., 2002; Drieux et al., 2008; CLSI 
guidelines, 2010).  Isolates are considered positive by the demonstration of synergy, referred to 
as the ‗keyhole‘ effect, between 3rd- or 4th- generation cephalosporin disks and amoxicillin 
clavulanic acid disk (CLSI guidelines, 2010).  ESBL phenotypes can also be determined by using 
E-test ESBL strips, a plastic drug-impregnated strip, in which a stable concentration gradient of 
cefepime is produced at one end and a stable gradient of cefepime plus clavulanic acid is 
generated at the other end (Sturenburg et al., 2004; Lee et al., 2010).  A reduction in cefepime 
MIC by at least 3 two-fold dilutions with clavulanic acid or presence of a phantom inhibition 
zone is indicative for ESBL-production (Sturenburg et al., 2004; Lee et al., 2010).  The Vitek 
method is a fast and semi-automated method for antimicrobial susceptibility testing and 
microbial identification that can be used to detect ESBLs in Enterobacteriaceae (Sanders et al., 
1996; Paterson et al., 2005; Taneja et al., 2008). 
According to Sanders et al. (Sanders et al., 1996), ESBL-production in E. coli and K. 
pneumoniae detected by the Vitek method showed 99.5% sensitivity and 100% specificity 
(Sanders et al., 1996).  The sensitivity and specificity of the E-test method ranged from 87-100% 
and 95-100%, respectively, with the double disk test giving 79-97% sensitivity and 94-100% 
specificity, respectively (Rawat et al., 2010).  In a study by Leverstein-van Hall et al. 
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(Leverstein-van Hall et al., 2002), 74 isolates of E. coli and Klebsiella spp. were tested for the 
production of ESBLs using the E-test, VITEK 1 (an older version of VITEK) and VITEK 2 
(updated VITEK) automated systems.  The sensitivity of the E-test was 100% while that of 
VITEK 1 and VITEK 2 automated systems was 78% and 100%, respectively (Leverstein-van 
Hall et al., 2002).  In another study, the E-test method was found to be the only method that 
showed 100% sensitivity and specificity for the detection of 55 isolates of K. pneumoniae 
(Mendonça et al., 2006).  In conclusion, the E-test method is regarded as a sensitive and specific 
phenotypic test that can be used for screening and verification of ESBL production (Leverstein-
van Hall et al., 2002; Spanu et al., 2002; Dashti et al., 2006).  Thus, this is considered the gold 
standard method in the field for the detection of ESBL-producing isolates (Marra et al., 2006).   
The performance of Brilliance ESBL agar, a novel chromogenic agar for the identification of 
extended spectrum β-lactamase producing Enterobacteriaceae, was evaluated in another study 
(Huang et al., 2010).  The sensitivity and specificity of this test was found to be 94.9% and 
95.7%, respectively, suggesting that this medium can act as an excellent screening tool for the 
quick exclusion of patients that do not harbour ESBL-producing isolates (Huang et al., 2010). 
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Table 2: Sensitivity and specificity of different phenotypic methods for the detection of ESBL-production in 
Enterobacteriaceae (Adapted from Drieux et al., 2008). 
 
Species studied 
 
Method  
 
Sensitivity (%) 
  
Specificity (%) 
 
All species (n = 144) 
Phoenix 98.8 52.2 
VITEK 2 85.9 78 
MicroScan 83.5 72.9 
DDST 94.1 81.4 
CDM 92.9 96.6 
ESBL Etests 94.1 84.7 
Escherichia coli, Klebsiella spp. (n = 104) 
Phoenix 100 51.5 
VITEK 2 84.5 93.9 
MicroScan 98.6 51.5 
DDST 94.4 72.7 
CDM 94.4 97 
ESBL Etests 98.6 72.7 
Enterobacter, Citrobacter and Serratia spp. (n = 28) 
Phoenix 90 33.3 
VITEK 2 100 38.9 
MicroScan 0 ND 
DDST 90 100 
CDM 80 100 
ESBL Etests 60 100 
DDST, double-disk synergy test; CDM, combination disk method; ND, not determined 
While the Vitek 2 method was effective, the standard disk diffusion tests are still the 
recommended tests for the detection of ESBL (Drieux et al., 2008; CLSI guidelines, 2010).  For 
confirmation purposes, it is best to combine the standard disk diffusion method with one of the 
other methods previously listed such as E-test ESBL.  This is because of the less than 100% 
sensitivity and specificity of each test (see Table 2).  Ultimately, the choice of the test method 
depends on the preferences and requirements of the tester and the availability of the testing 
material. 
1.9.2 Molecular methods for detection of ESBLs 
Polymerase chain reaction (PCR) is a molecular method that can be used to detect the presence 
or absence of individual genes (Garibyan et al., 2013).  It is based on the amplification of gene-
specific DNA sequences using specific primers to produce thousands to millions of copies of the 
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target sequence so that it can be readily detected by gel electrophoresis (Garibyan et al., 2013).  
PCR provides a plus/minus answer and is currently the most commonly used technique for the 
detection of different types of ESBL genes (Naas et al., 2010).  Quantitative real-time PCR 
(qRT-PCR) has the advantage of quantifying the synthesized product, and thus provides a higher 
throughput and more rapid method with which to assess gene content (Garibyan et al., 2013).  
However, PCR techniques cannot be used to determine whether a gene is functional or not, and 
in order to design primers, prior sequence data is required (Garibyan et al., 2013).  This method 
has demonstrated 100% sensitivity and specificity for the detection of all the different groups of 
known β-lactamases in ESBL-producing isolates (Pitout et al., 2004).   
Finally, pulsed-field gel electrophoresis (PFGE) is a method used for molecular typing of 
bacterial species (Durmaz et al., 2009).  Following digestion of DNA with a restriction enzyme, 
different sized DNA fragments are separated using an electric field that changes direction to a 
gel matrix (Schwartz et al., 1984; Durmaz et al., 2009).  When applied to provide rapid 
identification of multidrug resistant isolates of Salmonella spp., this method showed 98% 
sensitivity and 89% specificity (Fontana et al., 2003). 
1.10 Treatment options effective against ESBL-producing organisms 
Given the now widespread emergence of resistance to 3
rd-
 and 4
th-
 generation cephalosporins, 
alternatives to treat resistant bacteria are urgently needed.  Within the β-lactam antibiotic arsenal, 
carbapenems possess the broadest spectrum of activity and offer the most potency against Gram 
positive and Gram negative organisms (Edwards et al., 2000; Kanj et al., 2011).  In this class, 
meropenem and imipenem have been shown to be highly effective in the treatment of 
nosocomial infections (Nicolau, 2008).  Resistance to carbapenems is also becoming a major 
global problem (Castanheira et al., 2011).  Alternatives to carbapenems include tigecycline, a 
tetracycline analogue (member of glycylcycline) and fosfomycin, a broad spectrum antibiotic, 
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both of which are active against ESBL-producing E. coli and K. pneumoniae isolates (Petersen et 
al., 2006; Falagas et al., 2010; Kanj et al., 2011).  With so few new antibiotics being currently 
developed and with the on-going spread of resistant bacteria, the need for effective antibiotic 
stewardship programs has never been more important.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57 
 
1.11 Aims and objectives, and testable hypotheses. 
Testable hypotheses – 
 Do antimicrobial resistant isolates emerge from a common progenitor isolate? 
 Does carriage of antimicrobial resistance plasmids affect the fitness of the host 
bacterium? 
 Does antibiotic consumption correlate with the susceptibility of bacteria to different 
antibiotics? 
The aims of this study were to characterise the genetic and phenotypic properties of ESBL-
producing Escherichia coli and Klebsiella pneumoniae isolated from a hospital in Lebanon.  
Furthermore, to assess the fitness of isolates harbouring different sub-types of ESBLs in order to 
better understand the influence of the plasmid on the host bacterium.  Finally, to examine the 
correlation between hospital antibiotic consumption data and antimicrobial susceptibility profiles 
obtained over a three year period. This was achieved by: 
(1) Determining the antibiotic resistance profiles of E. coli and K. pneumoniae isolates 
obtained from a major Lebanese hospital in order to accurately describe resistance 
patterns.   
(2) Comparing the virulence gene content and genetic background of resistant isolates in 
order to ascertain the clonality of the isolates.   
(3) Examining the plasmid profile of selected isolates and where possible, comparing the 
sequence of the ESBL plasmids with those present in the GenBank database.   
(4) Assessing the transmissibility and fitness ‗cost‘ of ESBL plasmids harbouring 
different numbers and types of ESBL enzymes in order to ascertain their burden on 
the host bacterium. 
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(5) Calculating antibiotic consumption rates in the study hospital and performing 
correlation analysis to assess the relationship with bacterial susceptibility to different 
antibiotics.   
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Study background 
Clinical isolates that grew on MacConkey agar and exhibited resistance to at least one 3
rd-
 or 4
th-
 
generation cephalosporin (such as cefotaxime (30µg), ceftazidime (30µg), or cefepime (30µg)) 
were kindly provided to the author by the laboratory department of the Centre Hospitalier Du 
Nord (CHN), Lebanon.  Isolates were gathered between mid-2011 to the end of 2012.  In total, a 
panel of 140 presumptive ESBL-producing isolates was assembled for further study.  All isolates 
included were verified for species (see section 2.2.2) and ESBL production (see section 2.3.1).  
Specimens isolated from the same patient, same site of infection, and having the same 
antimicrobial susceptibility profile collected within a one year period were considered as 
duplicates and, therefore, excluded from the study. 
Antibiotic consumption data were collected from the hospital over the three years: 2010, 2011 
and 2012.  Confidentiality of patient data was respected by using a unique code number for each 
sample.  There was no harm or risk to humans because all tests were performed on bacterial 
isolates in vitro.  Ethical approval for this study was obtained from the University of Surrey and 
the University of Balamand. 
 
2.2 Characterisation of ESBL-producing clinical isolates 
2.2.1 Bacteria and media preparation 
The following media were routinely used: MacConkey media, Nutrient media, Luria Bertani 
media, Mannitol motility media, and Mueller-Hinton media (Oxoid
®
).  All media was prepared 
according to the manufacturer‘s instructions and autoclaved at 121°C for 15 minutes as required.  
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Where necessary, media was supplemented with 1.5% agar to solidify the media and cefotaxime 
(1µg/ml) was added to maintain selection of ESBL plasmids.  Prior to use, the sterility of batches 
of media was checked by incubating test agar plates or liquid media at 37°C, aerobically for 24 h 
and assessing for visible contamination. 
For routine culture, isolates were propagated on solidified media and incubated aerobically for 
16 h at 37°C.  Liquid cultures were prepared by transferring 1-2 colonies of each bacterial isolate 
from the agar plate into 5mL broth and incubating aerobically for 16 h with shaking (225rpm) at 
37°C.  For long-term storage, bacteria were maintained at -80 °C in LB supplemented with 60% 
glycerol.  These stock cultures were prepared by mixing 1200µL of an overnight (16 hr) LB 
broth culture with 400µL of a 60% glycerol solution in a Cryo vial. 
 
2.2.2 Identification of ESBL-producing species 
The API20E system (BioMerieux™, USA), a commercial kit designed for the identification of 
Enterobacteriaceae and other non-fastidious Gram negative bacteria, was used to identify the 
clinical isolates.  The test strips consist of twenty mini-test tubes that enable species 
identification to be made on the basis of the test organism‘s ability to perform a series of 
biochemical reactions.  The test wells contained O-nitrophenyl- β-D-galactosidase (ONPG); 
arginine dihydrolase; lysine and ornithine decarboxylase; citrate utilisation; hydrogen sulfide; 
urease; tryptophan deaminase; indole; Voges-Proskauer (acetoin); gelatin liquefaction; 
fermentation of the carbohydrates glucose, mannitol, inositol, sorbitol, rhamnose, sucrose, 
melibiose, amygdalin, and arabinose, respectively.  Bacterial suspensions were prepared by 
resuspending 2-3 colonies in 5mL of saline solution.  For each isolate, the bacterial suspension 
was added to every well on the API20E test strip and the strip incubated aerobically for 24 h at 
37°C.  After 24 hr, the colour reactions were read using the computerized APIweb™ software 
(Biomérieux) and the species of the test isolate ascertained. 
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Figure 3: API 20E test strip used for the identification of Enterobacteriaceae.  Each strip consists of 20 
miniaturised biochemical tests into which suspensions of test bacteria are placed.  The strip is then incubated 
aerobically for 24 h at 37°C.  Changes in colour which are indicative of enzymatic activity and enable species 
identification were compared to the database using the APIweb™ software (Biomérieux, USA).   
 
2.2.3 Bacterial growth experiments  
The growth characteristics of each bacterial isolate were determined in order to assess the 
relative fitness of the isolates.  To prepare the starting culture, bacterial isolates were cultured on 
LB agar for 16 h at 37°C and 1-2 colonies transferred aseptically into 5mL LB broth and 
incubated with shaking (225rpm) for 16 h at 37°C.  After incubation, a 100-fold dilution was 
made by mixing 10µl of culture with 990µl LB broth.  A further 10-fold dilution was prepared 
by then mixing 20µl of the diluted culture to 180µl of pre-warmed LB broth contained in the 
well of a 96-well plate.  The starting cell density was approximately 1 x 10
6
 CFU/ml.  The 96-
well plate was then incubated at 37°C with agitation (225 rpm) and the absorbance of each well 
read every h (for 9 hr) using a 96-well plate reader set to measure at an optical density (OD)630nm.  
Each isolate was grown in triplicate in two independent experiments.    
In order to calculate the generation time of isolates, isolates were grown under similar 
conditions, but in a larger volume of media (100mL) and the number of viable bacteria 
determined at each time point.  Viable counts were not performed on the cultures grown in the 
96-well plates because repeated sampling from the well resulted in less than 50% of the starting 
volume being left at the end of the sampling period.  It was thought that this affected the growth 
of the bacteria and also gave rise to more variable results.  Thus, bacterial isolates were grown on 
LB agar and then 1-2 colonies sub-cultured in LB broth for 16 h at 37°C with gentle agitation 
(225 rpm).  Following incubation, 100µl of the liquid culture was inoculated into 100ml of pre-
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warmed LB broth in a 250mL flask giving an equivalent starting density of approximately 1 x 
10
6
 CFU/mL.  The cultures were then placed on a shaking incubator (225rpm) and incubated at 
37°C, aerobically for 9 hrs.  At hourly intervals, samples were aseptically removed, serially 
diluted (10-fold) in PBS, and triplicate 10µl aliquots of each dilution spotted onto LB agar plates.  
Following incubation of the plates for 16 h at 37°C, aerobically, the resulting colonies were 
enumerated using a colony counter.  Each isolate was tested in triplicate.  Generation time was 
determined as follows:   
         k= log A-log B      generation time= 1 x 60 minutes 
                       0.301 x t    k 
k is the growth rate and t is the time interval between 2 points (Arbitrarily calculated between 2 and 4 h of growth).   
 
2.2.4 Metabolic profiling of ESBL-producing isolates using Biolog™ phenotypic microarrays 
Biolog™ was used to test the capability of each isolate to utilise a range of different carbon 
compounds as substrates.  This technology is based on the use of a tetrazolium dye which is 
oxidized (solution turns purple) in response to bacterial metabolic activity (Gorden et al., 1993).  
Experiments were performed according to the manufacturer‘s instructions.  Test bacteria were 
grown on LB agar plates for 16 h at 37°C, aerobically.  After incubation, several colonies were 
collected using a cotton swab and suspended in 15ml sterile water until the cell density equaled 
42% transmittance on a Biolog™ turbidimeter.  2ml of the suspension were then transferred to 
10ml inoculating fluid (IF-0) and 120µl dye A was added.  An aliquot of 100µl was used to 
inoculate each well of the 96-well plates.  Plates were then incubated in an OmniLog plate reader 
for 48 h at 37°C and the absorbance of each well read every 15 minutes.  Following incubation, 
utilisation of a carbon source was signified by the development of a purple colour and this 
pattern across the plate constituted the ―Metabolic Fingerprint‖ for each test organism.  The 
results were exported using OmniLog PM Software, and for each isolate, duplicate biological 
repeats were performed. 
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2.2.5 Motility test and mannitol utilisation assay  
In order to determine if the clinical isolates were motile, the mannitol motility test was 
performed.  Bacterial colonies grown on LB agar plates for 16 h at 37°C were transferred 
aseptically using an inoculating needle, into a test-tube containing mannitol motility medium.  
The cultures were stabbed into the media such that following aerobic incubation for 16 h at 
37°C, motile bacteria could be detected based on their diffuse growth outward from the 
inoculation line.  Conversely non-motile bacteria would grow along the line of the inoculation 
needle.  This assay also allowed assessment of the ability of the bacteria to utilise mannitol, a 
carbon substrate also present in the Biolog™ plate.  Bacteria that are able to ferment mannitol 
produce a red to yellow colour change in the media.  Tests were performed in duplicate. 
 
2.3 Phenotypic and genotypic methods for detection of β-lactamases 
2.3.1 Double Disk Synergy method 
The double disk synergy is recommended by the Clinical and Laboratory Standards Institute 
(CLSI) for the identification of ESBL-producing organisms (Drieux et al., 2008; Huang et al., 
2010; Rawat et al., 2010).  This test uses disks containing multiple ESBL antibiotics to facilitate 
the detection of different types of ESBLs (CLSI guidelines, 2010). 
A lawn culture of a 0.5 McFarland‘s suspension of test bacteria was inoculated onto Mueller-
Hinton agar plates and disks containing cefoxitin (30µg), cefotaxime (30µg), ceftazidime (30µg), 
cefpodoxime (10µg), cefepime (30µg) or aztreonam (30µg) placed on the agar surface at a 
distance of 25mm (center to center) from a centrally-located amoxicillin/clavulanic acid disk.  
The plates were then incubated for 16 h at 37°C, aerobically.  According to the CLSI guidelines 
(CLSI guidelines, 2010), isolates were considered ESBL-producers when the zone of inhibition 
around any of the extended spectrum cephalosporin disks show a visible expansion towards the 
centrally located antibiotic disk that contains amoxicillin/clavulanic acid (keyhole effect) (Jarlier 
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et al., 1988; Khan et al., 2008).  Resistance to 3
rd-
 generation cephalosporins accompanied by 
susceptibility to cefoxitin was considered indicative for ESBL-production whereas resistance to 
cefoxitin was considered indicative of chromosomal AmpC production (Peter-Getzlaff et al., 
2011).   
Table 3: Size of inhibition zones used in the double disk diffusion assay, to determine susceptibility or 
resistance in E. coli or K. pneumoniae to extended spectrum cephalosporins (Adapted from CLSI (CLSI 
guidelines, 2010)). 
 
Antibiotics and  
amount 
Susceptible  
( ≥ mm) 
Intermediate  
(mm) 
Resistant  
(≤ mm) 
Ceftazidime 30µg 21 18-20 17 
Cefotaxime 30µg 26 23-25 22 
Cefpodoxime 10µg 21 18-20 17 
Cefepime 30µg 18 15-17 14 
Cefoxitin 30µg 18 15-17 14 
Aztreonam 30µg 21 18-20 17 
 
2.3.2 E-test for ESBL production 
The E-test was performed on all presumptive ESBL-producing organisms as a phenotypic 
confirmatory test for ESBL production.  E-test strips were obtained from BioMerieux
®
 and 
consist of a plastic strip with a gradient concentration of ceftazidime at one end and ceftazidime 
plus clavulanic acid at the other.  The strips were placed on a Mueller-Hinton agar plate 
previously spread with a 0.5 McFarland‘s suspension of the test organism.  The plates were then 
incubated for 16 h at 37°C, aerobically.   
ESBL-production was considered positive if the ratio of the minimum inhibitory concentration 
(MIC) of ceftazidime to the MIC of ceftazidime plus clavulanic acid was ≥8 (Sanguinetti et al., 
2003).  The presence of a phantom zone (rounded zone) or a deformation around the ceftazidime 
strip was directly indicative of ESBL activity (Sturenburg et al., 2004; Linscott et al., 2005).  A 
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result was considered indeterminate if the MICs needed for the bacteria were outside the test 
range of concentrations shown on the E-test ESBL strip (Linscott et al., 2005).    
 
2.3.3 Detection of plasmidic AmpC production by phenylboronic acid disk method  
All clinical isolates were tested for the production of plasmidic AmpC β-lactamases using the 
phenylboronic acid disk method (Song et al., 2006; Tan et al., 2009).  A lawn culture of a 0.5 
McFarland‘s suspension was inoculated onto Mueller-Hinton agar plates.  Two cefoxitin disks 
were positioned at opposite sides of the agar plate and to one of the disks, 10µL of 
phenylboronic acid solution (400µg) was added.  The plates were left to dry for approximately 
15 minutes before being inverted and incubated for 16 h at 37°C, aerobically.  Following 
incubation, an increase of ≥5 mm in zone diameter around the cefoxitin disk containing 
phenylboronic acid versus that seen around the cefoxitin disk alone was considered positive for 
plasmidic AmpC production (Song et al., 2006).   
 
2.3.4 Determination of ESBL type using multiplex PCR  
Multiplex PCR was performed in order to identify the type(s) of ESBLs present in the clinical 
isolates.  Bacterial DNA was prepared by resuspending 1-2 colonies of each test isolate in 200µl 
dH2O and heating the solution at 95˚C for 10 mins.  The presence of blaCTX-M, blaSHV, blaTEM and 
blaOXA genes were tested for using previously published primer sets and conditions (Fang et al., 
2008).  The primer sequences and the expected amplicon size for each gene are listed in Table 4.  
Each reaction tube contained 10µl of Master mix (Qiagen), 4µl of primers, 1µl of DNA and was 
made up to 20µl total volume with sterile H2O.  The PCR reaction conditions consisted of a 15 
min denaturation step at 95˚C, followed by 30 amplification cycles of 30s at 94˚C, 90s at 62˚C 
and 60s at 72˚C, with a final extension step of 10 mins at 72˚C. 
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Table 4: Primer sequences and expected amplicon sizes of target ESBL genes. 
 
Genes Forward Primer 
(5’ to 3’) 
Reverse Primer 
(5’ to 3’) 
Amplicon 
size 
(bp) 
Reference 
blaSHV  CTTTATCGGCCCTC
ACTCAA 
AGGTGCTCATCATGG
GAAAG 
237 Fang et al., 
2008 
blaTEM  CGCCGCATACACTA
TTCTCAGAATGA 
ACGCTCACCGGCTCC
AGATTTAT 
445 Fang et al., 
2008 
blaCTX-M  ATGTGCAGYACCAG
TAARGTKATGGC 
TGGGTRAARTARGTS
ACCAGAAYCAGCGG 
593 Fang et al., 
2008 
blaOXA  ACACAATACATATC
AACTTCGC 
AGTGTGTTTAGAATG
GTGATC 
813 Fang et al., 
2008 
 
In order to visualize the PCR amplicons, samples were mixed with 4 µl of Thermo Scientific 
loading dye and loaded into the wells of a 1% agarose gel.  The gel was prepared by melting 1g 
of agarose in 100ml Tris-acetate-EDTA (TAE) buffer.  After the solution had cooled (but was 
still molten), 5 µl of Red Safe, a DNA chelating agent, was added before casting the gel in a gel 
tray.  Gels were run at 130 volts for 60 minutes.  Amplicons were visualised using a Ultra-Violet 
transilluminator system (DIGI DOC-IT System TM) for analysis.  Each gel had one well which 
contained a DNA ladder (100 bp, Thermo Scientific) in order to estimate the size of the DNA 
amplicons. 
 
2.4 PCR-based determination of virulence genes in the isolates  
PCR was used to examine the virulence gene content of the clinical isolates.  Genes included in 
this screen represent virulence factors commonly found in clinical E. coli isolates (Jacobsen et 
al., 2008) such as those involved in iron acquisition, toxin production, serum resistance and 
adhesins (Refer to table 5).  In addition, PCR was used to identify the lipopolysaccharide (LPS) 
core types of the isolates (Dissanayake et al., 2008).    
The primers and the expected amplicon sizes are listed in Table 5.  While it was unlikely the 
isolates contained the genes coding for Shiga-like toxins, this screen was included to ensure the 
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safety of laboratory personnel and that any positive isolates were handled under appropriate 
biocontainment conditions.   
For the detection of Shiga toxin genes, single PCR reactions were performed.  The reaction tube 
contained 0.1µl of Taq polymerase (Promega), 0.8µl of primers, 0.4µl of dNTPs (Promega), 4µl 
of Taq buffer, 0.5µl of DNA and was made up to 20µl total volume with dH2O.  The reaction 
conditions consisted of a 3 min denaturation step followed by 30 amplification cycles of 30s at 
95˚C, 30s at 63˚C and 60s at 72˚C, with a final extension of 5 min at 72˚C.  Samples were run 
out on a 1% agarose gel as described earlier. 
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Table 5: Primers used for the detection of virulence genes in E. coli. 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) size (bp) Function 
Single plex PCR primers (J. Ritchie, personnel communication; Reviewed in Meng et al., 2014) 
stx1 AAATCGCCATTCGTTGACTACTTCT TGCCATTCTGGCAACTCGCGATGCA 370 Toxin 
stx2 CAGTCGTCACTCACTGGTTTCATCA GGATATTCTCCCCACTCTGACACC 283 Toxin 
Five plex PCR primers (Johnson et al., 2008) 
iroN  AATCCGGCAAAGAGACGAACCGCCT GTTCGGGCAACCCCTGCTTTGACTTT 553 Siderophore receptor 
ompT  TCATCCCGGAAGCCTCCCTCACTACTAT TAGCGTTTGCTGCACTGGCTTCTGATAC 496 Outer membrane 
protein 
hlyF GGCCACAGTCGTTTAGGGTGCTTACC GGCGGTTTAGGCATTCCGATACTCAG 450 Hemolysin 
iss CAGCAACCCGAACCACTTGATG AGCATTGCCAGAGCGGCAGAA 323 Serum survival 
iutA  GGCTGGACATCATGGGAACTGG CGTCGGGAACGGGTAGAATCG 302 Siderophore receptor 
Eight plex PCR primers (Dissanayake et al., 2008; Hussein et al., 2013) 
R1 GGGATGCGAACAGAATTAGT TTCCTGGCAAGAGAGATAAG 551   Lipopolysaccharide 
  core types R2 GATCGACGCCGGAATTTTTT AGCTCCATCATCAAGTGAGA 1141 
R3 GGCCAAAACACTATCTCTCA GTGCCTAGTTTATACTTGAA 1785 
R4 TGCCATACTTTATTCATCA TGGAATGATGTGGCGTTTAT 699 
K12  TTCGCCATTTCGTGCTACTT TAATGATAATTGGAATGCTGC 916 
chuA  GACGAACCAACGGTCAGGAT TGTGAAGTGTCAGGAGACGCTG 279 Heme transport 
yjaA  CCGCCAGTACCAGGGACA ATGGAGAATGCGTTCCTCAA 211 Unknown 
TSPE GAGTAATGTCGGGGCATTCA CGCGCCAACAAAGTATTACG 152 Anonymous DNA 
fragment 
Nine plex PCR primers (Ewers et al., 2007; Kwon et al., 2008; Zhao et al., 2009; Schouler et al., 2012; Arabi et al., 2013; Momtaz et al., 2013) 
astA TGCCATCAACACAGTATATCC TCAGGTCGCGAGTGACGGC 116 Toxin 
irp2  AAGGATTCGCTGTTACCGGAC AACTCCTGATACAGGTGGC 413 Iron acquisition 
papC TGATATCACGCAGTCAGTAGC CCGGCCATATTCACATAA 501 Adhesin 
iucD ACAAAAAGTTCTATCGCTTCC CCTGATCCAGATGATGCTC 714 Iron acquisition 
tsh ACTATTCTCTGCAGGAAGTC CTTCCGATGTTCTGAACGT 824 Adhesin 
vat TCCTGGGACATAATGGTCAG  GTGTCAGAACGGAATTGT 981 Toxin 
cvi/cva  TGGTAGAATGTGCCAGAGCAAG GAGCTGTTTGTAGCGAAGCC 1181 Colicin V operon 
ibeA AGGCAGGTGTGCGCCGCGTAC TGGTGCTCCGGCAAACCATGC  171 Invasion 
sitA AGGGGGCACAACTGATTCTCG TACCGGGCCGTTTTCTGTGC 608 Binding protein 
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For the five plex PCR, the reaction tube contained 0.3µl of GoTaq (Promega), 0.5µl  of each 
primer, 1µl  of dNTPs (Promega), 2µl  of MgCl2, 5µl of GoTaq buffer (Promega), 3µl of DNA 
and was made up to a 25µl total volume with dH2O.  The PCR reaction conditions consisted of a 
5 min denaturation step at 95˚C, followed by 35 amplification cycles of 30s at 95˚C, 30s at 55˚C 
and 40s at 72˚C, with a 7 min elongation step at 72˚C.  Samples were electrophoresed on a 3% 
agarose gel (at 100 volts) and analysed as described above. 
For the eight plex PCR reaction, the reaction tube contained 0.3µl of GoTaq, 0.5µl  of each 
primer, 1µl  of dNTPs, 2µl  of MgCl2, 5µl of GoTaq buffer, 3µl of DNA and was made up to a 
25µl total volume with dH2O.  The PCR reaction conditions consisted of a 5 min denaturation 
step at 95˚C, followed by 2 amplification cycles of 30s at 95˚C, 30s at 50˚C and 60s at 72˚C, 
followed by 32 amplification cycles of 30s at 95˚C, 30s at 58˚C and 60s at 72˚C, with a 10 min 
elongation step at 72˚C.  Samples were electrophoresed on a 2% agarose gel (at 100 volts) and 
analysed as described above. 
For the nine plex PCR reaction, the reaction tube contained 0.3µl of GoTaq, 0.5µl  of each 
primer, 1µl  of dNTPs, 2µl  of MgCl2, 5µl of GoTaq buffer, 3µl of DNA and was made up to a 
25µl total volume with dH2O.  The PCR reaction conditions consisted of a 5 min denaturation 
step at 95˚C, followed by 35 amplification cycles of 30s at 95˚C, 30s at 55˚C and 2 min at 72˚C, 
with a 10 min elongation step at 72˚C.  Samples were electrophoresed on a 2% agarose gel (at 
100 volts) and analysed as described above. 
 
2.5 Pulsed Field Gel Electrophoresis 
To examine the clonality of the ESBL-producing organisms, isolates were subject to pulsed field 
gel electrophoresis (PFGE) and the resulting banding pattern compared using the BioNumerics™ 
software.  Bacterial isolates were streaked onto LB agar, and the following day single colonies 
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were added to a 2ml cell suspension buffer (Tris, EDTA) in order to create a bacterial 
suspension.  Aliquots of 200µl cell suspension were placed into labeled eppendorf tubes, treated 
with 10µl of 20 mg/ml proteinase K, prior to the addition of 200µl of molten plug agarose (54°C 
to 56°C).  The resulting solutions were mixed carefully to reduce likelihood of bubbles and 
immediately cast in plug molds.  Plugs were allowed to set for 15 minutes at room temperature, 
and then transferred to a 5ml of cell lysis buffer containing proteinase K at 0.1 mg/ml.  The plugs 
were incubated for 2 h at 54°C in a shaking bath, and the lysis buffer was decanted.  Washing 
twice with 15ml preheated water was done, and then washing 4 times with preheated TE buffer 
at 50°C was performed.  The last wash was decanted.  Then, 5ml of TE buffer was added, and 
transferred to labeled tubes for storage at 4°C.  On day three, plugs were cut in half and 
transferred to labeled eppendorf tubes.  200µl of Xba1 restriction enzyme mixture was added to 
each tube and incubated for 2 h at 37°C.  TE buffer was then added to stop the reaction, and the 
plugs were added to a 1% agarose gel.  Finally, the sample was electrophoresed and then imaged.  
DNA relatedness was calculated based on the difference in banding patterns as detected by the 
BioNumerics™ software (Applied Maths, Belgium).  The isolates were clustered in groups of 
70% similarity with subgroups of closely related (similarity ≥ 85%) PFGE profiles. 
 
2.6 Plasmid extraction, manipulation and transformation 
In order to further characterize ESBL carrying plasmids found within the isolates, a set of ten E. 
coli and K. pneumoniae isolates were chosen based on their different PFGE profiles and ESBL 
gene content (Table 11).  The number and size of plasmids, their ability to transfer conjugative 
plasmids to other isolates and the impact of ESBL plasmid carriage on host cell fitness, was 
determined.  In addition, the ESBL plasmid was extracted, sequenced and annotated for gene 
content.       
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2.6.1 Plasmid content of selected isolates 
To determine the number of plasmids present in each isolate, total plasmid DNA was prepared 
from each isolate and analysed by gel electrophoresis.  To prepare plasmid DNA, isolates were 
grown in LB broth for 16 h at 37°C, aerobically.  After incubation, cultures were centrifuged for 
5 min at 13000 rpm, the supernatants discarded, and the cell pellets resuspended in 20µl of Tris- 
ethylene diamine tetraacetic acid (EDTA) buffer.  To lyse the cells, 150µl of 3% SDS was added.  
The tube was mixed gently and heated at 55°C for 35 minutes and then 150µl of phenol-
chloroform-isoamyl alcohol was added to denature proteins and inactivate RNAses.  The tube 
was mixed gently and centrifuged at 13000 rpm for 10 min at 4°C to separate the fractions.  The 
supernatant containing the plasmid DNA was collected and subject to electrophoresis in a 0.8% 
agarose gel (Rohde, 2011 et al.; Wonglumsom et al., 2011).  The number and size of plasmids 
present in the isolates was then determined by examining the banding pattern seen when the gel 
was visualized under the Ultra-Violet transilluminator system. 
 
2.6.2 Generation of cured isolates  
In order to study the impact of ESBL plasmid carriage of host cell fitness, curing experiments 
were performed.  To remove the ESBL plasmid from the host bacterium, isolates were grown in 
the presence of 10% SDS, a chemical curing agent that induces the elimination of certain 
plasmid types (reviewed in Liu et al., 2012).  Briefly, 0.2ml of an overnight culture (incubated 
for 16 h at 37°C, aerobically at 225rpm) was added to 5ml LB broth containing 10% SDS, and 
incubated for 16 h at 37°C, aerobically.  After incubation, the broth cultures were subcultured on 
a Mueller Hinton agar plate.  The plates were incubated for 16 h at 37°C, aerobically after which 
colonies were screened for cefotaxime resistance using the disk diffusion method (Tula et al., 
2013).  Colonies that were now sensitive to cefotaxime were further processed to check for loss 
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of the ESBL plasmid.  A full antibiogram test was performed on the cured isolates and they were 
confirmed as identical to the original isolate by performing PFGE analysis.   
 
2.6.3 Generation of ESBL-producing transconjugants 
To determine whether the ESBL plasmids were able to transfer to recipient isolates (a non-
pathogenic K12 laboratory isolate or a non-ESBL clinical isolate), bacterial conjugation 
experiments were performed.  Briefly, bacteria were cultured in LB broth overnight (16hrs) at 
37˚C, aerobically with agitation (225rpm).  After incubation, the bacterial cultures were 
centrifuged (for 3 min at 13000 rpm) and the supernatant discarded.  The cell pellet was washed 
once with PBS and finally resuspended in PBS.  Conjugation experiments were performed by 
mixing equal volumes of the donor ESBL-producing isolate (500µl) and the recipient isolate 
(500µl).  Then 200µl of the mixture was transferred to a nitrocellulose filter placed on top of a 
minimal medium agar plate and incubated for 4 h at 37°C, aerobically.  After incubation, the 
bacterial cells were transferred from the filter paper and the resultant solution centrifuged to 
obtain a cell pellet.  The cell pellet was resuspended in PBS, serially diluted and spread on LB 
agar supplemented with cefotaxime (1µg/ml) and streptomycin (200µg/ml) (only transconjugants 
were able to grow on this mixture) (Baker et al., 2008).  Putative transconjugants, which grew on 
the agar plates were confirmed to contain the ESBL plasmid by PCR and re-growth on LB agar 
supplemented with cefotaxime and streptomycin.    
 
2.6.4 Re-introduction of ESBL plasmids into cured isolates by transformation 
To re-introduce the ESBL plasmid back into the cured isolate, cells were made chemically 
competent and subject to transformation.  Purified ESBL DNA was obtained following plasmid 
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extraction of the E. coli K-12 transconjugants obtained in section 2.6.3.  Putative plasmid 
containing transformants were selected on LB agar plates containing cefotaxime (1µg/ml).    
Bacterial cells were made competent by treatment with calcium chloride.  Bacterial cultures were 
grown overnight (16hrs) in LB and the following day, 10ml of culture was centrifuged (4000g 
for 5 min at 4˚C) to harvest the cells.  The supernatant was discarded and the cell pellet 
resuspended in 5ml of ice-cold, 100mM calcium chloride and stored for 30 min on ice.  Cells 
were harvested again by centrifugation and resuspended in 1ml of ice-cold, 100mM calcium 
chloride.  The cells were again incubated for at least 30 min on ice, and used as soon as possible.   
To transform the cells, 200µl of competent cells were dispensed into a tube and mixed gently 
with 5µl of extracted purified DNA.  The tube was incubated on ice for one h, before the cells 
were subject to heat shock by incubating the tube for 90 sec at 42˚C and returning it back to ice 
for 30 min.  To recover the cells, LB broth (1mL) was added to the tube and the tube then 
incubated at 37˚C.  Cells were harvested by centrifugation at 14,000 rpm for 2 min and the 
supernatant was discarded leaving a residual volume of approximately 200µl in which cells were 
resuspended by vortexing.  The final cell suspension was spread on LB agar with cefotaxime and 
incubated for 16 h at 37°C, aerobically.  Putative transformants were checked for the presence of 
the plasmid by determining their antimicrobial resistance profiles.    
 
2.6.5 Isolation of ESBL plasmids  
To extract plasmid DNA for sequencing, bacterial cultures were processed using the Qiagen kit 
according to the manufacturer‘s instructions.  Bacterial cultures were harvested by centrifugation 
at 6000 x g for 15 minutes at 4˚C.  The bacterial pellet was resuspended in 0.3ml Buffer P1.  
0.3ml of Buffer P2 was then added and mixed thoroughly by vigorously inverting 4-6 times and 
incubating at room temperature (15-25˚C) for 5 min.  0.3ml of prechilled P3 Buffer was then 
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added and mixed thoroughly by vigorously inverting 4-6 times and incubating on ice for 5 
minutes.  Centrifugation was done at 14000 x g for 10 minutes at 4˚C.   
Qiagen-tip was equilibrated by applying 1ml of Buffer QBT and the column was allowed to 
empty by gravity flow.  The supernatant was added to the Qiagen-tip and allowed to enter the 
resin by gravity flow.  The Qiagen-tip was then washed with 2 x 2ml of Buffer QC.   
DNA was eluted with 0.8ml Buffer QF into a clean 2ml vessel.  Then, DNA was precipitated by 
adding 0.56ml of isopropanol and centrifuged for 30 minutes at 14000 x g at 4˚C.  The pellet was 
washed with 1ml of 70% ethanol, after decanting the supernatant, and centrifuged for 10 minutes 
at 14000 x g.  The supernatant was decanted and the pellet was air-dried for 5 – 10 minutes and 
finally 30µl of distilled water was added. 
 
2.6.6 Plasmid sequencing and analysis  
Plasmid DNA was extracted as described above, quantified using Qubit®, and sent to the Animal 
and Plant Health Agency (APHA, UK) for sequencing using the Illumina NGS platform.  The 
sequence data was downloaded from the GenBank database and using BLASTn, each sequence 
file was compared to a number of reference plasmid replicon sequences present in the 
PlasmidFinder database.  Circular representations of the plasmid sequence were created using 
Unipro UGENE software and the sequenced plasmids were aligned and compared to reference 
replicon sequences using BioEdit software. 
 
2.7 Antibiotic consumption data and susceptibility of clinical isolates to antibiotics 
Antibiotic consumption data were collected on a monthly basis over a period of three years 
(2010, 2011 and 2012) from the pharmacy information system at the Centre Hospitalier Du Nord 
(CHN) in Lebanon.  Consumption data was gathered for 14 different antibiotic families.  These 
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were β-lactam antibacterials, penicillins, penicillins with extended spectrum (PES), β-lactamase 
resistant penicillins, combination of penicillins (including β-lactamase inhibitors), PES without 
anti-pseudomonal activity + β-lactamase inhibitors, PES with anti-pseudomonal activity + β-
lactamase inhibitors, other β-lactam antibacterials, first-generation cephalosporins, second-
generation cephalosporins, third and fourth generation cephalosporins, monobactams, 
carbapenems, and quinolone antibacterials, respectively.  The data were expressed as the number 
of defined daily doses (DDD) per 100 patient bed days using the ABC Calc software program 
(version 3.1), as recommended by the WHO and European Centre for Disease Prevention and 
Control (Monnet, 2006; Keuleyan et al., 2010).   
All E. coli and K. pneumoniae isolates obtained from the microbiology laboratory at CHN 
hospital over the three years were processed and their susceptibility profiles to several commonly 
prescribed clinical antibiotics determined using the disk diffusion assay by staff within the unit.  
Of the antibiotics included in the susceptibility screening, 8 were common for both species; 
amoxicillin + clavulanic acid, aztreonam, cefepime, ceftazidime, cefuroxime, cefoxitin, 
ciprofloxacin, and piperacillin + tazobactam, whereas ampicillin and piperacillin were only 
included in the susceptibility screening of E. coli isolates.    
The Spearman correlation coefficient (r) was used to determine if there was a relationship 
between antibiotic consumption and species susceptibility profiles in the hospital.  In the 
analysis, antibiotic consumption was considered the independent variable and expressed in 
DDD/100 bed-days, with antibiotic susceptibility considered the dependent variable and 
expressed as the percentage of E. coli and K. pneumoniae isolates susceptible to the specific 
antibiotics.   
Positive correlation coefficients indicated that increased antibiotic consumption was associated 
with increased susceptibility, or decreased antibiotic consumption was associated with decreased 
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susceptibility.  Conversely, negative correlation coefficients indicated that increased antibiotic 
consumption was associated with decreased susceptibility, or decreased antibiotic consumption 
was associated with increased susceptibility. 
 
2.8 Statistical Analysis  
Data including source of isolate isolation, ESBL gene type, and virulence gene content were 
tabulated in Microsoft Excel (2010), and mean values and standard deviations determined as 
required.  Statistical analysis including the use of t-tests, were performed using Graphpad Prism 
5 or SPSS Statistics version 17.0, respectively.  Differences between more than two variables 
were assessed using one-way ANOVA followed by Bonferroni‘s Multiple Comparison Test.  
Isolate generation times were computed from bacterial growth curves and values for plasmid-
containing versus plasmid-free constructs compared using Students t-test, with significance set at 
P≤0.05.  Antibiotic consumption data was determined using ABC Calc and expressed in DDD 
per 100 bed-days.  Associations between antibiotic consumption and isolate antimicrobial 
susceptibilities (expressed as a % of total isolates) were evaluated using the Spearman 
correlation coefficient (r) using the statistical package, SPSS (Chicago) Statistics version 17.0.    
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CHAPTER 3 
Characterisation of ESBL-producing E. coli and K. pneumoniae isolates 
obtained from a major Lebanese hospital 
3.1 Introduction and aims 
Gram-negative bacteria are frequently associated with infections and can cause prolonged 
illnesses and substantial mortality, particularly for patients in intensive care units.  Among the 
most commonly isolated species are isolates of E. coli and K. pneumoniae (Della-Latta et al., 
2011).  While both species are part of the normal microflora of humans and animals, some 
isolates are capable of causing disease when present at sites distal to their normal niche, or in 
patients with weakened immune systems.  For example, E. coli is one of the leading causes of 
urinary tract infections whereas respiratory infections caused by K. pneumoniae are frequently 
associated with hospital stays (Meyer et al., 1993).   
In recent years, the production of β-lactamases has been the most significant mechanism 
conferring resistance to β-lactam antibiotics found in Gram-negative bacilli (Hernandez et al., 
2005).  Furthermore, ESBL-producing E. coli and K. pneumoniae have been reported in many 
countries, including Lebanon and the United Kingdom, and are recognised as responsible for 
outbreaks in hospitalised nursing home patients, geriatric wards, paediatrics, and cancer centers 
(Kim et al., 2002).  Given their widespread occurrence and predominance in medical settings, it 
is important to gain a better understanding of the diversity of ESBLs present in medically 
important species. 
Thus, the aim outlined in this chapter was to determine the type and extent of antimicrobial 
resistance exhibited by E. coli and K. pneumoniae isolates obtained from a major Lebanese 
hospital and to examine the genetic relationships between different isolates of each species.  
These studies aimed to test the following hypothesis: if antimicrobial resistant isolates in the 
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hospital have emerged from a common progenitor isolate, then isolates should share a similar 
genetic background as assessed by PFGE and/or analysis of virulence gene content.  To address 
this question, a set of putative ESBL-producing isolates were obtained from the clinical 
microbiology laboratory of the ―Centre Hospitalier Du Nord‖ Hospital-North Lebanon, and the 
following objectives set:  
 
i. Determine the antibiotic resistance profiles of E. coli and K. pneumoniae clinical isolates 
obtained from a major Lebanese hospital in order to accurately describe resistance 
patterns.   
ii. Examine the genetic background of ESBL-harbouring isolates using PFGE in order to 
ascertain the clonality of the test isolates. 
iii. Quantify the virulence gene content and motility of the isolates in order to evaluate their 
pathogenic potential and identify common virulence determinants. 
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3.2 Results 
3.2.1 Origin and species confirmation of ESBL-producing isolates 
From the 1
st
 May 2011 to 31
st
 December 2012, a total of 140 putative ESBL-producing isolates 
were collected.  All isolates were subject to species identification using the API 20E system.  
Based on the pattern of biochemical reactions observed, 100 isolates were confirmed as E. coli 
and 40 were confirmed as K. pneumoniae. 
Most E. coli isolates were obtained from female patients (64%).  Furthermore, the majority were 
recovered from urine samples (88%), with the remainder obtained from sputum (6%), pus (4%), 
or blood samples (2%), respectively (Figure 4).  Interestingly, greater numbers of K. pneumoniae 
isolates were also obtained from female patients (57.5%).  Of the 40 Klebsiella isolates, more 
than half were obtained from urine (57.5%), with the remainder isolated from sputum (27.5%), 
pus (2.5%), blood (10%) as well as one (2.5%) from a catheter, respectively (Figure 4).  Given 
that the isolates were isolated from different patients and infection sites over an 18-month period, 
it is likely that they are representative of the microbial species present at the hospital during this 
time. 
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Figure 4: Distribution and number of ESBL-producing E. coli and K. pneumoniae isolates based on site of 
infection.  A total of 100 putative ESBL-producing E. coli and 40 K. pneumoniae isolates were obtained from 
patients in a major Lebanese hospital over a period of 18 months.  Isolates were isolated from a range of clinical 
specimens as indicated on the x-axis following growth on MacConkey agar plates.  Most E. coli and K. pneumoniae 
isolates were obtained from urine samples. 
 
3.2.2 β-lactamase production and antimicrobial resistance profiles of the isolates 
Initially, all isolates were putatively assigned as ESBL producers based on their ability to grow 
on Mueller-Hinton agar plates containing at least one 3
rd-
 or 4
th-
 generation cephalosporin.  In 
order to confirm their identity as ESBL producers at the start of this project, isolates were 
examined for their ability to produce ESBLs using two standard phenotypic tests; the double disk 
synergy method as recommended by CLSI and the commercially produced E-test strip (Drieux et 
al., 2008; Huang et al., 2010; Rawat et al., 2010).  In addition, the presence of other β-
lactamases was explored. 
3.2.2.1 ESBL production 
In the double disk synergy method, isolates are considered ESBL-producers when the zone of 
inhibition around any of the extended spectrum cephalosporin disks shows a visible increase 
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towards the centrally-located amoxicillin-clavulanic acid disk (referred to as the keyhole effect) 
(Jarlier et al., 1988).  All 140 isolates tested revealed enhanced zones of clearing and exhibited 
the expected keyhole effect towards the amoxicillin-clavulanic acid disk when examined by this 
method (Figure 5).   
               
    Figure 5: Representative plate obtained following the detection of ESBL production by the double disk 
synergy test.  Suspensions of test bacteria were spread over the surface of a Mueller Hinton agar plate and disks 
supplemented with ceftazidime (CAZ; 30µg), cefotaxime (CTX; 30µg), aztreonam (ATM; 30µg), cefpodoxime 
(CPD; 10µg), cefepime (CPM; 30µg), cefoxitin (FOX; 30µg) and amoxicillin clavulanic acid (AMC; 30µg) 
added.  Plates were incubated for 16 h at 37˚C, aerobically.  A keyhole effect was evident by the increased zone of 
clearing between the antibiotics and the centrally-located AMC disk (arrows). 
 
Many isolates exhibited keyhole effects to more than one antibiotic as reported previously (CLSI 
guidelines, 2010).  Approximately 80% of E. coli and K. pneumoniae isolates showed visibly 
increased zones of inhibition for cefepime (FEP) and aztreonam (ATM), whereas approximately 
two thirds did so towards ceftazidime (CAZ) and around half towards cefotaxime (CTX).  Only 
10% of isolates were positive in the presence of cefpodoxime (CPD) (Table 6; raw data in 
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appendices IV and V).  The biggest discrepancy between the two species was in their response 
towards ceftazidime, with 72% of E. coli and 60% of K. pneumoniae positive. 
Table 6: Percentage (%) of E. coli and K. pneumoniae isolates showing synergistic interactions to β-lactam 
antibiotics in the double disk synergy test.  Bacterial suspensions were grown on Mueller Hinton agar and disks 
supplemented with antibiotics and the β-lactamase inhibitor, amoxicillin-clavulanic acid, added.  Plates were 
incubated for 16 h at 37˚C, aerobically.  Many isolates exhibited keyhole effects towards more than one antibiotic, 
with the highest percentage for aztreonam and the lowest percentage for cefpodoxime.   
 
ATM: Aztreonam, FEP: Cefepime, CTX: Cefotaxime, CPD: Cefpodoxime, CAZ: Ceftazidime. 
 
Isolate 
 
ATM 
 
FEP 
 
CTX 
 
CPD 
 
CAZ 
 
E. coli 84% 82% 55% 13% 72% 
K. pneumoniae 82.5% 75% 57.5% 12.5% 60% 
 
 
ESBL production was also assessed using the E-test method (see Figure 6). 
 
Figure 6: Representative agar plate indicating an ESBL-producing organism using the E-test strip.  ESBL-
production was inferred when the ratios of the minimum inhibitory concentration (MIC) of ceftazidime to 
ceftazidime plus clavulanic acid were ≥ 8-fold.  Bacterial suspensions were spread evenly over the MHA plate and 
the E-test strip added.  Plates were incubated at 37˚C for 16 h and the size of the zone of clearing measured against 
the scale printed on the test strip.  For this test organism, there is large zone of clearing that is evident on the left-
hand side but is missing on the right-hand side of the plate. 
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For both species, MICs for ceftazidime were typically between 1.5 and 32μg/ml whereas those 
for ceftazidime plus clavulanic acid ranged from 0.064 to 0.38μg/ml.  As a consequence, all 140 
isolates gave ratios ≥ 8-fold and were deemed ESBL producers (raw data for each isolate can be 
found in the appendices VI and VII).  Both phenotypic tests confirmed that all 140 clinical 
isolates were ESBL-producing organisms. 
 
3.2.2.2 Antimicrobial resistance profiles 
The antimicrobial resistance profile of each isolate was assessed by measuring the size of the 
inhibition zone around each antibiotic test disk and comparing the diameter to the cut-off values 
listed in the CLSI guidelines (see section 2.3.1).  The majority of E. coli isolates were found to 
be resistant or intermediately resistant to aztreonam, cefotaxime, cefpodoxime and ceftazidime 
(Table 7).  In contrast, approximately 75% of the isolates were sensitive to cefoxitin and the β-
lactamase inhibitor, amoxicillin + clavulanic acid (Table 7; raw data in Appendix II).   
Similar data were obtained for K. pneumoniae.  The majority of the isolates (40 isolates) were 
resistant or intermediately resistant to cefotaxime, cefpodoxime and ceftazidime but most were 
sensitive to cefoxitin and the β-lactamase inhibitor, amoxicillin + clavulanic acid (Table 8; raw 
data in Appendix III).  This pattern of resistance is consistent with the definition of an ESBL-
producing organism (Livermore et al., 2001; Rupp et al., 2003).  Overall, because similar 
patterns of resistance were found for both E. coli and K. pneumoniae isolates, the data support 
the notion that resistance mechanisms were not attributable to species-specific traits.   
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Table 7: Antimicrobial susceptibility profiles of E. coli isolates from different clinical specimens.  Following assessment in the double disk synergy test, bacterial 
isolates were deemed resistant (R), intermediate (I) or sensitive (S) to each antibiotic based on the diameter of the zones of inhibition given in CLSI guidelines (CLSI 
Guidelines, 2010) and summarized in section 2.3.1.  Data were expressed as a percentage of the total number of isolates tested (100 in this study). 
 
β- lactamase 
inhibitor 2
nd-
 generation Monobactam 3
rd-
 generation cephalosporin 4
th-
 generation 
Antibiotic/ 
Specimen 
AMC 
(Amoxicillin 
clavulanic 
acid) 
FOX 
(Cefoxitin) 
ATM 
(Aztreonam) 
CTX 
(Cefotaxime) 
CPD 
(Cefpodoxime) 
CAZ 
(Ceftazidime) 
FEP 
(Cefepime) 
S% / I% / R% S% / I% / R% S% / I% / R% S% / I% / R% S% / I% / R% S% / I% / R% S% / I% / R% 
Urine (88) 69 / 22 / 9 76 / 17 / 7 1 / 5 / 94. 0 / 0 / 100 0 / 1 / 99 1 / 8 / 91. 19 / 37 / 44 
Sputum (6) 100 / 0 / 0 50 / 33/ 17 0 / 17 / 83 0 / 0 / 100 0 / 0 / 100 0/ 17 / 83 33 / 34 / 33 
Blood (2) 100 / 0 / 0 50 / 0 / 50 0 / 0 / 100 0 / 0 / 100 0 / 0 / 100 0 / 25 / 75 50 / 50 / 0 
Pus (4) 75 / 25 / 0 75 / 25 / 0 0 / 0 / 100 0 / 0 / 100 0 / 0 / 100 0 / 50 / 50 25 / 50 / 25 
Total (100) 72 / 20 / 8 74 / 18 / 8 1 / 5 / 94 0 / 0 / 100 0 / 1 / 99 1 / 10 / 89 21 / 37 / 42 
 
Table 8: Antimicrobial susceptibility profiles of K. pneumoniae isolates from different clinical specimens.  Following assessment by the double disk synergy test, 
bacterial isolates were deemed resistant (R), intermediate (I) or sensitive (S) to each antibiotic based on the diameter of the zones of inhibition given in the CLSI 
guidelines (CLSI Guidelines, 2010)  and summarized in section 2.3.1.  Data were expressed as a percentage of the total number of isolates tested (40 in this study). 
 
β- lactamase 
inhibitor 2
nd-
 generation Monobactam 3
rd-
 generation cephalosporin 4
th-
 generation 
Antibiotic/ 
Specimen 
AMC 
(Amoxicillin 
clavulanic 
acid) 
FOX 
(Cefoxitin) 
ATM 
(Aztreonam) 
CTX 
(Cefotaxime) 
CPD 
(Cefpodoxime) 
CAZ 
(Ceftazidime) 
FEP 
(Cefepime) 
S% / I% / R% S% / I% / R% S% / I% / R% S% / I% / R% S% / I% / R% S% / I% / R% S% / I% / R% 
Urine (23) 48 / 48 / 4 83 / 13 / 4 0 / 0 / 100 0 / 0 / 100 0 / 0 / 100 0 / 4 / 96 17 / 39 / 44 
Sputum (11) 64 / 27 / 9 82 / 18 / 0 9 / 0 / 91 0 / 0 / 100 0 / 0 / 100 0 / 18 / 82 55 / 36 / 9 
Blood (4) 50 / 50 / 0 75 / 25 / 0 0 / 25 / 75 0 / 0 / 100 0 / 0 / 100 0 / 25 / 75 25 / 50 / 25 
Pus (1) 100 / 0 / 0 100 / 0 / 0 0 / 0 / 100 0 / 0 / 100 0 / 0 / 100 0 / 0 / 100 0 / 0 / 100 
Catheter (1) 100 / 0 / 0 0 / 100 / 0 0 / 0 / 100 0 / 0 / 100 0 / 0 / 100 0 / 100 / 0 100 / 0 / 0 
Total (40) 55 / 40 / 5 80 / 18 / 2 3 / 3 / 94 0 / 0 / 100 0 / 0 / 100 0 / 13 / 87 30 / 38 / 32 
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3.2.2.3 Carriage of AmpC β-lactamases 
Because carriage of AmpC β-lactamases also confers resistance to cephalosporins and it is not 
uncommon for isolates to harbour more than one type of β-lactamase (Kolar et al., 2010), 
isolates were examined for the presence of AmpC enzymes.  Chromosomal AmpC β-lactamase 
carriage can be inferred indirectly based on a test organism‘s simultaneous resistance to 3rd- 
generation cephalosporins and the 2
nd-
 generation cephalosporin, cefoxitin (reviewed in Peter-
Getzlaff et al., 2011).  Considering the antibiotic resistance profiles of isolates obtained in this 
study (raw data in appendices II and III), approximately 25% of ESBL-producing E. coli and K. 
pneumoniae isolates (27 out of 100 and 8 out of 40, respectively) exhibited this pattern of 
resistance.  Thus, it seems likely that these isolates carry both an ESBL and an AmpC β-
lactamase. 
AmpC β-lactamases may also be plasmid-borne and it can be clinically important to make the 
distinction between whether the β-lactamase is chromosomal or plasmid-borne (Jacoby, 2009).  
In order to distinguish between chromosomal or plasmidic AmpC genes, isolates were subject to 
the phenylboronic acid disk method (reviewed in Song et al., 2006).  In this test, plasmidic 
AmpC production is inferred if there is an increase of ≥5 mm in zone diameter around the 
cefoxitin disk that contains phenylboronic acid versus that of cefoxitin alone (reviewed in Song 
et al., 2006) (see Figure 7).  None of the isolates from the hospital met the criteria and tested 
positive, indicating that none of the isolates harboured plasmid-borne AmpC genes.   
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Figure 7: Representative patterns of growth when bacterial isolates are assessed for plasmidic AmpC β-
lactamase production using the phenylboronic acid test.  Test bacterial suspensions were spread on MHA plates 
and disks supplemented with cefoxitin and cefoxitin + phenylboronic acid added to the agar surface.  Plates were 
then incubated for 16 hours at 37˚C, aerobically.  An increase of ≥5 mm in zone diameter for cefoxitin containing 
phenylboronic acid versus cefoxitin alone is considered positive for AmpC production.   
 
3.2.3 Genetic characterisation of genes coding for ESBL-production 
Multiplex PCR was performed in order to determine the type(s) of ESBLs present in each of the 
clinical isolates.  Sequence-specific primers capable of distinguishing the genes coding for the 
main ESBL types, namely blaCTX-M, blaSHV, blaTEM, and blaOXA, were used (reviewed in Fang et 
al., 2008).  Each reaction produced an amplicon of a different size allowing easy determination 
of which genes were present in a single reaction (Figure 8). 
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Figure 8: Representative gel showing multiplex PCR amplification of DNA for the detection of the different β-
lactamases present in E. coli and K. pneumoniae isolates.  The expected product sizes are: blaOXA 813 bp, blaCTX-
M 593 bp, blaTEM 445 bp and blaSHV 237 bp, respectively.  The gel shows 18 test isolates, a positive control (far right 
hand lane) and a 100bp DNA ladder (middle of gel).  As can be seen, isolates 1, 4, 5, 8, 12, 16, and 17 harboured 4 
β-lactamases; isolates 7, 10, 11, 14, and 15 harboured 3 β-lactamases; isolates 2, 6, 9, 13, and 18 harboured 2 β-
lactamases; and isolate 3 harboured 1 β-lactamase.  +: positive control, L: 100bp Ladder.   
    
Of 100 ESBL- producing E. coli, 14% harboured all 4 β-lactamase genes, 19% harboured 3 β-
lactamase genes, 53% harboured 2 β-lactamase genes, and 14% harboured just a single β-
lactamase gene.  In contrast to E. coli, all K. pneumoniae isolates contained more than one β-
lactamase gene, with 42% (17 out of 40) harbouring all 4 β-lactamase genes, 30% (12 out of 40) 
harbouring 3 β-lactamases, and 28% (11 out of 40) harbouring 2 β-lactamases (raw data in 
appendices VIII and IX).  The most common ESBL gene belonged to the CTX-M group, with all 
isolates of E. coli and K. pneumoniae containing this allele (Table 9).  TEM was the next most 
common ESBL enzyme type in both species with more than 2/3rds of isolates carrying this 
allele.  While SHV was found in 75% of K. pneumoniae isolates, it occurred in a much lower 
percentage of E. coli isolates (29%).  This finding is consistent with other studies where up to 
90% of ampicillin resistance was attributed to the presence of SHV-1 β-lactamases in K. 
pneumoniae (Zeba et al., 2004). 
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Table 9: Percentage (%) of E. coli and K. pneumoniae isolates containing genes coding for CTX-M, SHV, OXA 
or TEM type ESBLs.  Isolates were subject to multiplex PCR for detection of blaOXA (813bp), blaCTX-M (593bp), 
blaTEM (445bp) and blaSHV (237bp) genes and the gene content analysed by separating the mixture on a 1% agarose gel.  
All isolates were found to contain the blaCTX-M gene.                  
 
 
CTX-M SHV OXA TEM 
E. coli 
100% 29% 36% 68% 
K. pneumoniae 
100% 75% 52.5% 87.5% 
 
In order to determine which group the CTX-M allele belonged, sequencing of the CTX-M 
amplified product was performed at the APHA using Sanger sequencing.  Examination of the 
nucleotide sequence (using Nucleotide BLAST: Basic Local Alignment Search Tool) revealed 
that the CTX-M-15 allele was present in all isolates.  This finding indicates that CTX-M-15 is 
the most common type of ESBL found in this Lebanese hospital and is consistent with earlier 
findings (Moubareck et al., 2005). 
 
3.2.4 Genetic analysis of clonal relationships between ESBL-producing isolates 
Pulsed field gel electrophoresis (PFGE) is used for molecular typing of isolates in order to 
determine their genetic relatedness (reviewed in Tang et al., 2000).  Here, chromosomal DNA 
was subject to endonuclease digestion with XbaI followed by gel electrophoresis.  DNA banding 
patterns were compared using BioNumerics software (Applied Maths, Belgium) and the 
dendrogram was produced by the UPGMA (unweighted pair group method using arithmetic 
averages) algorithm, where the isolates were clustered in groups of 70% similarity according to 
the Dice similarity index, with isolates clustering in subgroups of closely related (similarity ≥ 
85%) PFGE profiles (Vu Khac et al., 2006).  Therefore, clonality would be inferred if the 
isolates showed over 85% similarity of their PFGE patterns.  A cut-off of 70% similarity was 
used to determine more distantly related isolates (Vu Khac et al., 2006).  Chromosomal DNA 
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from 95 E. coli and 40 K. pneumoniae isolates were subject to PFGE.  However, unfortunately 
poor banding patterns were obtained for 5 E. coli isolates, despite repeating the extraction of the 
DNA and the procedure twice. 
Clustering based on 70% (subtypes possibly related) and ≥85% (subtypes closely related) 
similarity resulted in 64 and 77 subgroups of E. coli, respectively (Figure 9).  The large number 
of subgroups even at the lower percentages for similarity indicated that the isolates were 
genetically diverse and unlikely to represent a clonal complex. 
Using the same criteria as applied to the E. coli isolates, PFGE analysis showed that K. 
pneumoniae isolates were clustered in 30 groups of 70% similarity with 31 subgroups of closely 
related (similarity ≥ 85%) PFGE profiles (Figure 10) (Vu Khac et al., 2006). 
PFGE analysis indicated that all the isolates belonged to different PFGE profiles, indicating 
significant diversity.  While a clonal complex was not evident within the ESBL population, it is 
possible that horizontal transfer of a specific ESBL-harbouring plasmid had occurred.  This was 
investigated further in chapter 4, where 10 different plasmids were sequenced, annotated for 
gene content and compared. 
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Figure 9: Dendrogram generated by BioNumerics software, showing distance calculated by the Dice 
similarity index of PFGE XbaI profiles among 95 ESBL-producing E. coli isolates.  The PFGE analysis showed 
that E. coli isolates were clustered in 64 groups of 70% similarity with 77 subgroups of closely related (similarity ≥ 
85%) PFGE profiles.  The degree of similarity (%) is shown on the scale. 
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Figure 10: Dendrogram generated by BioNumerics software, showing distance calculated by the Dice 
similarity index of PFGE XbaI profiles among 40 ESBL-producing K. pneumoniae isolates.  The PFGE analysis 
showed that K. pneumoniae isolates were clustered in 30 groups of 70% similarity with 31 subgroups of closely 
related (similarity ≥ 85%) PFGE profiles.  The degree of similarity (%) is shown on the scale. 
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3.2.5 Growth, motility and virulence gene content of ESBL-producing isolates 
3.2.5.1 Growth curves 
In order to assess the relative fitness of the different ESBL-producing isolates and allow 
meaningful conclusions to be drawn from the motility assay, isolates were tested for their ability 
to grow in rich (LB) media using a microplate reader.  Optical density (or absorbance) 
measurements were taken at hourly intervals at a wavelength of 630nm.  For each isolate, two 
biological and two technical repeats were performed.  In this assay, growth of none of the E. coli 
isolates differed greatly from each other, with all reaching a final OD of around 0.412.  Similar 
results were found for K. pneumoniae, with all the isolates reaching a final OD of around 0.413 
(Figure 11 and raw data in appendices X and XI).  These findings indicate that all isolates grow 
well under laboratory conditions and no particular isolate is better able to or less able to, grow 
under these conditions.  It is possible that isolate-specific differences would become more 
apparent if isolates were grown under a range of different conditions. 
               
Figure 11: Average growth curve of all E. coli and K. pneumoniae isolates.  Bacterial growth curves were 
performed in LB broth at 37˚C for 9 hr, aerobically with gentle agitation.  The results were read using a plate reader 
set at 630nm.  None of the E. coli isolates differed greatly from each other, and likewise for the K. pneumoniae 
isolates.  For each isolate, duplicate biological and technical repeats were performed.   
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3.2.5.2 Motility testing 
In order to assess the motility of the isolates, bacteria were cultured in mannitol motility medium 
and the extent to which they spread through the medium assessed (see Figure 12).  The motility 
test showed that all the test E. coli isolates were motile whereas all K. pneumoniae were non-
motile. 
 
Figure 12: Mannitol motility agar used to assess bacterial motility.  Using an inoculating needle, bacteria were 
stabbed into the media inside the tube.  Tubes were incubated for 16 h at 37˚C, aerobically.  Motile bacteria produce 
diffuse growth as evident by the cloudiness of the media in the tube on the left-hand side (positive control) whereas 
non-motile bacteria grow along the line of inoculation and the media remains clear (right-hand tube; negative 
control).  For each isolate, duplicate biological and technical repeats were performed. 
 
3.2.5.3 Virulence gene content 
The mutual occurrence of a set of virulence genes among Avian pathogenic E. coli (APEC) and 
uropathogenic E. coli (UPEC) isolates, in addition to similar phylogenetic background and 
disease patterns, indicates a genetic relationship between these two E. coli pathotypes (Kaper et 
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al., 2004; Moulin-Schouleur et al., 2006; Ron, 2006; Zhao et al., 2009).  Therefore, multiplex 
PCR-based detection of 22 virulence factors was performed in order to assess the pathogenic 
potential of the ESBL-producing E. coli isolates.  Because the chosen virulence genes were only 
described in E. coli and not in K. pneumoniae, these PCR tests were only performed on the E. 
coli isolates.   
Isolates were first tested for Shiga-like toxin genes 1 and 2, as the presence of these toxins would 
require any future work to be taken under Biosafety Level 3 conditions.  All 100 E. coli isolates 
tested negative for the presence of Shiga-like toxin 1 and 2 genes (Figure 13).   
     
Figure 13: Representative agarose gel illustrating PCR amplification of DNA for Shiga-like toxin 1 and 2 
genes.  The expected product sizes for stx1 and stx2 are 370bp and 283 bp, respectively.  This gel shows 15 isolates, 
a separate positive control for each stx gene (lanes denoted +) as well as a negative control (H2O).  L: 100 bp DNA 
ladder. 
 
Three different multiplex PCR reactions were used to test for the presence of 22 different 
virulence genes (Table 10, raw data in Appendix XII).  The genes represented components of 
iron-scavenging systems, lipopolysaccharide (LPS) types, transport systems, adhesins and 
putative virulence factors of unknown function.  All 100 E. coli isolates were tested for all genes 
(representative gels are shown in Figure 14 (for five plex), Figure 15 (for eight plex) and Figure 
16 (for nine plex)). 
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The most common virulence genes found in ESBL-producing E. coli isolates tested here were 
iutA (88%), irp2 (83%) and sitA (81%), all of which are involved in iron acquisition or putative 
iron transport systems.  Genes from other iron scavenging systems (e.g. iroN, chuA, iucD, hlyF) 
were also highly represented being present in approximately 2/3rds of the isolates.  The isolates 
were assigned into the main phylogenetic groups (A, B1, B2 and D) based on the presence or 
absence of chuA, yjaA and TSPE amplicons (Clermont et al., 2000).  Following Clermont‘s 
decision tree, 40%, 24%, 3% and 33% of the isolates were found to belong to groups B2, D, B1 
and A, respectively.  These findings place most (64%) of the isolates in group B2 or D, the 
groups most often associated with virulent extra-intestinal E. coli isolates (Picard et al., 1999; 
Johnson et al., 2000).  A significant number of isolates (33%) were categorized as belonging to 
group A, which is usually said to contain commensal bacteria (Picard et al., 1999). 
The most common lipopolysaccharide core type was K12 (30%), with less than 20% of isolates 
containing R1, R2 and R4 types, respectively.  Only 4% of isolates contained the R3 
lipopolysaccharide core type, which is consistent with the fact that R3 is more often associated 
with Shiga toxin-producing E. coli (Currie et al., 1999; Amor et al., 2000). 
Adhesins encoded by papC and tsh were present in approximately 10% of the isolates, whereas 
ibeA which is associated with invasion was found in only 12% of the isolates.  Toxin production 
does not seem to be a major pathogenic mechanism for these isolates as genes coding for the 
toxins, astA and vat, were found in only 19 and 5% of isolates, respectively.  Approximately one 
quarter of isolates harboured iss, a gene associated with increased survival in serum (Johnson et 
al., 2008) and slightly less (21%) contained genes coding for the colicin V operon (Ewers et al., 
2007).   
Some virulence genes (such as iss, tsh and four putative iron acquisition and transport systems) 
can be encoded on the same plasmid (Johnson et al., 2006).  In addition, Karisik et al. (Karisik et 
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al., 2008) proposed that extra-intestinal pathogenic E. coli isolates are defined by the presence of 
2 or more virulence genes from a subset including papA, papC, and iutA.  Given that extra-
intestinal pathogenic E. coli are often responsible for acute urinary tract infections (Pitout et al., 
2004; Karisik et al., 2008) and that most isolates in this study were originally obtained from 
urine samples, it is perhaps not surprising to observe the high prevalence of some of these genes.  
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Table 10: Percentage (%) of ESBL-producing E. coli isolates containing key virulence genes.  Several multiplex PCR reactions were used to determine the presence of 
the listed virulence genes.  Details relating to primer sequences and amplicon sizes can be found in section 2.4 (Table 5).   
 
Iron-related systems 
 
Lipopolysaccharide core 
 
Adhesin 
 
Toxin 
 
Phylogenetic 
 
Miscellaneous/virulence 
 
 iutA iroN irp2 chuA iucD hlyF R1 R2 R3 R4 K12 papC tsh astA vat yjaA TSPE iss ompT ibeA sitA 
cvi/ 
cva 
E. coli 88 61 83 64 61 47 19 15 4 14 30 13 9 19 5 64 3 27 9 12 81 21 
 
                                       
 
Figure 14: Representative agarose gel illustrating five plex PCR amplification of DNA for the detection of virulence genes.  The expected amplicon sizes were: 
iroN (553 bp), hlyF (450 bp), iutA (302 bp), ompT (496 bp), and iss (323 bp), respectively.  DNA from 18 test isolates (lanes 1-9 and 10-18), a negative control sample (-
ve; H2O) and the 100 bp DNA ladder (L) were loaded into the wells of a 3% agarose gel and separated by electrophoresis.  Note not all target genes were present in this 
group of test isolates and hence amplicons are missing for ompT and iss. 
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Figure 15: Representative agarose gel illustrating eight plex PCR amplification of DNA for the detection of 
lipopolysaccharide core types and virulence genes.  The expected amplicon sizes were R1 (551 bp), R2 (1141 bp), 
R3 (1785 bp), R4 (699 bp), K12 (916 bp), chuA (279 bp), yjaA (211 bp), and TSPE (152 bp).  DNA from 18 test 
isolates (lanes 1-10 and 11-18), a negative control sample (-ve; H2O) and the 100 bp DNA ladder (L) were loaded 
into the wells of a 2% agarose gel and the amplicons separated by electrophoresis.  Note not all target genes were 
present in this group of test isolates and hence amplicons are missing for R4 and TSPE. 
 
 
 
Figure 16: Representative agarose gel illustrating nine plex PCR amplification of DNA for the detection of 
virulence genes.  The expected amplicon sizes were iucD (714 bp), sitA (608 bp), papC (501 bp), irp2 (413 bp), 
astA (116 bp), tsh (824 bp), vat (981 bp), cvi/cva (1181 bp), and ibeA (171 bp).DNA from 10 test isolates (lane 1-6 
and 7-10), a negative control sample (-ve; H2O) and the 100 bp DNA ladder (L) were loaded into the wells of a 2% 
agarose gel and the amplicons separated by electrophoresis.  Note not all target genes were present in this group of 
test isolates and hence amplicons are missing for tsh, vat, cvi/cva, and ibeA.   
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3.2.5.4 Relationship between virulence gene content, phylogenetic group and ESBL-production 
The number of virulence-associated genes present in an organism has been used previously to 
provide a quantitative measure of the pathogenic potential of different isolates and allow 
comparative studies to be performed (Mokracka et al., 2011).  Thus, the average virulence gene 
content for isolates harbouring different numbers of ESBL β-lactamases or belonging to different 
phylogenetic groups was determined.  The average virulence gene content was based on the 
presence or absence of 17 genes in total.  The PCR reactions used to type the LPS core structure 
(K12, R1, R2, R3 or R4) were excluded from the analysis because no association with virulence 
has been made for these groups (Dissanayake et al., 2008).  Furthermore, stx genes were 
excluded from the calculation as they were absent from all isolates. 
The average virulence gene content for E. coli isolates harbouring 1, 2, 3, and 4 ESBL β-
lactamases enzymes was 7.3, 6.8, 6.2, and 6.3 genes, respectively.  There was no significant 
difference in the average virulence gene content of isolates containing different numbers of 
ESBLs (one way ANOVA p=0.33).  There was a trend towards declining virulence gene content 
with increasing numbers of ESBLs.  In contrast, the phylogenetic group to which the organisms 
belonged had a significant (one way ANOVA P≤0.0001) effect on the virulence gene content.  
Group B2, which contains isolates most often associated with extra-intestinal infections, had a 
higher average virulence gene content (mean = 8.1) than isolates belonging to group A (mean = 
5.5; P<0.001), group B1 (mean = 5.3; P≤0.05) and group D (mean = 6.1; P<0.0001).  There were 
no significant differences when comparing the average virulence gene content of groups A, B1 
and D. 
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3.3 Discussion 
The emergence and spread of ESBLs has complicated the treatment of infections in hospitals and 
communities worldwide.  Yet for some countries there are limited data regarding the extent of the 
problem and little knowledge of the factors driving their spread.  The overall aim of this chapter 
was to define and characterise the ESBL-producing organisms obtained from a major Lebanese 
hospital over the course of the study period extending from the 1
st
 of May 2011 to the 31
st
 of 
December 2012.  Within this time period, 140 ESBL-producing isolates were collected and 
characterized for their β-lactamase content, virulence gene content and antimicrobial resistance 
profile in order to provide basic epidemiological data for this region and obtain representative 
isolates for future analysis.   
Phenotypic and genetic characterization of the ESBL-producing organisms revealed that the isolates 
were E. coli (100 isolates) or K. pneumoniae (40 isolates) and all harboured a CTX-M type enzyme.  
DNA sequencing of the CTX-M gene showed that all isolates specifically harboured the CTX-M-15 
allele.  The predominance of CTX-M-15 in this clinical setting is consistent with an earlier report 
that found CTX-M-15 to be the most widespread β-lactamase in Lebanon (Moubareck et al., 2005; 
Salem et al., 2013). 
In addition to harbouring CTX-M-15, many isolates contained other ESBLs as well as 
chromosomal-encoded AmpC β-lactamases.  The most common combination of enzyme types 
found was CTX-M-15 in association with TEM (74%), followed by SHV (42%) and OXA (41%).  
14% of E. coli and 42% of K. pneumoniae isolates harboured all 4 ESBL enzymes.  25% produced 
chromosomal AmpC β-lactamase coupled with the ESBL, indicating a dual mechanism of 
resistance in these isolates.  None were found to harbour plasmidic AmpC β-lactamase.  These 
findings are consistent with the study conducted in Belgium by Smet et al., who reported that 35 
isolates (12%) produced both ESBL and AmpC β-lactamase (Smet et al., 2008).  While clinically 
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this has little impact on the treatment strategy chosen by the physician, scientifically it raises an 
interesting question.  Given that most organisms harbour two or more ESBL enzymes; does 
carriage of differing types and numbers of ESBL enzymes confer benefits other than resistance to 
antibiotics, to the organism? This question formed the focus of the next chapter. 
The prevalence of CTX-M-15 ESBLs in the population may reflect the spread of a clonal complex 
as has been reported elsewhere (Lavollay et al., 2006; Livermore et al., 2007).  Examination of the 
isolates by PFGE revealed a large clonal diversity.  Thus, rather than clonal expansion of one 
particular isolate, it is more likely that horizontal transfer of common ESBL-containing plasmids 
has occurred between non-clonally related isolates.  Similar results have been reported by Vaidya 
(Vaidya, 2011) who showed that resistance genes can be spread between multiclonal isolates 
through horizontal gene transfer mechanisms (Vaidya, 2011). 
Numerous detection strategies exist for the detection of β-lactamases (Linscott et al., 2005; Goyal et 
al., 2008).  In this study, ESBL production was tested using the double disk synergy method and 
confirmed using the E-test ESBL method.  There was 100% correlation between the two methods. 
As part of the characterisation of the ESBL-producing organisms, E. coli isolates were examined 
for their virulence gene content.  The results showed that the virulence gene most commonly 
detected was iutA, an aerobactin siderophore receptor gene (Johnson et al., 2008), followed by the 
iron acquisition genes encoded by irp2 (Ewers et al., 2005; Schouler et al., 2012) and sitA, which 
forms part of an ABC-type ferric iron transport system (Sabri et al., 2006).  The aerobactin 
receptor (iutA), which is part of the aerobactin siderophore system that is responsible for bacterial 
survival in fluids and in host tissues with limited iron availability, was the most frequently found 
virulence gene (65% of the isolates tested) in a study conducted by Koga et al. (Koga et al., 2014).  
Its prevalence in the isolates of this study therefore likely reflects that the majority of isolates have 
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evolved mechanisms to cope with survival under low iron environments, such as those found in 
urine.   
The highest average virulence gene score was found in phylogroup B2 (8.1) followed by group D 
(6.1), A (5.5), and B1 (5.3).  Similar results were reported by Mokracka et al. and Cunha et al. who 
mentioned that the highest average virulence factor score was found in phylogenetic group B2 
(1.87 and 6.5, respectively), followed by the other groups (Mokracka et al., 2011, Cunha et al., 
2014).  In addition, these results showed that there was a trend towards declining virulence gene 
content with increasing numbers of ESBLs. 
In summary, ESBL-producing organisms in this study were genetically diverse, yet all encoded the 
CTX-M-15 type enzyme.  Many of the isolates also encoded genes for other ESBL enzymes.  In 
order to explore whether ESBLs were encoded on transmissible plasmids, 10 ESBL-producing 
organisms were selected for further study, as described in chapter 4.  This subset of isolates 
comprised of 6 E. coli and 4 K. pneumoniae isolates and their selection was based on their isolation 
from a common clinical sample type (i.e. urine) and that each contained different numbers and/or 
types of β-lactamases. 
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CHAPTER 4 
Contribution of ESBL carriage to host cell fitness  
4.1 Introduction and aims 
Resistance to antibiotics is widely believed to be linked to a physiological cost for the host 
bacterium (Pope et al., 2010).  Depending on the mechanism of resistance and how resistance 
genes are carried by the host organism, cost may relate to the need to replicate extra-
chromosomal DNA elements, or the need to maintain increased levels of proteins involved in 
drug efflux systems (Schulz zur Wiesch et al., 2010).  Regardless, it evident that a burden on the 
organism‘s fitness is a major parameter in determining how rapidly resistance might emerge in 
populations (Martinez et al., 2014).  Additionally, because many antimicrobial resistance genes 
reside on mobile genetic elements such as conjugative plasmids, integrons and transposons, the 
transmissibility of the resistance element to other organisms per se is critical to understanding 
the spread of multidrug-resistant pathogenic isolates (Marcusson, 2007; Pranting, 2010). 
Fitness is the ability of an organism to survive, proliferate, and spread in a specific environment 
(Laurent et al., 2001).  Subsequently, fitness is relative and will vary depending on the 
environment.  Ideally, it should be determined under a number of different conditions.  Most 
assays to assess bacterial fitness in the context of antimicrobial resistance are based on 
comparing the in vitro growth and survival of antibiotic-resistant and antibiotic-sensitive 
organisms (Laurent et al., 2001; Skurnik et al., 2013).  Such studies have found that carriage of 
resistance genes can be detrimental, beneficial or have no effect on the organism (Pranting, 2010; 
Guo et al., 2012).  For example, antibiotic resistance mediated by gene mutations which interfere 
with basic cellular functions such as RNA transcription, protein synthesis, and cell wall synthesis 
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will lead to an obvious growth defect.  Such is the case in Bacillus subtilis, where mutations in 
the RNA polymerase caused changes in gene transcription and, thus, affected several other 
physiological processes (Maughan et al., 2004; Miskinyte et al., 2013).  The mechanisms that 
confer antibiotic resistance in Salmonella and E. coli are commonly mediated by one or more 
mutations or the acquisition of plasmids and/or chromosomal insertions that could have an 
important fitness cost (Giraud et al., 1999; Randall et al., 2005; Pranting, 2010).  Some 
resistances cause no measurable cost to the host bacterium such as in E. coli and S. typhimurium; 
lysine to arginine (at position 42) substitution that confers high-level resistance to streptomycin 
appears to be cost-free (Pranting, 2010; Guo et al., 2012).  Finally, it is possible that antibiotic 
resistance can confer a cost in one isolate and be beneficial in another.  For example, a mutation 
causing ciprofloxacin resistance in Campylobacter jejuni increased survival in the absence of 
antimicrobial selection, but exhibited a fitness cost when transferred to another Campylobacter 
isolate (Luo et al., 2005; Pranting, 2010). 
The overall aim of the work discussed in this chapter was to determine the genetic context of the 
ESBL genes and to assess the contribution of ESBL plasmids to the fitness of the host bacterium.  
Central to this aim was the generation of both plasmid-cured and new plasmid-containing 
isolates (transconjugants).  These experiments tested the hypothesis that carriage of antimicrobial 
resistance plasmids affects the fitness of the host bacterium.  Ten ESBL-producing isolates 
identified from those described in chapter 3 were used in these studies.  The 10 isolates, 
comprised of 6 E. coli and 4 K. pneumoniae isolates, were selected because they were all isolated 
from the same type of clinical sample i.e. urine, but harboured differing types and/or numbers of 
ESBL enzymes and thus represented the genetic diversity of isolates present in this study.  The 
following objectives were set: 
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i. Determine the plasmid profile of the isolates and where possible, compare the 
sequence of the ESBL plasmids with those present in the GenBank database.   
ii. Assess the transmissibility of the ESBL plasmid by performing conjugation 
assays using a non-pathogenic E. coli K12 laboratory isolate and a non-ESBL-
producing E. coli clinical isolate, as recipients.   
iii. Evaluate the cost associated with plasmid carriage in newly-formed 
transconjugants and in the original isolates cured of the ESBL-producing plasmid.   
iv. Examine the metabolic capability of transconjugants and plasmid-free isolates in 
order to uncover additional beneficial traits associated with carriage of the ESBL 
plasmid. 
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4.2 Results 
4.2.1 Selection, sequencing and plasmid profiling of the selected isolates 
In order to study the influence of ESBL carriage on host cell fitness, six E. coli and four K. 
pneumoniae isolates harbouring different types and number of β-lactamases enzymes were 
chosen from those described in Chapter 3 for further study (Table 11).  This included for both E. 
coli and K. pneumoniae, isolates that harboured all 4 ESBLs (CTX-M, OXA, TEM and SHV: 
isolates 35 and 110) as well as those that harboured 3 enzymes (isolates 9 and 101) and various 
combinations of 2 of the 4 enzymes (isolates 2, 11, 39, 103 and 105).  For E. coli only, an isolate 
harbouring the single ESBL, CTX-M-15, was also available (isolate 1). 
As genes coding for ESBLs are often carried by large, conjugative plasmids, the plasmid content 
of each isolate was examined using plasmid profiling and gel electrophoresis.  Isolates were 
found to harbour between one and three plasmids, ranging in size from 36Kb to 148Kb (Figure 
17).  From the gel electrophoresis, all isolates were observed to harbour at least one large 
plasmid, which was presumably associated with ESBL carriage. 
 
Figure 17: Plasmid profile of ESBL-producing E. coli and K. pneumoniae isolates.  Plasmid DNA was extracted 
from each isolate and subject to electrophoretic separation on a 0.8% agarose gel.  Lane 1 and 8 (+) contains DNA 
from a reference isolate (isolate 39R861) harbouring plasmids of a known size (148 Kb, 63 Kb, 36 Kb, 6.8 Kb as well 
as genomic DNA).  Subsequent lanes contain the isolates of interest: lanes 2 – 7 (labeled with isolates 1 up to 39) 
contain E. coli whereas lanes 9 -12 (labeled with isolates 101 up to 110 contain K. pneumoniae).  The results show 
that the test organisms harboured 1 to 3 plasmids.  The red arrows indicate the band associated with genomic DNA 
and the white arrows indicate plasmids. 
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DNA sequencing was performed in order to characterise the plasmids in more detail.  Plasmid 
DNA from each of the 10 different ESBL-producing isolates was extracted and sent for 
sequencing at the Animal and Plant Health Agency (APHA).  Unfortunately, the read quality of 
one isolate (isolate 105) was poor and not suitable for inclusion in the post-sequence analysis.  
The sequence data from the 9 other samples was analysed and compared to sequences already 
deposited in the GenBank database.  The plasmids were then classified, based on known origins 
of replication.  Using BLASTn, each sequence file was compared to a number of reference 
plasmid replicon sequences (e.g. FIB, P, I1, N, FII, FIC, Col156, FIA, and ColpVC) present in 
the PlasmidFinder database (Carattoli et al., 2014). 
The plasmids were found to have > 95% nucleotide identity to those found in pEC_L8 and Inc 
groups.  Circular representations of the plasmid sequence were obtained using Unipro UGENE 
software (Okonechnikov et al., 2012) (Figure 18) and the sequenced plasmids were aligned and 
compared to reference replicon sequences using BioEdit software to ensure that the plasmids 
sequences and designation were as accurate as possible to the reference replicons (representative 
data in Figure 19).  Isolates 1, 2, 39, and 103 carried IncI1 plasmid while isolates 9 and 35 
carried pEC_L8 plasmid.  Furthermore, isolate 11 carried IncF plasmid, and isolates 101 and 110 
carried IncFIIK plasmid (Figure 18).  The sequence data showed that the sequenced plasmids, 
carrying different assortments of replicons of the I1, N, FII, FIC, FIB, P, Col156, FIA, and 
ColpVC types were associated with the most relevant and widely disseminated resistance gene 
(CTX-M-15) (Carattoli et al., 2014).   
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Figure 18: Circular maps showing the numbers of sequenced plasmids classified into groups occurring in the different bacterial species of E. coli and K. 
pneumoniae.  The 9 sequenced plasmids were compared to database sequences (using BLASTn) submitted to GenBank and subsequently classified into Inc groups and 
pEC_L8 (using the criterion of > 95% nucleotide identity) using reference replicon sequences (I1, N, FII, FIC, FIB, P, Col156, FIA, and ColpVC) in the PlasmidFinder 
database.  Isolates 1, 2, 39, and 103 harboured IncI1 plasmids (red colour); isolates 9 and 35 harboured the pEC_L8 plasmid (blue colour); isolate 11 harboured the IncF 
plasmid (black colour); and isolates 101 and 110 harboured the IncFIIK plasmid (green colour).  The size of the plasmids ranged between 89503bp and 142788bp.  The 
circular representation of the plasmid sequencing was performed using Unipro UGENE software.  
The plasmids were not completely closed as this was beyond the scope of this thesis. 
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Figure 19: Sequence alignment of E. coli and K. pneumoniae isolates using BioEdit software.  The sequenced plasmids were aligned and compared to reference 
replicon sequences (Pubmed) to ensure that the plasmid designations were as accurate as possible to the reference replicons.  The plasmids are highlighted in violet and 
the nucleotide bases are highlighted in black (G), green (A), blue (C) and red (T). 
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Table 11: Characterisation of E. coli and K. pneumoniae isolates obtained from human urine samples.  The data illustrates that the test isolates harboured different 
β-lactamases (CTX-M mainly CTX-M-15, SHV, OXA, and TEM).  The 9 variants (I1, N, FII, FIC, FIB, P, Col156, FIA, and ColpVC) were detected using PlasmidFinder 
software and PlasmidFinder was able to recognise each variant correctly at a >95% match.  The plasmid numbers detected per isolate ranged between 1 and 3 and the 
isolates harboured IncI1, pEC_L8, IncF, IncFIIK plasmids and these were associated with the most relevant and abundant resistance gene (CTX-M-15).  Furthermore, all 
the isolates were subject to multiplex PCR for ESBL detection and the results indicated the presence of CTX-M, SHV, OXA and TEM genes (Moubareck et al., 2005; 
Smet et al., 2010; Zhang et al., 2013).  
Isolate Specimen Organism CTX-M SHV OXA TEM 
CTX-M 
type 
Replicons using 
PlasmidFinder Web 
server 
Plasmid 
Numbers 
Present 
ESBL 
Plasmid 
Type 
Plasmid 
size 
1 Urine E. coli +       CTX-M-15 I1, I1, I1, I1 3 IncI1 107552 bp 
2 Urine E. coli +     + CTX-M-15 N, FII, FIC, FIB, P, I1 2 IncI1 89503 bp 
9 Urine E. coli + +   + CTX-M-15 Col156 1 pEC_L8 118525 bp 
11 Urine E. coli +   +   CTX-M-15 FIB 2 IncF 99159 bp 
35 Urine E. coli + + + + CTX-M-15 FII, FIB, FIA 3 pEC_L8 118525 bp 
39 Urine E. coli + +     CTX-M-15 ColpVC, I1 1 IncI1 93037 bp 
101 Urine K. pneu + +   + CTX-M-15 
ColE10, ColE10, 
FII(K) 
2 IncFIIK 
142788 bp 
103 Urine K. pneu +     + CTX-M-15 Col156, I1 2 IncI1 107552 bp 
110 Urine K. pneu + + + + CTX-M-15 Col156, FIB, FII(K) 3 IncFIIK 142788 bp 
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4.2.2 Transfer of resistance plasmid to naïve E. coli 
To investigate whether ESBL genes were located on conjugative plasmids that could be 
transferred to other isolates, bacterial conjugation assays were performed.  Two different 
recipient isolates were used: a non-pathogenic laboratory E. coli K12 isolate and a non-ESBL-
producing E. coli clinical isolate.  To facilitate selection of transconjugants from the donor cell 
population, streptomycin-resistant recipient isolates were generated by spreading the recipient 
isolates on LB agar plates containing streptomycin at different concentrations (Springer et al., 
2001).  Despite repeated attempts, only one non-ESBL-producing E. coli clinical isolate and the 
non-pathogenic laboratory E. coli K12 isolate were generated as streptomycin-resistant 
recipients.  Thus, putative ESBL-producing transconjugants could be selected based on their 
growth on LB agar containing cefotaxime (1µg/ml) and streptomycin (200µg/ml).  Prior to the 
conjugation assays, the plasmid profile of the recipient isolates was determined as described 
(section 2.6.1).  The data confirmed that the E. coli K12 recipient isolate lacked any plasmids but 
the non-ESBL-producing E. coli clinical isolate contained one plasmid of approximately 148Kb.  
For each of the 10 ESBL-producing isolates, after conjugation several colonies representing 
putative transconjugants were observed.  Three representative colonies from each of the 
conjugation assays were subjected to plasmid profiling in order to confirm transfer of a plasmid.  
In all cases, the transconjugants were found to contain an additional band when compared to the 
plasmid profile of the recipient isolate (Figure 20).  The size of the band appeared similar to one 
of the bands present in the donor bacterium and together with the transconjugant‘s resistance to 
cefotaxime, this indicated that the genes coding for ESBL activity were located on a conjugative 
plasmid. 
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Figure 20: Plasmid content of the original ESBL-producing E. coli (donor) isolate, the putative 
transconjugant and the E. coli K12 (recipient) isolate.  Plasmid DNA was extracted from each of the isolates and 
subject to separation by gel electrophoresis in 0.8% agarose gel.  In this case, the original ESBL-producing isolate 
harboured two plasmids, the smaller of which was transferred to the recipient isolate and associated with resistance 
to cefotaxime.  Three putative transconjugants were examined for their plasmid content in each assay. 
 
The clinical significance of plasmid transfer via conjugation relates to the frequency with which 
this may occur.  In order to determine the frequency of plasmid transfer for the different clinical 
isolates, the number of transconjugants per donor was calculated for each isolate.  The number of 
donors and recipients used in each experiment were largely similar, ranging from 3.7 to 9.8 x 10
9
 
and 3.2 to 8.1 x 10
9
,
 
respectively (Tables 12 and 13). 
Table 12: Number of transconjugants and donors present in conjugation assays with E. coli K12.  Isolates 1, 2, 
9, 11, 35 and 39 are E. coli, and 101, 103, 105 and 110 are K. pneumoniae.  Number of transconjugants with E. coli 
K12 ranged between 3.9 and 9.4 x10
4 
and number of donor ranged between 3.7 and 9.8x10
9
.  Triplicate biological 
repeats were performed. 
 
Isolate number Plasmid 
Number of transconjugant 
with E. coli K12 (cfu/ml) 
Number of 
Donor (cfu/ml) 
                          
1 IncI1 9.4 x 104 9.1 x 109 
 2 IncI1 6.7 x 104 9.8 x 109 
 9 pEC_L8 6.7 x 104 8.3 x 109 
 11 IncF 4.5 x 104 7.2 x 109 
 35 pEC_L8 3.9 x 104 5.6 x 109 
 39 IncI1 8.6 x 104 6.9 x 109 
 101 IncFIIK 5.0 x 104 3.7 x 109 
 103 IncI1 6.6 x 104 7.1 x 109 
 105 Not available 5.2 x 104 4.6 x 109 
 110 IncFIIK 4.3 x 104 4.5 x 109 
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Table 13: Number of transconjugants and donors present in conjugation assays with non-ESBL-producing E. 
coli clinical isolate.  Isolates 1, 2, 9, 11, 35 and 39 are E. coli, and 101, 103, 105 and 110 are K. pneumoniae.  
Number of transconjugants with non-ESBL-producing E. coli clinical isolate ranged between 4.2 and 12.2 x10
4
 and 
number of donor ranged between 3.9 and 9.5x10
9
.  Triplicate biological repeats were performed. 
 
Isolate number Plasmid 
Number of transconjugant 
with non-ESBL-producing E. 
coli clinical isolate (cfu/ml) 
Number of Donor 
(cfu/ml) 
1 IncI1 8.7 x 104 9.5 x 109 
2 IncI1 1.15 x 105 8.3 x 109 
9 pEC_L8 1.00 x 105 7.3 x 109 
11 IncF 5.3 x 104 6.6 x 109 
35 pEC_L8 5.0 x 104 3.9 x 109 
39 IncI1 6.2 x 104 7.1 x 109 
101 IncFIIK 4.2 x 104 5.8 x 109 
103 IncI1 1.22 x 105 7.7 x 109 
105 Not available 4.2 x 10
4
 4.3 x 10
9
 
110 IncFIIK 5.0 x 104 4.8 x 109 
 
Approximately 10
4
 transconjugants were recovered in total in each experiment and the frequency 
of conjugation determined using the following equation:       
                Frequency of conjugation = Number of transconjugant cells 
                                                                          Number of donor cells           
The frequency of conjugation differed for the two recipient isolates depending on the 
characteristics of the plasmid (Figure 21).  For 4 of the 6 ESBL-producing E. coli isolates 
(numbers 2, 9, 11, 35), the rate of plasmid transfer was significantly greater (P<0.05) when the 
non-ESBL clinical isolate acted as a recipient rather than the laboratory E. coli K12 isolate.  For 
some isolates this resulted in almost twice as many transconjugants per donor cell.  The opposite 
was true for one isolate (isolate 39) and the remaining isolate (isolate 1), there was no significant 
difference in the frequency of conjugation for the two recipient isolates. 
Of the 4 ESBL-containing K. pneumoniae isolates, isolate 101 preferentially transferred its 
plasmid to the E. coli K12 isolate (P<0.05) whereas isolate 103 preferentially transferred to the 
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non-ESBL clinical E. coli isolate.  The remaining two isolates were also able to transfer their 
ESBL plasmids but showed no significant preference for one recipient isolate over the other.   
Overall, the frequency of conjugation was largely similar for both ESBL-harbouring E. coli and 
K. pneumoniae isolates ranging between 10
-5 
and 10
-6 
transconjugants per donor cell, with 
slightly higher rates of transfer occurring to the non-ESBL clinical E. coli isolate. 
                
 
Figure 21: Rate of conjugation of 10 ESBL-harbouring E. coli or K. pneumoniae isolates mated with non-
pathogenic E. coli K-12 or a non-ESBL-harbouring E. coli clinical isolate.  Conjugation assays were performed 
by mixing approximately equal numbers of donor and streptomycin-resistant recipient cells on solid media for 4 hrs.  
Transconjugants were selected following growth on media containing streptomycin (200µg/ml) and cefotaxime 
(1µg/ml).  The number of donors and recipients were also determined.  Data were expressed as the number of 
transconjugants per donor cell and triplicate experiments were performed for each isolate.  1, 2, 9, 11, 35 and 39 are 
E. coli, and 101, 103, 105 and 110 are K. pneumoniae. 
 
4.2.3 Impact of ESBL plasmid carriage on host fitness  
In order to assess the impact of ESBL plasmid carriage on the fitness of the host bacterium, two 
approaches were undertaken.  First, the relative growth rate of newly conjugated ESBL-
producing isolates was compared to that of the recipient bacterium for each of the ESBL plasmid 
types.  Secondly, the original ESBL-producing clinical isolates were subject to plasmid-curing in 
order to compare the growth rate of the equivalent plasmid-free isolate to that of the original 
ESBL-producing isolate. 
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In all growth experiments, bacteria were grown in LB broth and the numbers of viable cells 
(colony forming units, (CFU)) determined at different times by serial dilution and plating on 
selective plates.  From a plot of log CFU against time, the generation time of each isolate was 
calculated as follows:   
         k= log A-log B      generation time= 1 x 60 minutes 
                       0.301 x t    k 
 
where k is the specific growth rate, A and B are number of bacteria at the beginning and end of the time interval and 
t is the time interval between 2 points (Arbitrarily calculated between 2 and 4 h of growth). 
A growth curve for isolate 1 is shown in Figure 22, with arrows indicating the period of 
exponential growth from which generation times were calculated.  As was evident from the 
growth curve even though the differences in growth between the host isolate and the ESBL-
containing transconjugant were subtle, significant differences in generation times could be 
discerned. 
          
 
Figure 22: Average growth curve of the recipient isolate E. coli K12 and a transconjugant harbouring the 
ESBL plasmid from wild-type isolate 1.  Bacterial isolates were grown separately in LB broth at 37˚C, aerobically 
for 9 h with shaking and the number of viable bacteria determined by serial dilution and plating on LB agar plates.  
From the growth curve, the values and their corresponding time points (as indicated by arrows) were used to 
calculate generation times.  Triplicate biological repeats were performed for each isolate.   
Generation times were arbitrarily calculated between 2 and 4 h of growth. 
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Newly-conjugated isolates were generated by conjugation of each of the 10 ESBL-producing 
isolates (donors) with either the laboratory E. coli K-12 isolate or the non-ESBL E. coli clinical 
isolate.  The generation time of laboratory E. coli K-12 isolate was approximately 25 mins, 
whereas those for each of the ESBL transconjugants was significantly (P<0.05) longer at 
approximately 30 mins (Table 14).  These results suggest that during growth in rich media, the 
carriage of ESBL plasmids increases the generation time of the host bacterium.  In other words, 
the E. coli K-12 isolate carrying the ESBL plasmid takes longer to replicate than the plasmid-free 
variant.  This was true for all ESBL transconjugants, with little difference between those 
plasmids harbouring different numbers/types of ESBLs. 
Table 14: Generation time (min) of E. coli K-12 ESBL transconjugants and the E. coli K-12 recipient isolate.  
Transconjugants were obtained by mating streptomycin resistant E. coli K-12 with ESBL-harbouring clinical E. coli 
(isolates 1, 2, 9, 11, 35 and 39) and K. pneumoniae (101, 103, 105 and 110) isolates.  Following colony purification 
of transconjugants, their rate of growth in LB broth at 37˚C with shaking was compared to the growth under the 
same conditions of the recipient isolate.  Experiments were performed in triplicate and rates of growth compared 
using a T test. 
   
Isolate number 
 
Plasmid 
 
Generation time 
 
P Value 
 
1 IncI1 29.0 ± 0.6 8.4 x 10-5 
2 IncI1 28.5 ± 0.6 3.0 x 10-5 
9 pEC_L8 27.8 ± 0.6 6.6 x 10-5 
11 IncF 28.7 ± 1.2 2.2 x 10-5 
35 pEC_L8 28.7 ± 0.6 4.7 x 10-5 
39 IncI1 29.5 ± 0.6 8.6 x 10-5 
101 IncFIIK 27.7 ± 0.6 8.4 x 10-5 
103 IncI1 26.8 ± 0.1 1.6 x 10-5 
105 Not available 28.1 ± 0.6 8.2 x 10-5 
110 IncFIIK 28.6 ± 0.6 8.0 x 10-6 
E. coli K-12 recipient isolate 
 
25.7 ± 0.5 
 
 
In contrast, the average generation time of the non-ESBL-producing clinical isolate and the 
resultant ESBL-producing transconjugants (plasmid + clinical isolate) were similar at 
approximately 23 minutes (Table 15).  Thus, ESBL plasmid carriage had no significant impact 
(P>0.05) on growth of this recipient isolate (Figure 23).  A possible explanation might be that 
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because the non-ESBL-producing clinical isolate already harbours a plasmid, it is better able to 
adapt to the presence of an additional plasmid than the non-plasmid containing E. coli K-12 
isolate. 
                       
 
 
Figure 23: Average growth curve of the recipient non-ESBL harbouring E. coli clinical isolate and a 
transconjugant harbouring the ESBL plasmid from wild-type isolate 110.  Bacterial isolates were grown 
separately in LB broth at 37˚C for 9 h with shaking and the number of viable bacteria determined by serial dilution 
and plating on LB agar plates.  From the growth curve, the values and their corresponding time points (as indicated 
by arrows) were used to calculate generation times.  Triplicate biological repeats were performed for each isolate. 
Generation times were arbitrarily calculated between 2 and 4 h of growth. 
 
Table 15: Generation time (min) of E. coli ESBL transconjugants and the non-ESBL containing E. coli 
recipient isolate.  Transconjugants were obtained by mating streptomycin resistant E. coli recipient with ESBL-
harbouring E. coli (isolates 1, 2, 9, 11, 35 and 39) and K. pneumoniae (101, 103, 105 and 110) isolates.  Following 
colony purification of transconjugants, their rate of growth in LB broth at 37˚C with shaking was compared to the 
growth under the same conditions of the recipient isolate.  Experiments were performed in triplicate and rates of 
growth compared using the T test. 
 
Isolate number 
 
Plasmid 
 
Generation time 
 
P Value 
 
1 IncI1 22.9 ± 0.6 0.2 
2 IncI1 22.4 ± 0.6 0.5 
9 pEC_L8 21.8 ± 1.2 0.7 
11 IncF 22.8 ± 0.6 0.7 
35 pEC_L8 23.4 ± 1.2 0.2 
39 IncI1 21.3 ± 1.5 0.1 
101 IncFIIK 21.1 ±1.7 0.3 
103 IncI1 20.3 ± 2.1 0.6 
105 Not available 21.8 ± 1.0 0.2 
110 IncFIIK 21.4 ± 1.2 0.4 
Non-ESBL-producing E. coli recipient 
isolate 
 
23.2 ± 0.1 
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The impact of ESBL plasmid carriage was also studied by constructing plasmid-cured 
derivatives of the original ESBL-producing isolates.  It was expected that if the plasmid affected 
the ability of the organism to grow, then elimination of the plasmid would result in altered 
growth characteristics.  This approach complements the transconjugation study described 
previously and provides an alternative approach to verify the effect of the plasmid on the fitness 
of the bacterium. 
Plasmid curing was performed on both ESBL-producing E. coli and K. pneumoniae isolates by 
subjecting the cultures to growth in media supplemented with 10% SDS.  However, despite 
repeated attempts, only one E. coli (isolate 2) and one K. pneumoniae (isolate 101) were 
successfully cured of their respective ESBL-producing plasmids.  The cured isolates were 
confirmed as identical to the original isolate (other than for the presence of the plasmid) by 
performing PFGE analysis and a full antibiotic resistance profile on both isolates.  Following 
PFGE, identical banding patterns were observed for the cured and original ESBL-producing 
isolates, respectively (Figure 24).  Furthermore, the antimicrobial resistance profiles of the cured 
isolates indicated sensitivity to most antibiotics such as cefotaxime and ceftazidime in contrast to 
the original donor isolates.  These results are consistent with the loss of the ESBL plasmid from 
the original donor isolates. 
 
Figure 24: Dendrogram of PFGE patterns of ESBL-producing and cured E. coli or K. pneumoniae isolates 
following XbaI digestion.  Cured and original plasmid-bearing isolates were subject to PFGE in order to verify the 
identity of the isolates.  The PFGE results revealed the banding patterns produced were identical indicating 100% 
similarity between the cured and original ESBL-producing isolates for both E. coli and K. pneumoniae.   
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Finally, the cured isolates were subject to growth analysis as described previously.  Interestingly, 
the generation time of the cured isolates of both E. coli and K. pneumoniae were significantly 
faster (approximately 23 mins) than that of the original ESBL-producing isolates (P<0.05).  
Furthermore, re-introduction of the respective ESBL-plasmid into the cured isolates slowed the 
generation time of the host organism to its‘ original rate (of approximately 25 mins).  These 
results clearly demonstrate a role for the plasmid in increasing the generation time and slowing 
the growth of the clinical isolates, and thereby, reducing the organism‘s fitness under the 
conditions tested (Table 16; Figure 25). One must consider the potential pleiotropic effects of 
curing isolates using SDS and future studies could include curing studies using a system such as 
pCURE (Hale et al., 2010; Freire Martín et al., 2014). 
 
Table 16: Generation times (min) of E. coli and K. pneumoniae cured isolates, ESBL-producing E. coli and K. 
pneumoniae clinical isolates, and E. coli and K. pneumoniae isolates after plasmid transformation.  The 
generation time of the two cured isolates were approximately 23 min while the generation time of the two 
corresponding ESBL-harbouring clinical isolates were approximately 25 min (P<0.05).  Re-introduction of the 
respective ESBL-plasmid into the cured isolates returned the generation time of the organism to its original rate (of 
approximately 25 mins).  Triplicate growth curves were performed for each isolate and rates of growth compared 
using the T test. 
 
Isolate Generation time P Value 
 
Original E. coli 25.3 ± 0.3 
8.4 x 10
-5 
Cured E. coli 22.8 ± 0.6 
Plasmid transformation to E. coli 25.2 ± 0.7 
Original K. pneumoniae 24.6 ± 0.3 
2.8 x 10
-5 
Cured K. pneumoniae 23.0 ± 1.2 
Plasmid transformation to K. pneumoniae 25.0 ± 0.5 
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Figure 25: Average growth curve of the original ESBL-producing E. coli (left-hand) and K. pneumoniae 
(right-hand) clinical isolate and the isolates cured of the ESBL plasmid.  Bacterial isolates were grown 
separately in LB broth at 37˚C for 9 h with shaking and the number of viable bacteria determined by serial dilution 
and plating on LB agar plates.  From the growth curve, the values and their corresponding time points (as indicated 
by arrows) were used to calculate generation times.  Triplicate biological repeats were performed for each isolate. 
Generation times were arbitrarily calculated between 2 and 4 h of growth.   
 
4.2.4 Impact of ESBL plasmid on carbon utilisation by the host bacterium  
Genes coding for ESBLs represent a small fraction of the total number of genes present on these 
large conjugative plasmids.  As such, it is likely that gain or loss of the plasmid may result in 
changes in an organisms‘ fitness that is unrelated to their ability to withstand exposure to 
antibiotics or growth in nutrient-rich media.  The ability of bacteria to utilise preformed carbon 
sources is important to their growth and survival inside and outside of the host (Muñoz-Elías et 
al., 2006).  In order to determine if the presence of the ESBL-producing plasmid altered the 
ability of the host bacterium to utilise different carbon sources, the Biolog™ phenotypic 
microarray system was used.  In this assay, the respiratory activity of test bacterial isolates was 
used as a measure of their ability to utilise a range of different individual carbon sources.  Due to 
limitations of time, and because only the E. coli K12 isolate showed a significant difference in 
the generation time when compared to E. coli K12 harbouring the respective ESBL plasmids, 
only isolates from this genetic background were tested in the assay.  Furthermore, despite 
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repeated attempts, valid results could not be obtained for isolates 9 and 35 and therefore they 
were excluded from the Biolog analysis.    
Biolog PM1 plates, which contain 95 different individual carbon (C) sources, were incubated 
aerobically at 37°C for 48 hrs with the original E. coli K-12 recipient isolate or E. coli K-12 
ESBL derivatives obtained during the conjugation assays.  Differences in C utilisation profiles 
were compared after 48 hrs incubation using the OmniLog PM Software supplied by Biolog.  
The data analysis revealed some subtle differences (P<0.05) in respiration rates between the 
ESBL-harbouring transconjugants and the original wild-type E. coli K-12 isolate (mainly in A3 
(N-Acetyl-D-Glucosamine), B8 (D-Xylose), B12 (L-Glutamic Acid), C9 (α-D-Glucose), C10 
(Maltose), C11 (D-Melibiose), C12 (Thymidine), E2 (m-Tartaric Acid), G8 (N-Acetyl-β-D-
Mannosamine), G10 (Methyl Pyruvate), and H10 (D-Galacturonic Acid) carbon sources; Table 
17).  Interestingly, in some cases, the carbon utilisation by E. coli K12 was better than 
transconjugants (mainly in A3 (N-Acetyl-D-Glucosamine), B8 (D-Xylose), B12 (L-Glutamic 
Acid), C9 (α-D-Glucose), C10 (Maltose), C11 (D-Melibiose), C12 (Thymidine), E2 (m-Tartaric 
Acid), and G8 (N-Acetyl-β-D-Mannosamine)), but in others, this was reversed (mainly in G10 
(Methyl Pyruvate) and H10 (D-Galacturonic Acid)).  No additional C substrates were uniquely 
utilised in the presence of the respective ESBL plasmids (with the exception of D9 (α-D-
Lactose) and D10 (Lactulose) for isolate 110 only).  Moreover, all C sources that were utilised 
by E. coli K-12 were also utilised by all the 8 transconjugants (Figure 26).   
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Figure 26: Biolog PM1 plates illustrating the utilisation of different C sources after 48 h incubation, aerobically at 37°C.  Colonies from test 
bacteria were resuspended using a cotton swab in 15ml sterile water until the cell density equaled 42% transmittance on a Biolog turbidimeter.  To 
prepare the inoculating solution, 2ml of this suspension was transferred to 10ml inoculating fluid and 120µl tetrazolium dye added.  Aliquots of 100µl 
were added to each well of the 96-well PM1 plate and the plate incubated in an OmniLog plate reader for 48 h at 37˚C aerobically.  For each isolate, 
duplicate biological repeats were performed.  The yellow (K12 isolate) and red (transconjugant isolates) lines in each well represents cumulative 
respiratory activity on each C substrate.  Well A1 = negative (no C source) control. 
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Table 17: Differences in C source utilisation by E. coli K12 and ESBL transconjugant isolates using Biolog PM1.  Differences in utilisation patterns were 
scored using the following comparative system: + = carbon utilisation, ++ = higher carbon utilisation, and - = no carbon utilisation.  Substrates named as 
follows: A3 is N-Acetyl-D-Glucosamine, B8 is D-Xylose, B12 is L-Glutamic Acid, C9 is α-D-Glucose, C10 is Maltose, C11 is D-Melibiose, C12 is 
Thymidine, D9 is α-D-Lactose, D10 is Lactulose, E2 is m-Tartaric Acid, G8 is N-Acetyl-β-D-Mannosamine, G10 is Methyl Pyruvate, and H10 is D-
Galacturonic Acid.  For each isolate, duplicate biological repeats were performed.  T= transconjugant isolates, P= P-Value. 
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4.3 Discussion 
ESBL-positive isolates of E. coli and Klebsiella have been reported worldwide, yet detailed 
studies examining how or why these organisms predominate in different settings are limited.  
The burden or cost of resistance gene carriage to the organism is likely to be one of the most 
important factors influencing the frequency of their isolation and level of resistance spread 
within the microbial community (Pope et al., 2010; Pranting, 2010).  Therefore, the aim of the 
work described in this chapter was to determine the genetic context of the ESBL population 
present in a hospital setting in Lebanon and evaluate the contribution of the plasmid-borne ESBL 
determinants to the fitness of the host bacterium. 
Plasmid profiling and conjugation experiments revealed that the ESBL genes were located on  
large, conjugative plasmids.  Most isolates harboured between one to three plasmids, with the 
size ranging from 36 Kb to 148 Kb.  These findings were in coordinance with Trang et al. who 
also demonstrated that the CTX-M-15 and CTX-M-27 genes were located on transmissible 
plasmids of between 50 kb and 170 kb in size (Trang et al., 2013).  CTX-M-15 genes have been 
previously reported to be located on IncI1 and IncFII-related group plasmids (Zhang et al., 
2013).  In addition, Smet et al. reported that pEC_L8 carries the blaCTX-M-15 gene (Smet et al., 
2010).   
In the studies reported here, the sequenced plasmids (IncI1 plasmid, pEC_L8 plasmid, IncF 
plasmid, and IncFIIK plasmid) were associated with the CTX-M-15 gene.  These enzymes 
(CTX-M-15 type) may have been selected for by the increased and widespread use of antibiotics 
in the hospital setting (Trang et al., 2013).  Furthermore, variable associations among the β-
lactamase genes and plasmids can be observed where the same plasmid scaffold is associated 
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with different genes.  Moreover, different plasmids scaffolds can be associated with the same 
genes (Garcia-Fernandez et al., 2008).  These associations were also observed in this thesis. 
In order to study the fitness of these isolates and to investigate whether ESBL activity could be 
transferred to other isolates, conjugation studies were performed using two different recipient 
isolates (an E. coli K12 isolate and a non-ESBL-producing E. coli clinical isolate).  The literature 
suggests that the clinical consequence of plasmid conjugation is linked to the frequency by which 
it occurs (Andrup et al., 1999).  Therefore, the frequency of conjugation was assessed and found 
to range between 10
-5 
and 10
-6
.  These conjugation frequencies are similar to those previously 
reported by other authors, with rates ranging between 10
-3
 and 10
-7
, respectively (Mugnaioli et 
al., 2006; Amos et al., 2014; Zurfluh et al., 2014).   
Moreover, this study clearly demonstrated that ESBL plasmid carriage significantly reduced the 
replication rate of the non-pathogenic E. coli K12 laboratory isolate from approximately 25 
minutes to approximately 30 minutes.  This difference was statistically significant (P<0.05) 
indicating that the ESBL plasmid played a role in increasing the generation time of the 
transconjugants.  Zund et al. also showed that plasmid acquisition lengthened the host 
bacterium‘s generation time (Zund et al., 1980).  Evidently, this increase in generation time may 
have a negative effect by reducing the overall fitness of the bacterium.  Reduced generation 
times may influence a persister state as observed in a number of other important pathogens 
(Chambers et al., 1995; Smith et al., 2013).  This persister state may result in increased ability to 
subvert the effects of antimicrobials and disinfectants.  Furthermore, persister states may enable 
bacterial pathogens to survive in the target host and subvert the host defence systems (Smith et 
al., 2013; Ashida et al., 2014). 
Plasmid curing employing a 10% SDS methodology was used as an alternative approach to 
assess the effect of the plasmid on host fitness.  This method was successfully applied to two 
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isolates only (1 E. coli [IncI1 plasmid] and 1 K. pneumoniae [IncFIIK plasmid]).  The generation 
time of the cured isolates were significantly faster than that of the original ESBL-producing 
isolates (P<0.05).  Hence, the results of the growth curve of these 2 isolates proved again that the 
plasmid was responsible for increasing the generation time of the clinical isolates.  This 
phenomenon was also observed and discussed by Haft et al. who reported that plasmid-
containing isolates showed an increase in their doubling times (Haft et al., 2009). 
In order to further strengthen the data, complementation studies were performed.  Here, 
transformation of the ESBL plasmid was performed into the cured isolates (E. coli and K. 
pneumoniae).  It was postulated that the generation time would return to its original rate, 
confirming once again the role of the ESBL plasmid.  As anticipated, the re-introduction of the 
respective ESBL-plasmid into the cured isolates slowed the generation time of the host organism 
to its‘ original rate (of approximately 25 mins).  These results clearly demonstrate that the 
plasmid is increasing the generation time and slowing the growth of the clinical isolates, and 
thereby, reducing the organisms‘ fitness under the conditions tested. 
On a separate note, the generation time for the transconjugant (plasmid + non-ESBL clinical 
isolate) and the non-ESBL clinical host bacterium was similar (circa 23 mins), with no 
significant difference (P>0.05) observed between the two isolates.  A possible explanation might 
be that the non-ESBL clinical isolate already harboured a number of plasmids and hence showed 
similar generation time, or alternatively had become adapted to ESBL plasmid carriage. 
In conclusion this chapter discussed bacterial fitness and how the plasmid influenced bacterial 
host cell generation time.  The frequency of conjugation was also investigated.  It appears that 
plasmid transfer can occur readily and frequently, therefore this may be a significant contributor 
to the increased levels of bacterial resistance seen in hospital environments.  It seems that the 
ESBL-harbouring plasmids have no major effect on carbon utilisation profiles of the bacterium 
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under the studied conditions (with the exception of 2 carbon sources: D9 (α-D-Lactose) and D10 
(Lactulose) in isolate 110).  However, globally the presence of an ESBL plasmid does seem to 
alter the overall carbon utilisation pattern for E. coli and Klebsiella and thus this may have 
significant effects in vivo where nutrient availability may be poor.   
Another question that was addressed in this thesis was the link between antibiotic consumption 
and resistance.  One parameter which is affecting antibiotic resistance is antibiotic consumption.  
The misuse and overuse of antibiotics in veterinary and human practices has selected for resistant 
microorganisms and led to their rise and spread (Meyer et al., 2013).  The worldwide increase in 
antimicrobial resistance in bacteria, combined with the decreasing number of new antibiotics, has 
led to the possibility of losing the ability to treat common bacterial infections (Schulz zur Wiesch 
et al., 2010).  In order to halt this, urgent global action against AMR is required. 
One such action may be to decrease the level of antibiotic usage in humans, animals and 
agriculture.  Decreased levels of resistance have been reported following restricted antibiotic 
usage (Murki et al., 2010; Schulz zur Wiesch et al., 2010).  Since the rate and the extent of 
antibiotic resistance occurrence may be linked with a physiological cost for the bacterium, 
calculating antibiotic consumption and correlating it with the profiles of susceptibility to various 
antibiotics is important and will be discussed in Chapter 5. 
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CHAPTER 5 
Antibiotic Consumption 
5.1 Introduction and aims 
Antibiotics are one of the main medical interventions used for the treatment of bacterial 
infections in animals and humans.  Their clinical effectiveness has been declining due to the rise 
of antibiotic resistance, although there is some promise of a breakthrough (Ling et al., 2015) with 
new antimicrobials although generally a failure to develop new drugs has hampered progress 
(Hsu et al., 2008).  The overuse, misuse and abuse of antibiotics per se is thought to be largely 
responsible for the development of resistance (Levy, 2001; Meyer et al., 2013).  Continued use 
of antibiotics in the face of resistance within the target population allows resistant organisms to 
predominate and/or the resistance determinants to spread to other species.  Therefore, an 
effective option to reduce the development of resistance is to encourage the appropriate use of 
antimicrobials agents.  To this end, the World Health Organization (WHO) is actively addressing 
the issue of antimicrobial resistance through, for example, launching a new book that aims at 
raising awareness about antimicrobial resistance (World Health Organization, 2012).   
Antibiotic consumption in hospitals is recognised as one of the leading risk factors for the onset 
of antimicrobial resistance (Sharma et al., 2005; Borg et al., 2008; Bell et al., 2014).  A clear 
correlation between antibiotic consumption and the development of resistance is not always easy 
to establish because numerous other distinct contributing factors may also be involved (Cristino, 
1999).  Depending on the organism and on the type of antibiotic under study, positive, negative 
and insignificant correlations between consumption and resistance have been reported (Lai et al., 
2011; Plüss-Suard et al., 2013; Sedláková et al., 2014).  Nevertheless, tracking antibiotic usage 
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and the distribution of resistant organisms can be useful to gain a better understanding of the 
factors driving the emergence of resistant populations. 
Most studies use Defined Daily Dose (DDD) as a way to measure antibiotic consumption and 
evaluate links between antibiotic consumption and resistance.  The DDD methodology is 
internationally recognised and recommended by both the WHO and the ECDC, as the best 
method to determine antibiotic consumption rates (Truter et al., 1996).  An alternative way to 
measure antibiotic consumption is the number of days of therapy (DOT).  While DOT 
enumerates the administration of a single agent on a given day, it does not take into account the 
number of doses administered on that day (Polk et al., 2007). 
The DDD is the assumed average maintenance dose per day for a drug in its main indication for 
adults (Vander Stichele et al., 2004; WHO Collaborating Centre for Drug Statistics 
Methodology, 2010).  It is a unit of measurement used during drug use studies and does not 
essentially reflect the recommended or prescribed daily dose for individual patients or specific 
patient groups (Vander Stichele et al., 2004).  DDDs can be correlated to different denominators 
such as DDD per 100 occupied days, DDD per 100 patient days, DDD per 1000 patient days; 
and for the use of antimicrobials in the community, DDD per 1000 inhabitants per day is used 
(Mutnick et al., 2004).  When drug use by inpatients in hospitals is considered, drug 
consumption is usually presented as DDD/1000 inhabitants per day or DDD/100 bed-days.  
However, the WHO recommends the use of DDD/100 bed-days in hospitals.  The choice of 
denominator is important; as an example, 10 DDD/1000 inhabitants per day shows that 1% of the 
population on average might receive a certain drug or group of drugs daily; whereas, 70 
DDD/100 bed-days suggest that 70% of the inpatients might receive a DDD of a drug daily. 
In order to simplify the calculation of DDD, the National Center for Antimicrobials and Infection 
Control developed the ABC Calc software (Monnet, 2006; Keuleyan et al., 2010).  ABC Calc is 
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a simple computerized tool to measure antibiotic consumption in hospitals which transforms 
aggregated data supplied by hospital pharmacies into meaningful antibiotic utilisation rates 
(Gould et al., 2005; Monnet, 2006).   
Thus, the overall aim of this chapter was to determine the consumption of antibiotics in a major 
Lebanese hospital using ABC Calc and to assess the profile of microbial susceptibility to 
commonly prescribed antibiotics.  These studies tested the hypothesis that antibiotic 
consumption correlates with the susceptibility of microorganisms to various antibiotics.  In order 
to achieve this goal, data related to antibiotic consumption and microbial susceptibility for E. coli 
and K. pneumoniae were gathered from the hospital in Lebanon over a 3-year period and the 
following objectives were set: 
i. Calculate daily consumption rates for individual types and groups of antibiotics using 
ABC Calc and express these as DDD per 100 bed days. 
ii. Determine the profile of susceptibility to E. coli and K. pneumoniae using the disk 
diffusion method, which were kindly provided to the author by the laboratory department 
of the CHN hospital. 
iii. Define whether there is a correlation between antimicrobial consumption and antibiotic 
susceptibility to E. coli and K. pneumoniae using Spearman correlation coefficient (r). 
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5.2 Results 
5.2.1 Antibiotic consumption rates 
Antibiotic consumption data of in-patients were collected from the hospital over a short interval 
of time (three years): 2010, 2011 and 2012 and expressed as DDD per 100 bed days using the 
ABC Calc program.  Usage of other β-lactam antibiotics (cephalosporins, monobactams and 
carbapenems) represented the highest group corresponding to approximately 50 DDD per 100 
bed days each year.  Consumption of antibiotics belonging to β-lactam antibacterial, penicillins 
(penicillin M, ureidopenicillin, carboxypenicillin, and aminopenicillins) or quinolones were 
much lower, accounting for approximately 14 and 6 DDD per 100 bed days each year (Figure 
27). 
 
Figure 27: Antibiotic consumption data (DDD/100 bed days) of β-lactam antibacterial, penicillins, other β-
lactam antibiotics and quinolones from a major Lebanese hospital between 2010 and 2012.  Antibiotics usage 
in the hospital from 2010 to 2012 were determined using ABC Calc software and grouped based on the WHO 
classification of drugs and other medical products (Monnet, 2006).   
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Within the β-lactam antibacterials, penicillins, those with combination of penicillins including β 
-lactamase inhibitors (amoxicillin + clavulanic acid and piperacillin + tazobactam) were the most 
used antibiotics in this group (Figure 28).  Their use had slightly declined over the three years; 
while the penicillins with extended spectrum and β-lactamase resistant penicillins were 
approximately stable.   
 
Figure 28: Antibiotic consumption data (DDD/100 bed days) of penicillins with extended spectrum 
(ureidopenicillin, carboxypenicillin, and aminopenicillins), β-lactamase resistant penicillins (penicillin M), 
and combination of penicillins including β-lactamase inhibitors from a major Lebanese hospital between 2010 
and 2012.  Antibiotics usage in the hospital from 2010 to 2012 were determined using ABC Calc software and 
grouped based on the WHO classification of drugs and other medical products (Monnet, 2006).   
 
Further analysis of the data relating to the consumption of the other β-lactams antibacterials 
revealed that cephalosporins belonging to the 3
rd-
 and 4
th-
 generation were used more frequently 
than those belonging to the earlier generation cephalosporins (Figure 29).  Over the three years 
of the study, the use of 1
st-
, 2
nd-
 and 3
rd-
/4
th-
 generation antibiotics decreased.  Although 
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carbapenems were used at a much lower level, their use increased from 4.1 to 5 DDD per 100 
bed days per year (representing an approximately 20% increase).  Monobactams were used least 
frequently (Figure 29). 
 
 
Figure 29: Antibiotic consumption data (DDD/100 bed days) of other β-lactams antibacterials from a major 
Lebanese hospital between 2010 and 2012.  Antibiotics usage in the hospital from 2010 to 2012 were determined 
using ABC Calc software and grouped based on the WHO classification of drugs and other medical products 
(Monnet, 2006).   
 
5.2.2 Profiles of susceptibility for E. coli 
All E. coli isolates obtained from the microbiology laboratory at CHN hospital between 1/1/2010 
and 31/12/2012 were processed and their susceptibility profiles to several commonly prescribed 
clinical antibiotics determined.  Approximately 800 isolates were processed each year.  As 
shown in Table 18, all E. coli isolates obtained over the three years were susceptible to imipenem 
(a carbapenem) and fosfomycin, a phosphonic acid derivative with broad spectrum activity 
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(Souli et al., 2011).  Conversely, the lowest levels of susceptibility were observed to ampicillin 
and piperacillin (approximately 35%).  The percentage of isolates susceptible to most antibiotics 
including trimethoprim-sulfamethoxazole (TMS), nitrofurantoin, ciprofloxacin, amikacin, 
gentamicin and the monobactam, aztreonam remained stable over the three years.  There was a 
slight decrease in susceptibility to piperacillin-tazobactam (-6%) over the same time period 
(Table 18). 
The susceptibility trends of E. coli to the cephalosporin antibiotics are represented graphically in 
Figure 30.  There was evidence of reduced susceptibility to cefoxitin, (down from 93 to 81%), 
the percentage of E. coli susceptible to the other three cephalosporin antibiotics remained 
relatively constant. 
 
 
Figure 30: Susceptibility (%) of clinical E. coli isolates to cephalosporin antibiotics from 2010 to 2012.  All 
clinical isolates obtained at the hospital were tested using the disk diffusion method for their susceptibility to 
cephalosporin antibiotics including cefepime, ceftazidime, cefuroxime, and cefoxitin.  The disk diffusion method 
and interpretation of results was conducted according to the CLSI guidelines.  Note: while susceptibility to cefoxitin 
declines over the time period, this is not apparent for the other 3 antibiotics. 
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Table 18: Antimicrobial susceptibility (%) of clinical E. coli isolates obtained from a major Lebanese hospital between 2010 and 2012.  All clinical E. coli 
isolates processed by the microbiological laboratories at CHN hospital, Lebanon between 2010 and 2012 were screened for susceptibility to different antibiotics 
using the disk diffusion method.  Interpretations of drug sensitivities were based on CLSI guidelines.  Antibiotics included were: amikacin, amoxicillin + 
clavulanic acid, ampicillin, aztreonam, cefepime, ceftazidime, cefuroxime, cefoxitin, ciprofloxacin, fosfomycin, gentamicin, imipenem, nitrofurantoin, 
piperacillin, piperacillin + tazobactam, and TMS (trimethoprim-sulfamethoxazole).  S: Susceptibility, S1: Semester 1 (January to June), S2: Semester 2 (July to 
December).  Approximately 800 isolates were processed each year. 
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5.2.3 Correlation between antibiotic consumption and susceptibility to E. coli 
In order to explore the relationship between antibiotic consumption and susceptibility to E. coli, 
correlations between the two variables were examined using the Spearman correlation coefficient 
(r) (SPSS software).  Negative correlation coefficients indicated that increased antibiotic 
consumption was associated with decreased susceptibility, or vice versa.  Conversely, a positive 
correlation coefficient indicated that as antibiotic consumption increased or decreased, a similar 
directional change occurred in the susceptibility of the organisms. 
In general, correlation data showed strong statistical significance (r > 0.7 and P < 0.05) between 
consumption of β-lactam antibiotics and quinolone antibiotics, and resistance to various 
antibiotics.  Significant negative correlations were associated with use of each of the main 
groups of antibiotics considered; namely antibacterials for systemic use (total), the β-lactam 
antibacterial; penicillins, other β-lactams and the quinolones (Table 19).  Specifically, increasing 
consumption of carbapenems was correlated with decreasing susceptibility (and therefore 
increased levels of resistance) to a wide range of antibiotics including 3
rd-
/4
th-
 generation 
cephalosporins.  Even though a correlation was observed between the consumption of 
carbapenems and resistance to several antibiotics (amoxicillin + clavulanic acid, ampicillin, 
cefepime, ceftazidime, cefuroxime, cefoxitin, piperacillin, and piperacillin + tazobactam), a clear 
conclusion remains questionable since carbapenems are potent antibiotics with wide spectrum 
activity and a low level of resistance (EFSA, 2013).  Therefore, the correlation between the use 
of these drugs and the appearance of resistance should be evaluated in the future in the light of a 
potential increase in resistance to carbapenems.  Susceptibility to ciprofloxacin was also 
significantly correlated to the decreased consumption of a number of different antibiotic groups 
including antibacterials for systemic use (total), other β-lactam antibacterials including the 3rd-
/4
th-
 generation cephalosporins, and the quinolones.  Closer examination of the percentage 
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susceptibility data reveals that it does not follow a monotonic pattern (ie a simple increase or 
decrease), instead it dropped in 2011, but was higher in both 2010 and 2012.  This may confound 
the interpretation of the Spearman‘s test.  Finally, decreasing levels of susceptibility to ampicillin 
were negatively correlated to the consumption of β-lactam antibacterials, penicillins.   
In some instances, a positive or a negative correlation coefficient was observed between the 
consumption of some antibiotics and susceptibility to antibiotics (r > 0.7); there correlations were 
not statistically significant (p > 0.05).  This idea is illustrated for example in the case of 
consumption of β-lactams antibacterials, penicillin and susceptibility to cefuroxime (r = -0.714, 
p= 0.111).   
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Table 19: Correlation coefficients of antibiotic consumption data versus microbial susceptibility to selected antibiotics for E. coli.  Antibiotics usage in the hospital 
from 2010 to 2012 were determined using ABC Calc software and grouped based on the WHO classification of drugs and other medical products (Monnet, 2006).  J01 is 
a therapeutics subgroup of the anatomical therapeutic chemical classification system.  Susceptibility profiles of clinical E. coli isolated in the hospital microbiology 
laboratories over the same time were determined.  Correlations between the datasets were analysed using SPSS software.  Spearman‘s correlation coefficients (R) of 
greater than 0.7 were generally indicative of a significant interaction (P<0.05).  The highlighted cells represent significant correlations (R>0.7, P<0.05).   
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5.2.4 Profiles of susceptibility for K. pneumoniae  
Approximately 150 K. pneumoniae isolates per year were screened for their antibiotic 
susceptibility profiles as outlined previously for E. coli.  As shown in Table 20, nearly all clinical 
K. pneumoniae isolates obtained over the three year period were susceptible to imipenem and 
fosfomycin, but none were susceptible to ampicillin and piperacillin.  Susceptibility profiles to 
most of the other antibiotics including cefepime, ceftazidime, aztreonam, ciprofloxacin, 
cefuroxime, TMS, gentamicin, and piperacillin + tazobactam varied over time (2010-2012) 
showing slight variability around a more or less stable mean.  Finally, the percentage of 
Klebsiella isolates susceptible to amoxicillin + clavulanic acid and cefoxitin remained unchanged 
over the study period (Table 20 and representative data in Figure 31). 
      
 
Figure 31: Susceptibility (%) of clinical K. pneumoniae isolates to cephalosporin antibiotics from 2010 to 
2012.  All clinical isolates obtained at the hospital were tested using the disk diffusion method for their susceptibility 
to cephalosporin antibiotics including cefepime, ceftazidime, cefuroxime, and cefoxitin.  The disk diffusion method 
and interpretation of results was conducted according to the CLSI guidelines.  Note: Susceptibility to cefoxitin was 
higher compared to the other 3 antibiotics. 
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Table 20: Antimicrobial susceptibility (%) of clinical K. pneumoniae isolates obtained from a major Lebanese hospital between 2010 and 2012.  All 
clinical K. pneumoniae isolates processed by the microbiological laboratories at CHN hospital, Lebanon between 2010 and 2012 were screened for 
susceptibility to different antibiotics using the disk diffusion method.  Interpretations of drug sensitivities were based on CLSI guidelines.  Antibiotics included 
were: amoxicillin + clavulanic acid, ampicillin, aztreonam, cefepime, ceftazidime, cefuroxime, cefoxitin, ciprofloxacin, fosfomycin, gentamicin, imipenem, 
nitrofurantoin, piperacillin, piperacillin + tazobactam, and TMS (trimethoprim-sulfamethoxazole).  S: Susceptibility, S1: Semester 1 (January to June), S2: 
Semester 2 (July to December).  Approximately 150 isolates were processed each year. 
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5.2.5 Correlation between antibiotic consumption and susceptibility to K. pneumoniae 
In general, correlation data also showed strong statistical significance (r > 0.7 and P < 0.05) 
between consumption of mainly quinolones and β-lactam antibiotics and resistance to various 
antibiotics.  Significant positive correlations were associated with use of 1
st-
 and 2
nd-
 generation 
cephalosporins and susceptibility to cefoxitin (Table 21).  On the other hand, susceptibility to 
amoxicillin + clavulanic acid was also significantly correlated to the decreased consumption of a 
number of different antibiotic groups including antibacterials for systemic use (total), β-lactam 
antibacterials, penicillins, combination of penicillins including β-lactamase inhibitors, other β- 
lactam antibacterials including third and fourth generation cephalosporins, and quinolones 
antibacterials.  Increasing levels of susceptibility to ciprofloxacin and piperacillin + tazobactam 
were negatively correlated to the consumption of antibacterials for systemic use (total), other β- 
lactam antibacterials, and quinolones antibacterials.  Finally, the consumption of antibacterials 
for systemic use (total) and consumption of quinolones antibacterials was negatively correlated 
with susceptibility to aztreonam and ceftazidime. 
In some cases, a positive or a negative correlation coefficient was observed between the 
consumption of some antibiotics and susceptibility to antibiotics (r > 0.7); this correlation was 
not statistically significant (p > 0.05).  One example illustrating this idea would be the case of 
consumption of β-lactam, penicillins and susceptibility to piperacillin + tazobactam (r = -0.736; 
p= 0.096).   
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Table 21: Correlation coefficients of antibiotic consumption data versus microbial susceptibility to selected antibiotics for K. pneumoniae.  Antibiotics usage in 
the hospital from 2010 to 2012 were determined using ABC Calc software and grouped based on the WHO classification of drugs and other medical products (Monnet, 
2006).  J01 is a therapeutics subgroup of the anatomical therapeutic chemical classification system.  Susceptibility profiles of clinical K. pneumoniae isolated in the 
hospital microbiology laboratories over the same time were determined.  Correlations between the datasets were analysed using SPSS software.  Spearman‘s correlation 
coefficients (R) of greater than 0.7 were generally indicative of a significant interaction (P<0.05).  The highlighted cells represent significant correlations (R>0.7, 
P<0.05). 
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5.3 Discussion 
Antimicrobial susceptibility testing facilitates the treatment of infections and promotes better 
patient outcomes (Mach et al., 2011; Liu et al., 2014).  As such, antimicrobial susceptibility 
profiles combined with clinical evidence aids the selection of the most appropriate antibiotic 
therapy and also reduces the risk of resistant bacterial populations developing.  While 
antimicrobial resistance in E. coli and K. pneumoniae has increased globally over the past two 
decades, susceptibility patterns can show significant geographic variation.  Other contributing 
factors include differences relating to clinical settings and population demographics (Kibret et al., 
2011).  Thus, here the susceptibility profiles of clinical E. coli and K. pneumoniae isolates gathered 
from a major Lebanese hospital were examined.  Both bacterial species were found to be highly 
susceptible to imipenem and fosfomycin, making these antibiotics the treatment of choice 
(including for ESBL-producing organisms).  These findings are consistent with other studies (Kanj 
et al., 2011; Rawat et al., 2010).  However, with the prevalence of carbapenem-resistant and 
fosfomycin-resistant Enterobacteriaceae also increasing, the utility of these antibiotics may be 
short-lived (reviewed in Lee et al., 2014). 
Antibiotic consumption is considered a major contributor to emerging antimicrobial resistance 
(Threlfall et al., 2000; Borg et al., 2008; Landers et al., 2012).  The data in this chapter confirm 
the presence of a correlation between these two factors.  For example, the consumption of 1
st
 and 
2
nd-
 generation cephalosporins was positively correlated with the susceptibility of K. pneumoniae 
to cefoxitin.  The data also indicated that reduced use of these antibiotics was associated with 
decreased susceptibility (although the antimicrobial susceptibility (%) only changes from 92.5% 
to 91.5% over the three years) of the isolates.  This result is somewhat counterintuitive, but may 
suggest that factors, other than exposure to the antibiotics maybe driving the emergence of 
resistance.  Negative correlation coefficients were found between the consumption of 
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antibacterials for systemic use (total), β-lactam antibacterials, penicillins, other β- lactam 
antibacterials and quinolones, and the susceptibility of E. coli and K. pneumoniae.  According to 
the literature, the major factor prompting the spread of ESBL-producing Enterobacteriaceae is 
exposure to the 3
rd-
 generation cephalosporin, ceftazidime (Rahal et al., 1998; Lin et al., 2003).  
On average the consumption of β-lactam antibiotics in Eastern and Southern Mediterranean 
hospitals accounts for more than half of all antibiotics prescribed, with a notable emphasis on 3
rd-
 
generation cephalosporins when compared to other families of antibiotics in the clinical setting 
(Borg et al., 2008).  Quinolone consumption is also especially high in some countries and 
institutions such as in Cypriot hospitals and the institutions from Jordan and Lebanon (Borg et 
al., 2008).   
In summary, the consumption of β-lactam antibiotics and quinolones was strongly correlated 
with the development of resistance to various antibiotics in E. coli.  The strongest correlation 
was associated with the consumption of carbapenems and susceptibility of E. coli to cefepime (r 
= -1.000).  Similar findings were seen in K. pneumoniae; where the consumption of β-lactam 
antibiotics and quinolones was also strongly correlated with resistance to various antibiotics.  In 
this case, the strongest correlation associated with the consumption of quinolones was 
susceptibility of K. pneumoniae to amoxicillin + clavulanic acid (r = -0.986).  These findings are 
consistent with data from other studies that found that increased consumption of β-lactam and 
quinolones was associated with increased resistance in E. coli and K. pneumoniae (Sabir et al., 
2004; Davies et al., 2010; Meyer et al., 2010).  Even though the use of cephalosporins, 
quinolones, and carbapenems has been reported as an important factor leading to the increased 
number of ESBL-producing isolates; aminoglycosides and other antibiotic families have also 
been reported (Demirdag et al., 2010). 
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Selection of antibiotic resistance is an inevitable consequence of antibiotic usage.  The 
correlation between use of antibiotics and resistance to them is becoming a promising research 
tool.  Though reports on ESBL-producing Enterobacteriaceae have focused on hospitalized 
patients, ESBL-producing organisms have also been reported from community patients, 
signifying that the community may act as a reservoir for the incidence of resistance in bacterial 
isolates (Mesa et al., 2006).  Based on these findings, it is important to emphasize that the 
consumption of broad spectrum antibiotics is one parameter that can explain the emergence of 
more resistant bacteria mostly E. coli and K. pneumoniae and suggest the essential need for 
improvements in the antibiotic stewardship programs in order to limit the rise of resistant 
microorganisms.  It is crucial to understand that antibiotics are needed to sustain high health 
quality (Baquero et al., 2002).  In the cases in which correct antibiotics are prescribed, the 
benefits to patient health far outweigh the potential risks, including resistance to the antibiotic 
(Baquero et al., 2002).  Therefore, one could suggest that only the unnecessary use of antibiotics 
constitutes a serious problem for public health.  Furthermore, in addition to bacterial factors 
(incidence of antibiotic resistant and susceptible isolates); both cultural factors and human 
genetics may interact to impact both the spread and control of antibiotic resistance (Baquero et 
al., 2002). 
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CHAPTER 6 
Discussion and Conclusion 
Bacterial resistance to antibiotics is a major global issue that has concerned researchers, 
physicians and veterinarians for many years (Wise et al., 1998; Salem et al., 2013; Carlet et al., 
2014).  The increasing prevalence of antibiotic resistant bacteria and their ability to evade the 
action of an ever increasing arsenal of antibiotics is a threat to human and animal patients and 
health care systems alike.  Without concerted global efforts the risk of untreatable common 
infections is a reality.  This thesis sought to further understand the pathobiology of antimicrobial 
resistance in two common bacterial pathogens (E. coli and K. pneumoniae) causing infections in 
both animals and humans.   
The production of extended spectrum β-lactamases (ESBLs) is one of the main mechanisms by 
which Gram negative bacilli obtain resistance to β-lactam antibiotics (Hawkey et al., 2009; 
Salem et al., 2013).  ESBLs have been increasing in many countries, including Lebanon (Hunter 
et al., 2010; Rishi et al., 2011; Salem et al., 2013).  The consequences of infection with ESBL-
producing organisms can be detrimental and lead to increased morbidity and mortality (Daoud et 
al., 2006).  During the 1990s, ESBLs mainly belonged to the TEM and SHV β-lactamase 
families.  They are now most frequently associated with carriage of CTX-M (Coque et al., 2008).  
The spread of resistant isolates has occurred despite resistance being costly to the host organism; 
therefore, it is important to rigorously test how bacterial fitness might be affected by the 
acquisition of plasmids carrying these enzymes.  In addition, the use of particular antibiotics 
within the clinic may be an important factor driving the emergence of bacterial resistance (Rahal 
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et al., 1998; Kanafani et al., 2005).  Thus, the relationship between drug use and microbial 
susceptibility to different antibiotics was examined.   
In order to have a focused view of the current situation in Lebanon, two microorganisms (E. coli 
and K. pneumoniae) were selected for further study.  These organisms were selected as they were 
the most commonly isolated resistant organisms detected in the Lebanese hospital at the center of 
this work.  Among the Enterobacteriaceae family, E. coli and K. pneumoniae have been 
described as problematic pathogens with regard to antimicrobial resistance and emerging 
virulotypes in many other countries (Daoud et al., 2003; Huehn et al., 2010; Robino et al., 2003).   
Over the past two decades, the incidence of resistance to 3
rd-
 generation cephalosporins among 
ESBL-producing isolates of E. coli and K. pneumoniae has increased considerably (Lautenbach 
et al., 2001).  Several factors are thought to have contributed to the increased prevalence of 
ESBL-producing organisms such as prior hospitalization of patients, antibiotic choice and 
duration of treatment, and the use of catheters (Lautenbach et al., 2001; Kim et al., 2002).   
Based on the results presented here, all the E. coli and K. pneumoniae isolates that were found to 
be resistant to 3
rd-
 generation cephalosporins were ESBL-producers.  Consistent with other 
studies (e.g. Shamim et al., 2007; Daoud et al., 2011), approximately two thirds of ESBL-
producing isolates in this study were isolated from female patients.  Specifically, 36% of the E. 
coli isolates came from male patients while 64% were from female patients.  43% of the K. 
pneumoniae isolates were from male patients, while 57% were from female patients.  This 
discrepancy between genders may be related to anatomical factors that predisposes females to 
infection and specifically UTI infections.  With regards to the number and type of isolates 
recovered from infections, Daoud et al. (Daoud et al., 2011) demonstrated that the number of E. 
coli isolates was higher than K. pneumoniae mainly because the predominate pathogen isolated 
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from patients with UTIs is usually E. coli (Kahlmeter, 2003).  This was also observed in another 
study that was based on faecal samples from intensive care patients which showed that of 111 
isolates, 95 isolates were E. coli and 16 were K. pneumoniae (Daoud et al., 2006).  Similar 
findings were also observed in the studies here, where the number of E. coli isolates was 100 
(71% of total isolates) while that of K. pneumoniae was 40 isolates (29% of total isolates), 
respectively. 
Paterson et al. stated that urine samples are an important epidemiological indicator for bacterial 
colonization and their analysis facilitates the detection of ESBLs (Paterson et al., 2005).  In the 
study presented here, 88% of E. coli isolates and 57.5% of K. pneumoniae isolates were collected 
from urine, respectively, with the remainder isolated from sputum (6% of E. coli and 27.5% of 
K. pneumoniae), pus (4% of E. coli and 2.5% of K. pneumoniae), blood (2% of E. coli and 10% 
of K. pneumoniae), and one isolate from a catheter (2.5% of K. pneumoniae).  A recent study by 
Daoud et al. reported that ESBL-production in organisms isolated from urinary tract infections 
(UTI) at Saint George Hospital-University Medical Center in Beirut increased from 2.3% to 
16.8% over a period of 9 years (Daoud et al., 2011).  This increase has been previously reported 
in this hospital as well as in other institutions in the country (Daoud et al., 2003; Kanj et al., 
2008).  Thus, the increasing incidence of UTI in the general population has led to an increased 
number of medical consultations and consequently, an increase in the number of antibiotic 
prescriptions. 
The double disk synergy assay has been widely used for the detection of ESBL-producing 
organisms (Drieux et al., 2008; Huang et al., 2010; Rawat et al., 2010).  A comparison between 
different methods for the detection of ESBLs showed that the E-test is a reliable method for 
detecting ESBL-producing E. coli and K. pneumoniae (Dashti et al., 2006).  Rawat et al. has also 
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shown that the double disk synergy method and the E-test ESBL method are highly sensitive and 
specific for the detection of ESBL-producers (Rawat et al., 2010).  In this thesis, both methods 
were employed and the data indicate 100% agreement between them.  For instance, all 140 
isolates of E. coli and K. pneumoniae that displayed resistance to at least one 3
rd-
 or 4
th-
 
generation cephalosporin revealed a positive result when tested using the double disk synergy 
method, evident by the presence of a ―keyhole‖ effect.  Likewise all isolates tested positive for 
ESBL production using the E-test ESBL strip.   
ESBL production was also analysed at the enzymatic level by studying the patterns of growth 
inhibition around different β-lactam antibiotics.  For E. coli, synergy between 
amoxicillin/clavulanic acid and aztreonam, cefepime, and ceftazidime was seen in 84%, 82%, 
and 72% of isolates, respectively (raw data in Appendix IV).  As for K. pneumoniae, the synergy 
between amoxicillin/clavulanic acid and aztreonam, cefepime, and ceftazidime was 82.5%, 75% 
and 60% of the cases, respectively (raw data in Appendix V).  The increased hydrolytic activity 
against aztreonam, cefepime, and ceftazidime that was observed has been previously described to 
be driven by CTX-M-15 production (Wang et al., 2011).  In order to verify this association, 
DNA sequencing of the ESBL gene was performed.  First, PCR analysis revealed that all E. coli 
and K. pneumoniae isolates harboured a CTX-M gene and then sequencing confirmed that the 
CTX-M genes were of the CTX-M-15 type.  These findings were consistent with the conclusions 
of a study by Moubareck et al. which showed that CTX-M-15 was the most widespread ESBL in 
Lebanon with a prevalence of 83% in resistant isolates (Moubareck et al., 2005).  In the United 
Kingdom, over 90% of the E. coli isolates proved to have a CTX-M-15 enzyme (Livermore et 
al., 2007).  In addition to harbouring CTX-M-15, 41% of isolates tested were positive for OXA, 
42% for SHV, and 74% for TEM.  Kiratisin et al. showed that 87.3%, 77% and 3.8% of the 
ESBL-producing isolates in Thailand were carriers of the blaCTX-M, blaTEM, and blaSHV genes, 
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respectively (Kiratisin et al., 2008).  These findings indicate that ESBL-producing isolates can 
harbour more than one β-lactamase gene and that this is common in UTI derived isolates.  This 
finding was also previously reported for E. coli and K. pneumoniae (Apisarnthanarak et al., 
2008).   
The virulence gene content of the E. coli isolates was assessed using conventional PCR.  These 
studies showed that the most common virulence gene present in the E. coli isolates was the 
aerobactin receptor gene, iutA.  Similarly, Oteo et al. and Karisik et al. found that the majority of 
E. coli isolates tested for virulence genes harboured aerobactin receptor (iutA) gene (Oteo et al., 
2006; Karisik et al., 2008).  The iutA gene is part of the aerobactin siderophore system that is 
responsible for microbial survival in fluids with limited iron availability (Koga et al., 2014).  The 
presence of the genes in the test isolates may indicate that the majority of isolates have 
developed mechanisms to survive under low iron environments, such as in the blood stream.  
The highest average virulence gene score (8.1) was found in isolates belonging to phylogroup 
B2.  Approximately 40% of E. coli isolates belonged to group B2, supporting the idea that this 
group harbours mainly virulent extra intestinal E. coli.  Other studies have also found members 
of this phylogroup to contain the most virulence genes (Mokracka et al., 2011, Cunha et al., 
2014). 
PFGE profiles of the resistant isolates show large genetic diversity and suggest that horizontal 
transfer of ESBL-harbouring plasmids may have occurred (Chapter 3), as has also been reported 
by others (e.g. Sabra et al., 2009; Vaidya, 2011).  Therefore, resistance genes may be spread 
between isolates through horizontal gene transfer rather than by clonal spread of the resistant 
isolates. 
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Chromosomally determined AmpC β-lactamases in Enterobacteriaceae were first documented 
when the functional classification scheme was published in 1995, and plasmid-encoded AmpC 
genes were initially described in 1989 (Bush et al., 1995; Bauernfeind et al., 1989; Jacoby, 
2009).  A study conducted by Peter-Getzlaff et al. showed that 18 out of 51 isolates were 
positive for AmpC production (Peter-Getzlaff et al., 2011).  In addition, 23% of E. coli and 18% 
of K. pneumoniae isolates obtained from urine samples were positive for AmpC β-lactamases 
(Rajni et al., 2008).  In this thesis, among the ESBL positive isolates, 27 isolates of E. coli and 8 
isolates of K. pneumoniae were also positive for chromosomal AmpC β-lactamase indicating a 
double mechanism of resistance in these isolates.  None of the isolates were found to contain a 
plasmid-borne AmpC β-lactamase. 
The cost of resistance to the host bacterium may be an important factor determining both the 
prevalence of the isolate and the rate of resistance development.  Since many antimicrobial 
resistance genes are encoded on plasmids, numerous efforts have been dedicated to their study 
(Colomer-Lluch et al., 2011; Freire Martín et al., 2014).  Data from these studies as well as that 
presented in this thesis indicate that plasmid-encoded β-lactamases reside on highly promiscuous 
conjugative plasmids, which may be responsible for the emergence of resistant isolates in E. coli 
and K. pneumoniae.  Plasmid profiling showed that resistant isolates harboured between 1 to 3 
plasmids, and that the ESBL plasmids harboured the CTX-M-15 gene and likely belonged to the 
following plasmid types: IncI1 plasmid, pEC_L8 plasmid, IncF plasmid, and IncFIIK plasmid.  
Smet et al. and Zhang et al. reported that the spread of CTX-M-15 gene have been mediated by 
IncI1, pEC_L8, and IncFII-related group plasmids (Smet et al., 2010; Zhang et al., 2013).  The 
CTX-M-15 enzyme may have been selected by the increased usage of antibiotics in the hospital 
(Trang et al., 2013).   
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A clear link among the β-lactamase genes and the plasmids (IncI1 plasmid, pEC_L8 plasmid, 
IncF plasmid, and IncFIIK plasmid) can be seen where different plasmids scaffolds/replicons 
(FIB, P, I1, N, FII, FIC, Col156, FIA, and ColpVC) were associated with the same gene in this 
case the CTX-M-15 (Smet et al., 2010; Zhang et al., 2013; Carattoli et al., 2014).  This link has 
also been discussed by Garcia-Fernandez et al., who mentioned that the same plasmid scaffold 
can be associated with different genes and different plasmids scaffolds can be associated with the 
same gene (Garcia-Fernandez et al., 2008). 
To investigate whether ESBL genes were located on conjugative plasmids and if resistance could 
be transferred, bacterial conjugation studies were performed.  These studies revealed that the 
conjugation frequency for the 6 ESBL-producing E. coli (1, 2, 9, 11, 35, and 39) and the 4 
ESBL-producing K. pneumoniae isolates (101, 103, 105, and 110) was between 10
-5
 and 10
-6
 
which was comparable to the results of a studies conducted by Gomez et al., Mugnaioli et al., 
Amos et al., and Zurfluh et al. (Gomez et al., 2005; Mugnaioli et al., 2006; Amos et al., 2014; 
Zurfluh et al., 2014).  In addition, according to Smith et al., a significant longer lag phase was 
observed in the clone transformed with the largest plasmid (Smith et al., 1998).  Similar findings 
were seen in this thesis.  The ESBL plasmid increased the generation time in E. coli and K. 
pneumoniae, thus potentially creating a less fit microorganism.  This biological cost was also 
reported by Haft et al. who described the influence of plasmids on the generation time of E. coli 
(Haft et al., 2009).  
Antimicrobial susceptibility testing is usually performed in vitro in order to predict the most 
appropriate antibiotics that will be used in vivo for the clinical treatment of patients.  Antibiotic 
resistance in E. coli and K. pneumoniae has increased worldwide and its prevalence varies from 
patient to patient, from hospital to hospital and from year to year (Tonkic et al., 2005; Mesa et 
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al., 2006).  This study focused on resistance in two species, E. coli and K. pneumoniae.  The two 
panels of organisms showed approximately 100% susceptibility to imipenem and fosfomycin and 
the lowest susceptibility rates for ampicillin and piperacillin.  Based on the susceptibility 
findings, imipenem and fosfomycin may be used as treatment options for E. coli and K. 
pneumoniae isolates (including ESBL-producing organisms).  Similar results were described by 
Kanj et al., who described that carbapenems and fosfomycin are considered the main antibiotics 
used to treat infections caused by these organisms (Kanj et al., 2011).  A large number of 
acquired carbapenemase enzymes have been isolated among Gram negative pathogens, including 
E. coli and K. pneumoniae from USA, Europe, Latin America, and India (Castanheira et al., 
2011; Deshpande et al., 2010; reviewed in van Hoek et al., 2011), such as the New Delhi metallo 
β-lactamase (NDM) (Deshpande et al., 2010; Rimrang et al., 2012).  Therefore, detection of 
carbapenemase-producing organisms is also of major importance in order to successfully treat ill 
patients.   
Antibiotic consumption has been reported as a major cause of resistance (Sharma et al., 2005; 
Borg et al., 2008).  Many studies assessing the correlation between antibiotic consumption and 
resistance have been useful in highlighting the role of antibiotic pressure on the selection of 
resistant pathogens (Borg et al., 2010).  This point does not apply at all times; some studies have 
shown positive correlation while others have shown negative correlations, based on the 
microorganism in question and the antibiotic tested (Lai et al., 2011; Plüss-Suard et al., 2013; 
Sedláková et al., 2014).  Starting with E. coli, a negative correlation was described between 
consumption of antibacterials for systemic use (total), β-lactam antibacterials; penicillins, 
penicillins with extended spectrum, combination of penicillins (including β-lactamase 
inhibitors), other β-lactam antibacterials, third and fourth generation cephalosporins, 
carbapenems, and quinolones antibacterials and susceptibility of E. coli to various antibiotics.  In 
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contrast for K. pneumoniae, a positive correlation was seen between consumption of first and 
second generation cephalosporins and susceptibility of K. pneumoniae to cefoxitin.  However, a 
negative correlation was described between the consumption of antibacterials for systemic use 
(total), β-lactam antibacterials; penicillins, combination of penicillins (including β-lactamase 
inhibitors), other β-lactam antibacterials, third and fourth generation cephalosporins, 
monobactams, and quinolones antibacterials and susceptibility of K. pneumoniae to various 
antibiotics.  Tonkic et al. showed that the 3
rd-
 generation cephalosporin groups are the most 
frequently prescribed antibiotics to patients in hospital (Tonkic et al., 2005).  According to 
Kanafani et al. the consumption of 3
rd-
 generation cephalosporins was considered the highest risk 
factor associated with patients harbouring ESBL-producing isolates (Kanafani et al., 2005).  This 
antibiotic is not the sole culpable agent for increasing the prevalence of ESBL-producing 
isolates; other antibiotics have been described to be associated with outbreaks of ESBL-
producing Enterobacteriaceae such as quinolones, aminoglycosides, and carbapenems (Rupp et 
al., 2003; Demirdag et al., 2010; Rawat et al., 2010).  The data presented here have shown a 
strong correlation between the consumption of quinolones and β-lactams, and resistance to 
numerous antibiotics (amoxicillin + clavulanic acid, aztreonam, ampicillin, cefepime, 
ceftazidime, cefuroxime, cefoxitin, piperacillin, piperacillin + tazobactam, and ciprofloxacin).  
Based on these outcomes, it is important to highlight that the consumption of broad and extended 
spectrum antibiotics is one parameter that is influencing the emergence of resistant bacteria. 
In conclusion, antibiotics have been used to treat patients with infectious diseases and have 
greatly reduced morbidity and mortality worldwide.  Conversely, the extensive use of these 
drugs has allowed microorganisms to adapt, thus making the antibiotics less effective and in 
some instances, totally ineffective.  Therefore, bacterial resistance is now leading to significantly 
increased risks of mortality and morbidity, disease complications, and treatment failures.  A 
155 
 
further consequence of antimicrobial resistance is the widespread economic implications 
associated with prolonged sick leave and hospital stays.   
Antimicrobial resistance in Gram-negative and Gram-positive organisms is a significant global 
issue (Baquero, 1997; Souli et al., 2008).  Of great concern is the potential increase in frequency 
of infections caused by these organisms (Baquero, 1997; Weinstein, et al., 2005).  In the last 15 
years, ESBLs in Gram-negative isolates have changed from being an interesting scientific 
observation to a reality of enormous medical importance (Bradford, 2001).  In Lebanon, the 
diversity and increasing incidence of ESBLs found among the Enterobacteriaceae family, mainly 
E. coli and K. pneumoniae, mirrors that found worldwide and poses a serious problem for 
physicians, veterinarians and para-professionals with regards to antimicrobial selection.  The 
main type of β-lactamase produced by these isolates is CTX-M-15-type ESBLs.  Their location 
on conjugative plasmids is likely a key factor influencing the emergence and rapid spread of 
resistance in E. coli and K. pneumoniae (Doumith et al., 2011), as well as other species including 
Proteus, Salmonella, and non-fermenting bacteria such as Pseudomonas aeruginosa (Pagani et 
al., 2002; Threlfall et al., 1997; Carattoli, 2003; Liebana et al., 2005; Malloy et al., 2011; Freire 
Martín et al., 2014).  Furthermore, a clear relationship has been observed between bacterial 
resistance and antibiotic usage, primarily between the consumption of β-lactams and quinolones 
and resistance in these isolates.  This relationship is subject to changes depending on the 
bacterial type, the antibiotic in question, and the particular ecological niche (Rashid, 2013).  The 
isolation of ESBLs is now common place in both livestock and companion animals and of 
specific concern is the high prevalence of ESBLs in intensive livestock systems such as the 
poultry, pig and dairy industries (Mesa et al., 2006; Horton et al., 2011; Freire Martín et al., 
2014). 
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Given the significant issues posed by ESBL resistance, there is an urgent need for new 
antibiotics to be developed, enhancements in the antibiotic stewardship programs, and the careful 
monitoring and regulation of antibiotics use in both human and veterinary medicine.  This must 
be complemented by active and scanning surveillance and epidemiological studies to monitor the 
global spread of plasmid encoded β-lactamases and indeed other forms of resistance. 
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Future perspectives 
The increasing incidence and spread of ESBL-producing organisms in hospitals and 
communities remains problematic and will continue to affect the clinical outcome of patients 
both now, and in the future.  As such, worldwide surveillance, effective diagnostic and screening 
measures, and strict treatment guidelines are needed to try to slow the dissemination of resistant 
infectious agents.  The findings from this study have led to the identification of several areas of 
future research that may help address this global problem including: 
 
1- Further characterisation of ESBL-producing isolates and their plasmids in order to better 
understand the microbial factors contributing to the spread of antimicrobial resistant 
elements within bacterial populations.  For example, the plasmid sequences should be 
completely closed and any additional ESBL genes (TEM, SHV, and OXA genes) present 
in the isolates, sequenced.  Such data will also help decipher the evolutionary 
relationships between different antimicrobial resistance genes and plasmids.  Further, 
examining the relationship between different plasmid types (replicons) and their relative 
transmissibility in bacterial populations may be informative to understanding their 
prevalence.   
 
2- Sequencing of the host bacteria to determine whether the genetic background of the host 
bacterium influences plasmid acquisition, stability and transfer.  Furthermore, does the 
host bacterium‘s genetic background or prior plasmid content influence the burden 
associated with plasmid acquisition? 
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3- Testing of the stability and/or spread of resistant elements in experimental hosts.  In this 
thesis, fitness of resistant bacteria versus susceptible derivatives were tested using a 
simple growth assay performed in rich media under laboratory conditions.  However, 
fitness can be environment-specific and therefore, it would be interesting to explore the 
relative fitness of the isolates in an experimental host.  For example, it may be possible to 
orally inoculate mice with mixtures of antibiotic-resistant and antibiotic-sensitive isolates 
of E. coli and examine their recovery over time.  This would allow examination of the 
impact of intestinal passage on resistant and sensitive microorganisms.  Such data will 
help provide a more realistic estimate of their relative fitness as well as the risk of 
resistant elements spreading within microbiota present in the mammalian intestine.   
 
4- Monitoring the consumption of other families of antibiotics such as aminoglycosides and 
tetracyclines, and the emergence of expected and novel antimicrobial resistance 
populations.  The relationship between antibiotic consumption and antimicrobial 
resistance is highly complex but could offer insights into how novel resistances develop 
within microbial populations. 
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Appendices 
          Appendix I: Summary list of reagents and equipement.   
Material Manufacturer/ Provider 
MacConkey and Mueller–Hinton agar Oxoid ® 
Calcium Chloride HiMedia 
®
 
Antibiotics BBL 
TM
, sensi-disk 
E-test (ESBL) BioMerieux 
®
 
Pipette tips BioMérieux 
®
 
Agarose gel HiMedia 
®
 
Primers + dNTPs Fermentas 
®
 
Ethanol Riedel-de-Haën 
®
 
Ethidium Bromide AMERSCO 
®
 
Taq polymerase and supplements Fermentas 
®
 
Multiplex PCR Kit Qiagen 
®
 
TBE buffer Amersco 
®
 
Ultraviolet transilluminator DIGI DOC-IT System 
TM
 
Vortex VELPA Scientifica 
®
 
Incubator Sanyo 
®
 
-80˚C Refrigerator Samsung ® 
API 20E BioMérieux 
®
 
Analytical balance Shimadzu
 ®
 
OmniLog Biolog 
®
 
0.5 McFarland‘s Standard HiMedia ® 
4°C Refrigerator Samsung 
®
 
Autoclave Astell 
®
 
Bunsen Burners Labtech 
®
 
Centrifuge Jouan 
®
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Cotton Swabs Citotest 
®
 
Cryogenic Vials Corning 
®
 
Forceps Sklar 
®
 
Glass Pipettes Volac 
®
 
Glassware Boeco 
®
 
Gloves Innovative 
®
 
Falcon Tubes Starsted 
®
 
Glycerol HiMedia 
®
 
Hot Plate Stirrer Clifton 
®
 
Nutrient Broth HiMedia 
®
 
Loops HiMedia 
®
 
Luria Broth HiMedia 
®
 
Micropipettes (1000µL, 100 µL and 10µL) Finnpipette 
®
 
Pasteur Pipettes Plastilab 
®
 
Petri Dishes PlastiLab 
®
 
Phenylboronic Acid (PBA) Sigma-Aldrich 
®
 
Polystyrene Tubes BD Falcon 
®
 
Scale Radwag 
®
 
Serological Pipettes Corning 
®
 
Sodium dodecyl sulfate (SDS) Sigma 
®
 
Water Distiller System Millipore 
®
 
Urine Cups PlastiLab 
®
 
Crystal violet Fluka 
®
 
96-well plates Costar 
®
 
Mannitol motility medium HiMedia 
®
 
Eppendhorf Tubes PlastiLab 
®
 
Microscope Leica 
®
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Appendix II: Origin and size of inhibition zones (mm) around different β-lactam antibiotics for E. coli 
isolates.  Isolates were cultured from the clinical samples listed and their antibiotic resistance profile determined 
using the disk diffusion assay.  Zones of growth inhibition around each disk was measured.  Antibiotics tested 
included cefoxitin (FOX), aztreonam (ATM), cefepime (FEP), cefotaxime (CTX), cefpodoxime (CPD), ceftazidime 
(CAZ) and the β-lactamase inhibitor, amoxicillin clavulanci acid (AMC). 
Isolate Specimen Organism AMC FOX ATM FEP CTX CPD CAZ 
1 Urine E. coli 19 18 8 16 8 8 16 
2 Urine E. coli 19 17 10 11 6 6 6 
3 Urine E. coli 22 17 6 14 6 6 14 
4 Urine E. coli 17 15 6 10 6 6 10 
5 Urine E. coli 18 18 15 14 7 6 15 
6 Urine E. coli 11 17 8 8 8 8 8 
7 Urine E. coli 19 21 10 11 6 6 6 
8 Urine E. coli 19 18 15 18 9 6 17 
9 Urine E. coli 11 18 17 18 10 6 15 
10 Urine E. coli 19 18 11 13 6 6 13 
11 Urine E. coli 24 21 18 19 14 6 20 
12 Urine E. coli 22 18 6 16 6 6 16 
13 Urine E. coli 18 16 6 9 6 6 9 
14 Urine E. coli 12 15 11 15 8 6 12 
15 Urine E. coli 17 12 10 12 6 6 13 
16 Urine E. coli 16 18 14 14 7 6 14 
17 Sputum E. coli 19 24 15 15 6 6 13 
18 Urine E. coli 20 19 6 17 6 6 14 
19 Urine E. coli 17 18 8 10 8 8 10 
20 Urine E. coli 19 18 11 13 6 6 14 
21 Urine E. coli 21 21 8 18 8 8 18 
22 Urine E. coli 20 18 13 16 6 6 16 
23 Urine E. coli 20 13 14 15 6 6 14 
24 Urine E. coli 16 20 11 12 6 6 11 
25 Urine E. coli 20 15 6 6 6 6 6 
26 Urine E. coli 20 19 18 18 9 6 18 
27 Urine E. coli 22 16 11 19 9 6 14 
28 Urine E. coli 17 18 15 18 8 6 17 
29 Urine E. coli 22 16 16 8 10 16 8 
30 Urine E. coli 20 14 6 8 6 6 12 
31 Pus E. coli 17 16 13 17 6 6 16 
32 Urine E. coli 22 20 13 19 6 6 14 
33 Urine E. coli 20 17 16 15 10 10 20 
34 Urine E. coli 16 19 13 15 6 6 15 
35 Urine E. coli 24 18 8 17 8 8 17 
36 Urine E. coli 16 15 13 15 6 6 15 
37 Urine E. coli 20 23 16 17 9 6 17 
38 Urine E. coli 18 17 15 19 8 6 16 
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Isolate Specimen Organism AMC FOX ATM FEP CTX CPD CAZ 
39 Urine E. coli 20 18 16 21 7 6 18 
40 Urine E. coli 16 14 6 6 6 6 6 
41 Urine E. coli 18 25 14 6 14 18 6 
42 Urine E. coli 21 19 16 15 6 10 6 
43 Sputum E. coli 25 26 19 19 11 6 18 
44 Urine E. coli 17 26 14 17 8 6 14 
45 Urine E. coli 18 26 22 22 16 6 21 
46 Urine E. coli 19 24 15 17 10 6 15 
47 Urine E. coli 16 17 6 6 6 6 6 
48 Blood E. coli 23 24 6 18 6 6 18 
49 Urine E. coli 19 23 6 17 6 6 17 
50 Urine E. coli 20 24 19 18 11 6 17 
51 Urine E. coli 20 24 6 16 6 6 14 
52 Urine E. coli 16 19 11 12 6 6 10 
53 Urine E. coli 20 26 18 20 10 10 17 
54 Urine E. coli 22 23 6 15 6 6 13 
55 Urine E. coli 25 22 6 21 6 11 16 
56 Urine E. coli 23 22 6 6 6 6 6 
57 Urine E. coli 18 24 14 15 6 6 14 
58 Urine E. coli 22 26 6 6 6 6 6 
59 Urine E. coli 18 26 6 6 6 6 6 
60 Urine E. coli 19 26 16 16 8 6 16 
61 Urine E. coli 20 21 11 13 6 6 10 
62 Urine E. coli 14 19 6 11 6 6 8 
63 Urine E. coli 24 26 7 12 7 7 12 
64 Urine E. coli 23 22 6 6 6 6 6 
65 Urine E. coli 7 23 6 17 6 6 13 
66 Pus E. coli 20 18 15 16 10 6 14 
67 Urine E. coli 24 18 6 15 6 6 12 
68 Urine E. coli 8 20 11 14 6 8 14 
69 Urine E. coli 20 19 8 12 8 8 12 
70 Urine E. coli 19 17 14 17 7 6 15 
71 Urine E. coli 20 19 17 17 10 6 17 
72 Urine E. coli 18 20 6 15 6 6 14 
73 Sputum E. coli 23 21 14 15 6 6 15 
74 Urine E. coli 19 21 15 16 6 6 16 
75 Blood E. coli 21 13 6 15 8 6 16 
76 Urine E. coli 17 14 6 15 6 6 6 
77 Urine E. coli 18 14 10 12 6 6 12 
78 Urine E. coli 22 23 14 17 8 7 17 
79 Urine E. coli 6 18 6 6 6 6 6 
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Isolate Specimen Organism AMC FOX ATM FEP CTX CPD CAZ 
80 Urine E. coli 20 19 15 15 6 6 16 
81 Urine E. coli 18 20 8 15 6 6 11 
82 Urine E. coli 13 18 13 12 6 6 12 
83 Pus E. coli 18 18 13 10 6 6 14 
84 Urine E. coli 16 25 12 16 6 6 14 
85 Urine E. coli 6 21 6 6 6 6 6 
86 Urine E. coli 18 19 10 12 6 6 13 
87 Sputum E. coli 19 13 13 14 6 6 14 
88 Pus E. coli 19 26 15 19 12 6 18 
89 Urine E. coli 14 22 13 14 8 6 14 
90 Urine E. coli 19 26 15 19 12 6 18 
91 Urine E. coli 16 19 12 13 6 6 13 
92 Urine E. coli 20 22 17 19 10 6 17 
93 Urine E. coli 23 22 6 7 6 6 7 
94 Urine E. coli 19 17 16 16 6 6 16 
95 Urine E. coli 23 22 16 17 6 8 17 
96 Urine E. coli 15 16 11 12 6 6 12 
97 Urine E. coli 20 18 17 18 6 6 18 
98 Sputum E. coli 19 15 8 8 8 8 8 
99 Urine E. coli 15 18 10 11 6 6 12 
100 Sputum E. coli 21 17 16 20 6 6 17 
 
Appendix III: Origin and size of inhibition zones (mm) around different β-lactam antibiotics for K. 
pneumoniae isolates.  Isolates were cultured from the clinical samples listed and their antibiotic resistance profile 
determined using the disk diffusion assay.  Zones of growth inhibition around each disk was measured.  Antibiotics 
tested included cefoxitin (FOX), aztreonam (ATM), cefepime (FEP), cefotaxime (CTX), cefpodoxime (CPD), 
ceftazidime (CAZ) and the β-lactamase inhibitor, amoxicillin clavulanci acid (AMC). 
Isolate Specimen Organism AMC FOX ATM FEP CTX CPD CAZ 
101 Urine K. pneu 18 13 13 18 11 6 14 
102 Catheter K. pneu 23 17 17 21 6 6 20 
103 Urine K. pneu 18 18 15 19 8 6 16 
104 Urine K. pneu 22 15 8 12 8 8 12 
105 Urine K. pneu 10 21 17 16 9 6 19 
106 Urine K. pneu 16 20 6 9 6 6 9 
107 Pus K. pneu 19 20 6 12 6 6 12 
108 Urine K. pneu 15 21 15 14 7 6 14 
109 Urine K. pneu 16 25 6 6 6 6 6 
110 Urine K. pneu 19 20 6 6 6 6 6 
111 Sputum K. pneu 19 19 6 20 6 6 15 
112 Urine K. pneu 17 26 17 16 10 6 16 
113 Urine K. pneu 17 20 6 11 6 6 6 
114 Sputum K. pneu 11 20 8 15 9 6 9 
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Isolate Specimen Organism AMC FOX ATM FEP CTX CPD CAZ 
115 Urine K. pneu 19 20 16 15 6 6 15 
116 Sputum K. pneu 20 20 8 13 8 8 13 
117 Urine K. pneu 20 20 8 17 6 8 17 
118 Sputum K. pneu 20 16 17 18 6 6 18 
119 Urine K. pneu 15 17 6 15 6 6 8 
120 Blood K. pneu 20 20 6 16 6 6 16 
121 Sputum K. pneu 18 21 13 15 7 6 12 
122 Urine K. pneu 19 18 8 18 8 8 11 
123 Blood K. pneu 18 20 18 24 6 6 20 
124 Sputum K. pneu 16 26 29 24 17 7 14 
125 Sputum K. pneu 18 19 15 18 13 6 16 
126 Sputum K. pneu 17 22 15 17 10 6 14 
127 Blood K. pneu 16 19 13 14 8 6 14 
128 Sputum K. pneu 18 21 12 16 9 6 10 
129 Urine K. pneu 15 18 11 15 9 6 11 
130 Sputum K. pneu 19 23 16 20 6 6 17 
131 Blood K. pneu 16 17 11 15 10 6 11 
132 Urine K. pneu 17 20 15 17 9 7 16 
133 Urine K. pneu 16 20 13 14 7 6 14 
134 Urine K. pneu 21 18 16 20 13 7 17 
135 Urine K. pneu 19 20 16 15 6 6 15 
136 Sputum K. pneu 16 17 17 18 11 6 18 
137 Urine K. pneu 16 17 6 12 6 6 6 
138 Urine K. pneu 17 21 16 17 9 6 16 
139 Urine K. pneu 22 18 6 6 6 6 6 
140 Urine K. pneu 21 19 9 10 9 9 10 
 
Appendix IV:  E. coli isolates showing synergistic interactions to β-lactam antibiotics in the double disk 
synergy test.  Bacterial suspensions were grown on Mueller Hinton agar and disks supplemented with antibiotics 
(aztreonam (ATM), cefepime (FEP), cefotaxime (CTX), cefpodoxime (CPD), ceftazidime (CAZ)) and the β-
lactamase inhibitor, amoxicillin-clavulanic acid, added.  Plates were incubated for 16 h at 37˚C, aerobically.    
Isolate ATM FEP CTX CPD CAZ 
1 + + - - + 
2 + + - - + 
3 + + + - + 
4 + + - - + 
5 + - - - + 
6 - + + - - 
7 + - + - - 
8 - - - - + 
9 - + + - + 
10 + + + - + 
11 + + - - + 
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Isolate ATM FEP CTX CPD CAZ 
12 - + - - + 
13 + + + - + 
14 + + + - + 
15 + + - + + 
16 + + + - + 
17 + + - - + 
18 + + - - + 
19 + + - - + 
20 - + - - - 
21 + + - - + 
22 - + - - + 
23 + + - - + 
24 + + - - - 
25 - + - - + 
26 - + + - + 
27 + - + + - 
28 + + + - + 
29 - + - - + 
30 + + - - + 
31 + + + - + 
32 + + - - + 
33 - + - - + 
34 + + + - + 
35 + + - - + 
36 - + - + - 
37 + + + - + 
38 + + + - - 
39 + + - - - 
40 + - + - + 
41 + - + - + 
42 + + - - + 
43 + + - - + 
44 - + + - + 
45 - - + + - 
46 + + + - + 
47 + + - - - 
48 + - + + - 
49 + + - - + 
50 + + + - + 
51 + + + - + 
52 - + + + + 
53 + + + - - 
54 + - + - - 
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Isolate ATM FEP CTX CPD CAZ 
55 + + + - + 
56 + + + - - 
57 + - + - + 
58 + + + + + 
59 + + - - + 
60 + + + - + 
61 + + + - + 
62 + + - - - 
63 + + + - - 
64 + + + + + 
65 + + + + + 
66 + - - - - 
67 + + + + + 
68 + + + - + 
69 + - + - + 
70 + + + - + 
71 + + - - - 
72 + + + + + 
73 + + - - + 
74 + - + - - 
75 - + - - - 
76 + + + - + 
77 + + + - + 
78 + + + - + 
79 + + + - + 
80 + + + - + 
81 + + - - - 
82 + + - - - 
83 + + + - + 
84 - + - - - 
85 + + - - + 
86 + + - - + 
87 + + + - + 
88 + - - - - 
89 + - - - + 
90 + - - - - 
91 + + - - + 
92 + + + - + 
93 + + + - + 
94 + + + - + 
95 + - + - - 
96 + + + + + 
97 + + + + + 
98 + + + - + 
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Isolate ATM FEP CTX CPD CAZ 
99 + - - - - 
100 + + - - - 
 
Appendix V:  K. pneumoniae isolates showing synergistic interactions to β-lactam antibiotics in the double 
disk synergy test.  Bacterial suspensions were grown on Mueller Hinton agar and disks supplemented with 
antibiotics (aztreonam (ATM), cefepime (FEP), cefotaxime (CTX), cefpodoxime (CPD), ceftazidime (CAZ)) and 
the β-lactamase inhibitor, amoxicillin-clavulanic acid, added.  Plates were incubated for 16 h at 37˚C, aerobically.    
 
Isolate ATM FEP CTX CPD CAZ 
101 + - + - + 
102 + + - - + 
103 + + - + + 
104 + + + - + 
105 + + - - - 
106 - - - - + 
107 - + - - + 
108 + + + - + 
109 + + - - - 
110 - + + - - 
111 + + + - + 
112 + + - - - 
113 + - + - - 
114 + + - - - 
115 + + - - + 
116 + - + - - 
117 + - + - - 
118 - + - - + 
119 + + + - + 
120 + + + - + 
121 + + - - + 
122 + + + - + 
123 + + - - - 
124 + + - - - 
125 - + + - + 
126 + + + - - 
127 - + + - - 
128 + - - - + 
129 + + + - + 
130 + + + + + 
131 + + + - + 
132 + - - - - 
133 + + + + + 
134 + - - - - 
135 + + + + + 
136 + + + - + 
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Isolate ATM FEP CTX CPD CAZ 
137 + + + + + 
138 + - + - - 
139 - + - - + 
140 + - + - - 
 
Appendix VI:  E. coli isolates indicating an ESBL-producing organism using the E-test strip.  ESBL-
production was inferred when the ratios of the minimum inhibitory concentration (MIC) of ceftazidime to 
ceftazidime plus clavulanic acid were ≥ 8-fold.  Bacterial supsensions were spread evenly over the MHA plate and 
the E-test strip added.  Plates were incubated at 37˚C for 16 hours and the size of the zone of clearing measured 
against the scale printed on the test strip.    
 Isolate 
Ceftazidime 
(μg/ml) 
Clavulanic acid 
(μg/ml) Ratio 
ESBL Producer 
1 24 0.094 24/0.094 + 
2 12 >4 12/>4 + 
3 6 0.094 6/0.094 + 
4 >32 0.094 >32/0.094 + 
5 8 0.064 8/0.064 + 
6 8 0.094 8/0.094 + 
7 16 0.094 16/0.094 + 
8 8 <0.064 8/<0.064 + 
9 24 0.125 24/0.125 + 
10 4 0.094 4/0.094 + 
11 32 0.125 32/0.125 + 
12 6 0.064 6/0.064 + 
13 6 0.064 6/0.064 + 
14 24 0.064 24/0.064 + 
15 6 0.094 6/0.094 + 
16 >32 0.125 >32/0.125 + 
17 12 0.094 12/0.094 + 
18 >32 0.25 >32/0.25 + 
19 >32 0.125 >32/0.125 + 
20 >32 0.125 >32/0.125 + 
21 >32 0.125 >32/0.125 + 
22 32 0.125 32/0.125 + 
23 8 0.094 8/0.094 + 
24 32 0.125 32/0.125 + 
25 32 0.25 32/0.25 + 
26 32 0.19 32/0.19 + 
27 4 0.064 4/0.064 + 
28 8 0.094 8/0.094 + 
29 12 0.094 12/0.094 + 
30 12 0.19 12/0.19 + 
31 6 0.064 6/0.064 + 
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 Isolate 
Ceftazidime 
(μg/ml) 
Clavulanic acid 
(μg/ml) Ratio 
ESBL Producer 
32 12 0.094 12/0.094 + 
33 >32 0.25 >32/0.25 + 
34 12 0.064 12/0.064 + 
35 24 0.125 24/0.125 + 
36 1.5 0.064 1.5/0.064 + 
37 >32 0.19 >32/0.19 + 
38 >32 0.125 >32/0.125 + 
39 >32 0.094 >32/0.094 + 
40 >32 0.25 >32/0.25 + 
41 12 0.064 12/0.064 + 
42 24 0.19 24/0.19 + 
43 >32 0.25 >32/0.25 + 
44 >32 0.19 >32/0.19 + 
45 >32 0.125 >32/0.125 + 
46 >32 0.19 >32/0.19 + 
47 6 0.064 6/0.064 + 
48 >32 0.125 >32/0.125 + 
49 3 0.094 3/0.094 + 
50 16 0.094 16/0.094 + 
51 >32 0.38 >32/0.38 + 
52 8 0.094 8/0.094 + 
53 >32 0.125 >32/0.125 + 
54 8 0.094 8/0.094 + 
55 12 0.125 12/0.125 + 
56 >32 0.125 >32/0.125 + 
57 >32 0.25 >32/0.25 + 
58 12 0.125 12/0.125 + 
59 >32 0.19 >32/0.19 + 
60 12 0.064 12/0.064 + 
61 >32 0.25 >32/0.25 + 
62 16 0.094 16/0.094 + 
63 >32 0.38 >32/0.38 + 
64 >32 0.125 >32/0.125 + 
65 >32 0.25 >32/0.25 + 
66 >32 0.25 >32/0.25 + 
67 >32 0.25 >32/0.25 + 
68 32 0.094 32/0.094 + 
69 4 0.094 4/0.094 + 
70 >32 0.094 >32/0.094 + 
71 12 0.125 12/0.125 + 
72 >32 0.19 >32/0.19 + 
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Appendix VII:  K. pneumoniae isolates indicating an ESBL-producing organism using the E-test strip.  ESBL-
production was inferred when the ratios of the minimum inhibitory concentration (MIC) of ceftazidime to 
ceftazidime plus clavulanic acid were ≥ 8-fold.  Bacterial supsensions were spread evenly over the MHA plate and 
the E-test strip added.  Plates were incubated at 37˚C for 16 hours and the size of the zone of clearing measured 
against the scale printed on the test strip.    
 Isolate 
Ceftazidime 
(μg/ml) 
Clavulanic acid 
(μg/ml) Ratio 
ESBL Producer 
101 >32 0.75 >32/0.75 + 
102 >32 0.38 >32/0.38 + 
103 16 0.094 16/0.094 + 
104 12 0.094 12/0.094 + 
105 8 0.064 8/0.064 + 
106 6 0.064 6/0.064 + 
 Isolate 
Ceftazidime 
(μg/ml) 
Clavulanic acid 
(μg/ml) Ratio 
ESBL Producer 
73 >32 0.19 >32/0.19 + 
74 12 0.064 12/0.064 + 
75 >32 0.38 >32/0.38 + 
76 >32 0.38 >32/0.38 + 
77 >32 0.19 >32/0.19 + 
78 >32 0.125 >32/0.125 + 
79 4 0.064 4/0.064 + 
80 32 0.25 32/0.25 + 
81 12 0.064 12/0.064 + 
82 12 0.094 12/0.094 + 
83 16 0.25 16/0.25 + 
84 8 0.094 8/0.094 + 
85 16 0.094 16/0.094 + 
86 >32 0.064 >32/0.064 + 
87 >32 0.38 >32/0.38 + 
88 24 0.094 24/0.094 + 
89 >32 0.19 >32/0.19 + 
90 24 0.094 24/0.094 + 
91 8 0.064 8/0.064 + 
92 6 0.094 6/0.094 + 
93 16 0.094 16/0.094 + 
94 8 0.125 8/0.125 + 
95 8 0.125 8/0.125 + 
96 >32 0.19 >32/0.19 + 
97 12 0.19 12/0.19 + 
98 >32 0.25 >32/0.25 + 
99 >32 0.125 >32/0.125 + 
100 12 0.125 12/0.125 + 
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 Isolate 
Ceftazidime 
(μg/ml) 
Clavulanic acid 
(μg/ml) Ratio 
ESBL Producer 
107 >32 0.094 >32/0.094 + 
108 12 0.064 12/0.064 + 
109 6 0.094 6/0.094 + 
110 24 0.25 24/0.25 + 
111 >32 0.19 >32/0.19 + 
112 32 0.125 32/0.125 + 
113 >32 0.125 >32/0.125 + 
114 >32 0.25 >32/0.25 + 
115 >32 0.25 >32/0.25 + 
116 >32 0.19 >32/0.19 + 
117 24 0.094 24/0.094 + 
118 12 0.19 12/0.19 + 
119 >32 0.5 >32/0.5 + 
120 >32 0.25 >32/0.25 + 
121 >32 0.19 >32/0.19 + 
122 >32 0.25 >32/0.25 + 
123 16 0.19 16/0.19 + 
124 >32 0.19 >32/0.19 + 
125 >32 0.38 >32/0.38 + 
126 32 0.19 32/0.19 + 
127 >32 0.125 >32/0.125 + 
128 >32 0.125 >32/0.125 + 
129 >32 0.38 >32/0.38 + 
130 16 0.094 16/0.094 + 
131 >32 0.25 >32/0.25 + 
132 8 0.094 8/0.094 + 
133 >32 0.094 >32/0.094 + 
134 32 0.125 32/0.125 + 
135 >32 0.25 >32/0.25 + 
136 8 0.125 8/0.125 + 
137 >32 0.38 >32/0.38 + 
138 12 0.125 12/0.125 + 
139 >32 0.19 >32/0.19 + 
140 24 0.19 24/0.19 + 
 
Appendix VIII:  E. coli isolates containing genes coding for CTX-M, SHV, OXA or TEM type ESBLs.  
Isolates were subject to multiplex PCR for detection of blaOXA (813bp), blaCTX-M (593bp), blaTEM (445bp) and blaSHV 
(237bp) genes and the gene content analysed by separating the mixture on a 1% agarose gel.    
Isolate CTX-M SHV OXA TEM 
1 +       
2 +     + 
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Isolate CTX-M SHV OXA TEM 
3 +     + 
4 +       
5 +       
6 +     + 
7 +     + 
8 +     + 
9 + +   + 
10 +     + 
11 +   +   
12 +     + 
13 +     + 
14 +     + 
15 +     + 
16 +     + 
17 +   +   
18 +   +   
19 +     + 
20 +   +   
21 +     + 
22 +   +   
23 + +   + 
24 +       
25 +     + 
26 +       
27 +     + 
28 + +   + 
29 + +   + 
30 + +   + 
31 +   + + 
32 +       
33 +     + 
34 + +   + 
35 + + + + 
36 +       
37 +   +   
38 +       
39 + +     
40 + + + + 
41 +       
42 + + + + 
43 +     + 
44 +   +   
45 +       
46 +     + 
229 
 
Isolate CTX-M SHV OXA TEM 
47 +     + 
48 +   +   
49 +     + 
50 + +     
51 +   +   
52 +       
53 + +   + 
54 +       
55 +     + 
56 +   +   
57 +   +   
58 + + + + 
59 +     + 
60 +       
61 + + + + 
62 + + + + 
63 + + + + 
64 +     + 
65 + +   + 
66 + + +   
67 +     + 
68 + +   + 
69 + + + + 
70 +     + 
71 + +   + 
72 +   +   
73 +   + + 
74 +     + 
75 + + +   
76 + + + + 
77 + + + + 
78 +     + 
79 + +   + 
80 +       
81 + + + + 
82 +     + 
83 +   + + 
84 + + + + 
85 +     + 
86 +     + 
87 +   + + 
88 +   + + 
89 + + + + 
90 +     + 
230 
 
Isolate CTX-M SHV OXA TEM 
91 +     + 
92 +     + 
93 +     + 
94 +   +   
95 +     + 
96 +   +   
97 + + + + 
98 +   + + 
99 +     + 
100 +     + 
 
Appendix IX:  K. pneumoniae isolates containing genes coding for CTX-M, SHV, OXA or TEM type ESBLs.  
Isolates were subject to multiplex PCR for detection of blaOXA (813bp), blaCTX-M (593bp), blaTEM (445bp) and blaSHV 
(237bp) genes and the gene content analysed by separating the mixture on a 1% agarose gel.    
Isolate CTX-M SHV OXA TEM 
101 + +   + 
102 +     + 
103 +     + 
104 + +   + 
105 + +     
106 +     + 
107 +     + 
108 +     + 
109 +     + 
110 + + + + 
111 + + + + 
112 +     + 
113 + +   + 
114 + +   + 
115 + + + + 
116 + + +   
117 + + + + 
118 + + + + 
119 + + + + 
120 + +   + 
121 + +   + 
122 + + + + 
123 +     + 
124 +   + + 
125 + + + + 
126 + + +   
127 + + + + 
128 + + + + 
129 + + + + 
231 
 
Isolate CTX-M SHV OXA TEM 
130 + + + + 
131 + + +   
132 + +   + 
133 + + + + 
134 + + + + 
135 + + + + 
136 +     + 
137 + + + + 
138 + + + + 
139 + +   + 
140 + +     
 
Appendix X: Growth curve of E. coli test isolates.  Bacterial growth curves were performed in LB broth at 37˚C 
for 9 hours, aerobically and the results were read using a plate reader set at 630nm.   
Isolate T0 T1 T2 T3 T4 T5 T6 T7 T8 T9 
1 0 0.004 0.0365 0.1075 0.1715 0.2295 0.283 0.3235 0.39 0.407 
2 0 0.0055 0.043 0.14 0.2005 0.2715 0.3295 0.357 0.4045 0.4225 
3 -0.0005 0.003 0.046 0.1535 0.219 0.28 0.321 0.3525 0.414 0.429 
4 0 0.0045 0.043 0.144 0.2125 0.276 0.328 0.361 0.4075 0.424 
5 -0.0005 0.0015 0.026 0.1245 0.194 0.2675 0.3115 0.3545 0.4005 0.4165 
6 -0.0015 0.0005 0.032 0.1285 0.2015 0.2595 0.3145 0.341 0.379 0.3955 
7 -0.0015 0.0005 0.032 0.1235 0.193 0.255 0.305 0.3425 0.3895 0.411 
8 -0.001 0.006 0.0475 0.156 0.2115 0.2595 0.2985 0.325 0.3745 0.39 
9 -0.001 0.0035 0.0465 0.157 0.2215 0.284 0.325 0.3335 0.3545 0.361 
10 0.0005 0.0075 0.058 0.173 0.232 0.2935 0.3505 0.3815 0.4375 0.446 
11 0 0.0045 0.041 0.136 0.209 0.272 0.3255 0.3635 0.439 0.46 
12 0.0005 0.003 0.029 0.113 0.1885 0.253 0.2965 0.327 0.4075 0.427 
13 0 0.01 0.064 0.1725 0.244 0.3175 0.376 0.418 0.4705 0.4835 
14 -0.0045 -0.0005 0.024 0.117 0.2055 0.2655 0.345 0.374 0.429 0.4415 
15 -0.001 0.0005 0.0315 0.1275 0.201 0.261 0.311 0.356 0.4125 0.432 
16 -0.0035 -0.0035 0.0075 0.059 0.1485 0.1935 0.2415 0.2755 0.311 0.329 
17 -0.0045 0.0005 0.035 0.127 0.195 0.25 0.298 0.3375 0.3945 0.411 
18 -0.0035 0 0.0285 0.1295 0.207 0.265 0.324 0.3655 0.4185 0.439 
19 -0.0015 0.0005 0.032 0.1245 0.194 0.251 0.3045 0.35 0.412 0.427 
20 -0.0015 0.0025 0.041 0.14 0.2095 0.262 0.3155 0.3585 0.418 0.4435 
21 -0.001 0.004 0.039 0.138 0.197 0.245 0.299 0.352 0.425 0.453 
22 -0.001 0.002 0.0365 0.131 0.199 0.2575 0.306 0.344 0.4035 0.419 
23 -0.0015 0.002 0.0245 0.11 0.204 0.278 0.3385 0.3695 0.398 0.4125 
24 0.0005 0.003 0.0395 0.1405 0.2095 0.272 0.3275 0.3685 0.4175 0.4325 
25 0.0005 0.002 0.0345 0.125 0.195 0.258 0.301 0.336 0.3835 0.398 
26 -0.0005 0.0055 0.046 0.1485 0.2075 0.2715 0.3295 0.3785 0.432 0.452 
27 0 0.003 0.0395 0.1285 0.196 0.2505 0.2965 0.3355 0.3955 0.417 
232 
 
Isolate T0 T1 T2 T3 T4 T5 T6 T7 T8 T9 
28 -0.002 -0.0005 0.0235 0.1095 0.208 0.2835 0.3405 0.382 0.418 0.429 
29 -0.0015 0.0005 0.0315 0.1395 0.22 0.288 0.3455 0.391 0.435 0.4485 
30 -0.001 0.001 0.032 0.1355 0.2175 0.2825 0.342 0.386 0.4365 0.444 
31 -0.0015 0.002 0.04 0.14 0.212 0.275 0.3295 0.3785 0.4395 0.4665 
32 -0.0025 -0.0005 0.022 0.108 0.1885 0.2475 0.303 0.3425 0.401 0.43 
33 -0.002 -0.0015 0.0165 0.0925 0.178 0.228 0.281 0.324 0.3835 0.3955 
34 -0.001 0.002 0.0345 0.138 0.221 0.282 0.3425 0.3785 0.424 0.433 
35 -0.0015 0.0025 0.025 0.113 0.207 0.281 0.345 0.4015 0.445 0.4605 
36 0 0.0025 0.0315 0.124 0.203 0.272 0.3315 0.3905 0.436 0.466 
37 -0.002 0.0015 0.0285 0.121 0.209 0.2895 0.345 0.385 0.455 0.474 
38 0 0.004 0.037 0.1355 0.2155 0.284 0.3475 0.396 0.462 0.4735 
39 -0.002 0.0025 0.0285 0.135 0.225 0.2885 0.3515 0.3895 0.4315 0.4405 
40 -0.001 0.001 0.0165 0.091 0.1945 0.2615 0.3265 0.3725 0.4145 0.432 
41 -0.0025 -0.001 0.021 0.1085 0.192 0.248 0.3015 0.345 0.4105 0.4325 
42 -0.0015 0 0.0265 0.1195 0.203 0.2695 0.3195 0.3535 0.388 0.3985 
43 -0.0025 0 0.0295 0.0955 0.1655 0.2285 0.2865 0.3355 0.3905 0.409 
44 -0.002 -0.001 0.016 0.089 0.192 0.241 0.2835 0.3225 0.382 0.404 
45 -0.0005 0 0.0255 0.109 0.196 0.2535 0.3055 0.348 0.4045 0.432 
46 0 0.0005 0.0185 0.086 0.1765 0.2345 0.2945 0.3425 0.4045 0.4315 
47 0.0005 0.0005 0.0205 0.075 0.143 0.208 0.29 0.3565 0.42 0.454 
48 0.0015 0.0015 0.0205 0.101 0.1815 0.2525 0.31 0.369 0.4145 0.4365 
49 0 -0.0005 0.013 0.0845 0.1755 0.2585 0.3345 0.3805 0.417 0.437 
50 -0.001 -0.0005 0.02 0.1035 0.199 0.2745 0.332 0.379 0.4365 0.4655 
51 -0.001 -0.001 0.0145 0.0905 0.1825 0.2395 0.2945 0.3305 0.3685 0.3925 
52 -0.002 -0.001 0.0135 0.0845 0.1775 0.229 0.277 0.316 0.3625 0.394 
53 -0.0005 -0.0005 0.0155 0.101 0.1895 0.252 0.3075 0.352 0.4025 0.426 
54 0.0005 0.0005 0.0205 0.1045 0.202 0.2655 0.32 0.364 0.422 0.4455 
55 -0.001 0.001 0.027 0.112 0.1825 0.2235 0.2815 0.333 0.402 0.4385 
56 0.0015 0 0.0155 0.085 0.1735 0.2325 0.2845 0.3305 0.3835 0.4195 
57 -0.0015 0.002 0.022 0.102 0.1945 0.249 0.303 0.3405 0.3965 0.4105 
58 0.0005 0.0005 0.012 0.0715 0.171 0.2475 0.3175 0.371 0.419 0.4415 
59 0 0.001 0.0165 0.0945 0.1955 0.256 0.305 0.352 0.402 0.4145 
60 -0.002 -0.001 0.0115 0.068 0.1455 0.2215 0.283 0.344 0.3935 0.4135 
61 0.002 0.0055 0.0275 0.1075 0.1345 0.233 0.287 0.327 0.3525 0.3615 
62 0 0.0045 0.037 0.136 0.1595 0.2355 0.282 0.315 0.3495 0.3785 
63 0.002 0.005 0.0345 0.12 0.1435 0.2335 0.281 0.312 0.3715 0.398 
64 0.001 0.0025 0.028 0.109 0.147 0.228 0.2905 0.3375 0.355 0.375 
65 0.002 0.0065 0.04 0.1395 0.1625 0.247 0.3055 0.337 0.3605 0.3885 
66 0.005 0.005 0.0245 0.093 0.1245 0.199 0.239 0.285 0.319 0.335 
67 0.004 0.004 0.0275 0.0995 0.1255 0.1975 0.256 0.319 0.3375 0.353 
68 0.004 0.003 0.009 0.052 0.089 0.1685 0.219 0.279 0.3185 0.34 
233 
 
Isolate T0 T1 T2 T3 T4 T5 T6 T7 T8 T9 
69 -0.0005 0.003 0.0255 0.106 0.1345 0.228 0.2845 0.3415 0.3705 0.3705 
70 0.002 0.0085 0.032 0.122 0.154 0.3145 0.368 0.4275 0.4735 0.4985 
71 0.001 0.0045 0.028 0.116 0.151 0.304 0.391 0.432 0.4875 0.4955 
72 0.0015 0.0035 0.023 0.0975 0.128 0.257 0.3095 0.3635 0.3895 0.391 
73 0 0.0035 0.0205 0.086 0.1315 0.2495 0.3085 0.3535 0.384 0.399 
74 0.001 0.0025 0.016 0.0685 0.102 0.1995 0.2585 0.3005 0.3255 0.3405 
75 -0.0005 0.002 0.0215 0.089 0.125 0.213 0.271 0.3185 0.354 0.3765 
76 -0.0005 0.0025 0.023 0.096 0.132 0.2165 0.278 0.3205 0.351 0.381 
77 0.002 0.003 0.026 0.098 0.1395 0.248 0.292 0.3305 0.3725 0.396 
78 0 -0.0005 0.0085 0.0555 0.096 0.19 0.254 0.304 0.339 0.367 
79 0.001 0.002 0.016 0.0675 0.101 0.193 0.26 0.3125 0.354 0.3865 
80 0.002 0.0025 0.0125 0.0535 0.1045 0.2055 0.253 0.2965 0.3295 0.349 
81 0.001 0.002 0.0165 0.0715 0.112 0.2325 0.2985 0.3605 0.4055 0.4295 
82 0.001 0.002 0.0225 0.0965 0.1335 0.228 0.258 0.2965 0.329 0.3545 
83 0 0.002 0.022 0.088 0.129 0.2295 0.2685 0.3225 0.3545 0.3805 
84 0.0005 0.0025 0.0185 0.082 0.1265 0.2465 0.2925 0.3385 0.3705 0.392 
85 0.0015 0.0035 0.022 0.099 0.139 0.2925 0.361 0.42 0.4485 0.469 
86 0.0015 0.0035 0.0185 0.101 0.1425 0.246 0.2885 0.3305 0.3645 0.399 
87 0.0015 0.002 0.015 0.073 0.119 0.238 0.307 0.36 0.3985 0.415 
88 0 0.002 0.0145 0.0695 0.112 0.2405 0.286 0.3325 0.3625 0.371 
89 0 0.002 0.0185 0.0895 0.135 0.248 0.312 0.3615 0.409 0.4365 
90 -0.0015 0 0.012 0.055 0.0975 0.1925 0.2505 0.3065 0.336 0.3545 
91 -0.002 0 0.0145 0.068 0.098 0.1915 0.249 0.298 0.327 0.351 
92 -0.0025 0 0.0155 0.075 0.1135 0.212 0.271 0.3235 0.3605 0.3855 
93 0.0025 0.0015 0.0225 0.0905 0.1275 0.2235 0.275 0.3195 0.364 0.3935 
94 0.007 0.0035 0.011 0.048 0.0845 0.177 0.2235 0.265 0.2985 0.3195 
95 0.0055 0.0025 0.016 0.074 0.111 0.1985 0.2645 0.315 0.357 0.3845 
96 0.0035 0.0015 0.011 0.0645 0.101 0.191 0.2485 0.2885 0.333 0.3665 
97 -0.0005 -0.0015 0.0115 0.064 0.1025 0.1985 0.2705 0.3055 0.356 0.372 
98 0.0015 0.0015 0.0185 0.0905 0.1415 0.2475 0.329 0.378 0.4375 0.47 
99 0 0.001 0.0145 0.0705 0.1065 0.194 0.255 0.2955 0.352 0.379 
100 -0.001 0.0015 0.017 0.083 0.127 0.2505 0.327 0.3685 0.4245 0.446 
Average -0.00011 0.001995 0.025625 0.105075 0.16748 0.24585 0.301875 0.34563 0.392035 0.41219 
SD 0.001913 0.002239 0.011151 0.028423 0.040965 0.031322 0.033278 0.033224 0.039055 0.038577 
 
Appendix XI: Growth curve of K. pneumoniae test isolates.  Bacterial growth curves were performed in LB broth 
at 37˚C for 9 hours, aerobically and the results were read using a plate reader set at 630nm.   
Isolate T0 T1 T2 T3 T4 T5 T6 T7 T8 T9 
101 -0.0005 0.002 0.02 0.1055 0.1965 0.282 0.344 0.3735 0.4205 0.4365 
102 0.001 0.0025 0.028 0.118 0.2005 0.264 0.3385 0.383 0.4305 0.4575 
103 -0.0015 0.001 0.022 0.095 0.179 0.2485 0.32 0.3795 0.4305 0.465 
234 
 
Isolate T0 T1 T2 T3 T4 T5 T6 T7 T8 T9 
104 -0.001 -0.0005 0.0135 0.0915 0.1905 0.2675 0.3335 0.3925 0.444 0.4605 
105 -0.0005 -0.001 0.006 0.0555 0.143 0.186 0.2365 0.2855 0.342 0.369 
106 -0.0025 -0.0025 0.0055 0.0435 0.149 0.2265 0.297 0.345 0.38 0.4055 
107 -0.0015 -0.0015 0.014 0.086 0.1855 0.25 0.312 0.354 0.4035 0.424 
108 0 -0.001 0.0135 0.0775 0.156 0.217 0.2925 0.3515 0.4035 0.428 
109 -0.001 -0.001 0.012 0.0755 0.172 0.23 0.3055 0.369 0.4245 0.452 
110 0 0.005 0.034 0.119 0.1465 0.246 0.3085 0.354 0.381 0.3905 
111 -0.001 0.0025 0.0245 0.0985 0.1165 0.193 0.241 0.271 0.31 0.345 
112 0.0005 0.0035 0.031 0.122 0.1335 0.2325 0.297 0.352 0.4045 0.4195 
113 0.001 0.0055 0.0475 0.1495 0.1735 0.2535 0.3055 0.34 0.3645 0.3745 
114 0.002 0.0055 0.0395 0.1375 0.1555 0.2225 0.2835 0.3085 0.3475 0.3825 
115 0.001 0.0055 0.037 0.1335 0.1635 0.255 0.3315 0.3905 0.4245 0.44 
116 0.003 0.005 0.027 0.108 0.148 0.2295 0.2815 0.3125 0.332 0.352 
117 0.005 0.0045 0.025 0.096 0.1285 0.2115 0.262 0.3095 0.3415 0.3565 
118 0.002 0.004 0.0265 0.1 0.1335 0.2235 0.267 0.3205 0.358 0.3735 
119 -0.001 0 0.0125 0.0695 0.096 0.181 0.223 0.266 0.299 0.322 
120 0.0015 0.004 0.0335 0.124 0.1565 0.2555 0.3125 0.3705 0.3955 0.405 
121 0.001 0.0035 0.028 0.1135 0.1415 0.244 0.2915 0.349 0.389 0.4085 
122 0.0015 0.004 0.03 0.1215 0.149 0.253 0.2965 0.3545 0.3835 0.3975 
123 0.001 0.0035 0.0195 0.0845 0.1265 0.2395 0.306 0.3675 0.4005 0.4095 
124 0.001 0.0035 0.0265 0.1065 0.14 0.231 0.2795 0.3165 0.3475 0.375 
125 0.001 0.003 0.019 0.09 0.129 0.23 0.2885 0.3465 0.3665 0.383 
126 -0.0015 0.0015 0.0135 0.0765 0.121 0.2275 0.2895 0.349 0.395 0.417 
127 -0.0005 0.003 0.025 0.119 0.156 0.256 0.3215 0.377 0.4265 0.4495 
128 0.002 0.0035 0.0245 0.114 0.145 0.234 0.285 0.3355 0.3745 0.4 
129 0.0005 0.0015 0.0105 0.0595 0.108 0.2145 0.289 0.3505 0.4045 0.437 
130 0.006 0.0065 0.0185 0.0915 0.1295 0.238 0.297 0.352 0.399 0.4285 
131 0.0025 0.0045 0.0235 0.108 0.1475 0.269 0.3425 0.3865 0.4535 0.4985 
132 0.0015 0.0025 0.008 0.036 0.0825 0.2205 0.2945 0.3655 0.4175 0.4575 
133 0.001 0.002 0.014 0.0715 0.1195 0.2415 0.3185 0.385 0.4285 0.448 
134 -0.002 -0.0005 0.008 0.051 0.0875 0.188 0.25 0.306 0.341 0.3635 
135 0 0.002 0.0135 0.076 0.1215 0.236 0.32 0.3715 0.405 0.4355 
136 0.0025 0.0005 0.015 0.075 0.1095 0.195 0.272 0.3125 0.3645 0.3965 
137 0.004 0.0015 0.0125 0.0685 0.1085 0.211 0.279 0.344 0.3885 0.4065 
138 0.001 0.002 0.015 0.079 0.136 0.281 0.336 0.3925 0.428 0.465 
139 0.0025 0.002 0.0065 0.0295 0.0655 0.193 0.2805 0.3405 0.4035 0.4405 
140 0.0035 0.004 0.017 0.0805 0.133 0.268 0.3355 0.387 0.447 0.4815 
Average 0.000875 0.002425 0.020513 0.091425 0.1395 0.233638 0.296625 0.347938 0.390013 0.413938 
SD 0.00187 0.002209 0.009909 0.028013 0.030354 0.025948 0.029271 0.032871 0.037656 0.0403 
235 
 
Appendix XII: ESBL-producing E. coli containing key virulence genes. Several multiplex PCR reactions were used to determine the presence of the listed virulence genes.   
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